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CHAPTER	  1	  	  	  AIM	  
	   	   1	  
1 Aim	  	  
Malnutrition	   in	   hospitalised	   patients	   is	   a	   serious	   and	   often	   underestimated	   problem.	   It	   is	   well	  
established	   that	   the	   recognition	   and	   adequate	   treatment	   of	   malnutrition	   upon	   hospitalisation	   is	   of	  
highest	  importance	  for	  a	  successful	  patient	  outcome.	  Nevertheless,	  the	  knowledge	  level	  for	  most	  health	  
care	  professionals	  insofar	  as	  nutritional	  assessment	  and	  appropriate	  nutritional	  support	  is	  still	   low	  and	  
training	   inadequate,	   especially	   that	   of	   the	   attending	   physicians	  who	   have	   first	   contact	  with	   patients.	  
Errors	   in	   medication	   and	   nutritional	   therapy	   lead	   to	   increased	   morbidity	   and	   mortality,	   as	   well	   as	  
prolonged	   treatment.	   Prevention	   of	   these	   oversights	   enables	   optimised	   and	   safe	   clinical	   nutritional	  
therapy	  and	  also	  medication	  treatment.	  An	  interdisciplinary	  nutrition	  support	  team	  (NST)	  comprising	  a	  
physician,	  dietitian,	  nurse	  and	  pharmacist	  is	  necessary	  for	  the	  good	  nutritional	  management	  of	  a	  patient	  
from	   admission	   until	   discharge	   as	   well	   as	   further	   care	   at	   home.	   Their	   function	   includes	   nutritional	  
assessment,	  evaluation	  and	  determination	  of	  individual	  nutritional	  requirements,	  recommendations	  for	  
nutritional	   therapy	  and	  management	  of	   the	  nutritional	   care	  plan.	  There	  are	  different	   forms	  of	   clinical	  
nutrition	   therapy	   to	   prevent	   and	   treat	   malnutrition	   when	   physiological	   feeding	   is	   not	   possible	   or	  
insufficient.	   In	   particular,	   patients	   who	   are	   to	   receive	   home	   parenteral	   nutrition	   (HPN)	   require	  
continuous	  monitoring	  by	  a	  well-­‐educated	  NST.	  From	  the	  outset,	   the	  patient	  will	  be	   in	  steady	  contact	  
with	  the	  hospital	  due	  to	  the	  need	  for	   long-­‐term	  follow-­‐up	  and	  mandatory	  monitoring	  for	  this	  complex	  
and	  challenging	  treatment.1,2	  
	  
The	   pharmacy	   profession	   is	   undergoing	   major	   transformations,	   therefore	   additional	   skills	   and	  
knowledge	  are	  required	  to	  achieve	  best	  pharmaceutical	  practice	  and	  care.	  Many	  changes	  have	  occurred	  
and	   thus,	   interdisciplinary	   cooperation	   becomes	   more	   important	   and	   HPN	   is	   used	   more	   and	   more,	  
increasing	  the	  challenges	  of	  the	  pharmacist	  with	  these	  complex	  parenteral	  nutrition	  (PN)	  formulations.	  
Technical	   and	   pharmaceutical	   developments	   have	   helped	   to	   establish	   safe,	   convenient	   and	   effective	  
HPN.	  The	  pharmacist,	  as	  a	  member	  of	  an	  NST,	  can	  contribute	  by	  defining	  and	  evaluating	  best	  practices	  
and	  efficiency	  to	  prevent	  medication	  errors,	  thus	  ensuring	  an	  increased	  quality	  of	  life	  (QoL).	  The	  role	  of	  
the	  pharmacist	  as	  part	  of	   an	  NST	  depends	  on	   specific	  pharmaceutical	  expertise,	   including	  knowledge,	  
experience	  and	  skills	  in	  the	  field	  of	  clinical	  nutrition,	  particularly	  in	  PN.	  Nutritional	  therapy	  as	  part	  of	  a	  
patient’s	   overall	   treatment	   plan	   and	   therefore	   embedded	   in	   the	   medication	   therapy,	   requires	   the	  
involvement	  of	  the	  pharmacy.3	  
	  
This	  thesis	  investigates	  pharmaceutical	  aspects	  in	  the	  field	  of	  clinical	  nutrition,	  focusing	  on	  aspects	  of	  PN	  
in	  particular.	  The	  main	  objective	  of	  this	  thesis	  is	  to	  illustrate	  the	  various	  pharmaceutical	  activities	  in	  an	  
NST	  throughout	  the	  clinical	  nutrition	  process	  with	  a	  focus	  on	  PN.	  To	  clarify,	  the	  research	  aims	  are:	  	  
• What	  role	  should	  the	  pharmacist	  play	  in	  an	  NST?	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• Is	  he/she	  prepared	  for	  the	  professional	  challenges?	  
• Which	  best	  practices	  can	  the	  pharmacist	  provide	  to	  increase	  the	  quality	  of	  treatment,	  safety	  and	  
QoL	  for	  a	  patient?	  
To	  this	  end,	  four	  independent	  projects	  were	  defined	  in	  order	  to	  reach	  the	  aims:	  
	  
(I)	   What	  is	  the	  importance	  and	  role	  of	  the	  pharmacist?	  	  
• Identification	  of	  malnourished	  patients	  or	  patients	  at	  nutritional	  risk,	  where	  the	  
pharmacist	  can	  make	  an	  important	  contribution.	  
• Responsibility	   for	  maintenance	  of	  professional	   competence	   in	  nutrition	  support	  
management	  by	  providing	  education	  and	  skills	  training.	  	  
	  
(II	  a	  +b)	   Which	  contributions	  can	  the	  pharmacist	  give	  to	  provide	  a	  safe	  and	  effective	  drug	  and	  
nutritional	  therapy	  and	  therefore	  an	  improved	  QoL?	  
• Monitoring	   and	   optimisation	   of	   nutrition	   support	   therapies	   including	   care	   for	  
HPN	   patients	   and	   management	   of	   good	   nutritional	   supply,	   providing	   safe	   and	  
effective	  treatment	  and	  therefore	  improving	  the	  patient’s	  QoL.	  Specific	  focus	  was	  
given	   to	   the	   so	   far	   not	   prospectively	   analysed	   situation	   in	   Swiss	   adult	   HPN	  
patients	  and	  benefit	  of	  HPN	  on	  QoL	  in	  patients	  with	  specific	  disease.	  	  
(III)	   Which	   compounding	   related	   questions	   arise	   and	   which	   stability	   and	   compatibility	  
assessments	  have	  to	  be	  done	  to	  ensure	  medication	  safety?	  
• Patients	   with	   long-­‐term	   PN	   or	   critically	   ill	   patients	   especially	   need	   additional	  
components	   or	   medications	   added	   to	   a	   PN	   admixture,	   requiring	   strict	   aseptic	  
compounding	  and	  previous	  stability	  and	  compatibility	  assessments.	  	  
	  
These	   different	   aspects	   of	   pharmaceutical	   expertise	   are	   part	   of	   the	   thesis	   as	   shown	   in	   the	   four	  
presented	  studies	  in	  Chapter	  4	  and	  highlight	  how	  a	  pharmacist	  with	  appropriate	  training	  and	  experience	  
can	  contribute	  to	  the	  activities	  in	  an	  NST	  and	  therefore	  improve	  a	  patient’s	  outcome	  and	  QoL.	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2 Introduction	  
2.1 Disease-­‐related	  malnutrition	  
Malnutrition	   in	   hospitalised	   patients	   is	   a	   serious	   problem,	   also	   in	   industrialised	   countries.	   A	   	   consent	  
definition	  for	  malnutrition	  is	  often	  lacking	  due	  to	  different	  screening	  systems	  and	  assessment	  methods.	  
Therefore,	  there	  is	  a	  wide	  range	  of	  prevalence	  of	  hospital	  malnutrition.	  
	  
2.1.1 Definition	  and	  prevalence	  of	  disease-­‐related	  malnutrition	  
Although	  malnutrition	   is	   a	   common	  subject,	  different	  definitions	   for	  malnutrition,	   for	   the	  appropriate	  
nutritional	   screening	   method	   and	   for	   the	   assessment	   of	   the	   nutritional	   status	   exist.	   The	   European	  
Society	   of	   Clinical	  Nutrition	   and	  Metabolism	   (ESPEN)	   has	   developed	   a	   consensus	   for	   the	   definition	   of	  
undernutrition:	   “A	   state	   resulting	   from	   lack	   of	   uptake	   or	   intake	   of	   nutrition	   leading	   to	   altered	   body	  
composition	   (decreased	   fat	   free	  mass	   and	   body	   cell	  mass)	   leading	   to	   diminished	   physical	   and	  mental	  
function	   and	   impaired	   clinical	   outcome	   from	   disease”.4	   The	  most	   frequent	   reason	   for	  malnutrition	   in	  
developed	  countries	  is	  disease	  associated	  with	  increased	  requirements	  for	  nutrients	  because	  of	  stress-­‐
induced,	  altered	  metabolism	  and	  which	  will	  be	  referred	  to	  as	  disease-­‐related	  malnutrition	  (DRM).	  The	  
causes	  of	  DRM	  are	  multifactorial	  and	  are	  principally	  associated	  with	  insufficient	  food	  or	  nutrient	  intake	  
and	   impaired	   nutrient	   digestion	   or	   absorption.	   DRM	   and	   disease	   interfere	   with	   each	   other.	   Chronic	  
diseases,	   including	  cancer,	  AIDS,	  chronic	  obstructive	  pulmonary	  disease	  (COPD)	  or	  acute	  diseases	  such	  
as	   infection,	   burns	   or	   trauma	   can	   lead	   to	   reduced	   intake	   with	   anorexia,	   malabsorption	   and	   finally	  
cachexia.	   Drug-­‐related	   side	   effects	   can	   also	   cause	   anorexia	   or	   interfere	   with	   the	   insufficient	  
intake/absorption	  of	  nutrients,	  e.g.	  chemotherapies,	  antibiotics,	  morphine,	  neuroleptics,	  proton-­‐pump-­‐
inhibitors,	   etc.	   Furthermore,	   social	   and	   psychological	   factors	   can	   also	   contribute	   to	   decreased	   food	  
intake,	  including	  problems	  with	  shopping	  or	  cooking,	  living	  alone,	  depression	  and	  poverty.5	  
	  
DRM	  among	  hospital	  patients	   is	  a	  serious,	  widely	  prevalent	  and	  often	  underestimated	  problem.	  Many	  
studies	  have	  been	  performed	  in	  hospitals	  and	  found	  a	  prevalence	  of	  20-­‐50%	  of	  DRM.	  The	  wide	  range	  of	  
prevalence	  of	  malnutrition	  is	  due	  to	  the	  lack	  of	  a	  definition	  of	  malnutrition,	  non-­‐existence	  of	  a	  uniform	  
screening	  method,	  different	  medical	  settings	  and	  different	  patient	  groups.6	  Several	  studies	  indicate	  that	  
morbidity	   (more	   fractures,	   infections,	   decubiti	   and	   impaired	   wound	   healing),	   mortality,	   length	   of	  
hospital	  stay	  (LOS),	  complication	  rate	  (mainly	  infections)	  and	  thereby	  the	  health	  care	  costs,	  increase	  in	  
malnourished	  patients	   or	   patients	   at	   nutritional	   risk.	   This	   patient	   group	   also	   shows	   a	   diminished	  QoL	  
with	  physical	   and	  mental	  problems.7,8,9,10	   Therefore,	   it	   is	   very	   important	   to	   start	  early	  with	  nutritional	  
support	   including	   oral	   nutritional	   supplements	   (ONS),	   enteral	   nutrition	   (EN)	   or	   even	   PN	   to	   treat	   and	  
prevent	  DRM.	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2.1.2 Nutritional	  screening	  
DRM	   is	   a	   treatable	   comorbidity.	   Therefore,	   rapid	   and	   simple	   identification	   of	   patients	   at	   risk	   and	  
effective	   nutritional	   management	   are	   essential.	   Optimised	   nutritional	   management	   including	   rapid	  
identification	   and	   treatment	   of	   DRM	   should	   be	   available	   in	   each	   hospital	   and	   patients	   should	   be	  
supported	  by	  an	  interdisciplinary	  NST.	  Clinical	  nutrition	  and	  particularly	  PN	  needs	  the	  support	  of	  an	  NST.	  
Their	  tasks	  include	  the	  identification,	  assessment,	  prevention	  and	  treatment	  of	  malnutrition,	  increasing	  
the	  efficiency	  and	  safety	  of	  the	  nutritional	  management.2,11	  	  The	  guidelines	  suggest	  that	  a	  patient	  should	  
be	   screened	   as	   part	   of	   the	   admission	   procedure,	   assessed	   and	   nutritional	   support	   should	   be	  
commenced	  immediately.	  Nutritional	  screening	  should	  be	  conducted	   in	  all	  patients	  upon	  admission	  to	  
the	  hospital	  and	  within	  24-­‐48	  hours.	  Additionally,	  the	  outcome	  should	  be	  monitored	  and	  a	  patient	  care	  
plan	   created.12	   Different	   standardised,	   reliable,	   rapid	   and	   simple	   screening	   methods	   exist	   and	   these	  
validated	  tests	  support	  staff	  to	  identify	  patients	  at	  nutritional	  risk	  early	  and	  to	  start	  nutritional	  therapy	  
without	  loss	  of	  time.	  The	  Nutritional	  Risk	  Screening	  (NRS	  2002),	  the	  Mini	  Nutritional	  Assessment	  (MNA),	  
the	  Subjective	  Global	  Assessment	  (SGA)	  and	  the	  Malnutrition	  Universal-­‐Screening	  Tool	  (MUST)	  are	  the	  
most	  common	  screening	  tools.13	  The	  NRS	  2002	  is	  recommended	  in	  hospitals	  and	  allows	  for	  identification	  
of	  patients	  at	  nutritional	  risk	  within	  a	  few	  minutes.14	  
	  
2.1.3 Education	  and	  training	  in	  clinical	  nutrition	  
DRM	  is	  often	  not	  detected	  when	  a	  patient	  is	  admitted	  to	  hospital	  because	  of	  insufficient	  knowledge	  and	  
experience	  of	  the	  medical	  staff.	  In	  2001,	  the	  Dutch	  Diabetes	  Association	  conducted	  a	  national	  screening	  
for	   DRM	   in	   6150	   hospital	   patients,	   the	   results	   indicating	   that	   approximately	   25%	   of	   them	   were	  
undernourished.	  Unfortunately,	  not	  even	  half	  of	  these	  patients	  were	  identified	  properly	  by	  the	  nursing	  
and	  medical	   staff.	  Therefore,	   the	  awareness	  of	  DRM	  among	  medical	   staff	   should	  be	   increased.	  Often,	  
the	  nutritional	  status	  of	  patients	  worsens	  during	  the	  hospital	  stay	  due	  to	  the	  lack	  of	  nutritional	  support,	  
the	   disease	   itself,	   the	   therapy	   or	   other	   interventions	   which	   can	   further	   increase	   the	   risk	   of	  
complications,	   LOS	   and	   overall	   costs.15	   A	   study	   conducted	   in	   Denmark	   showed	   that	   almost	   40%	   of	  
patients	   in	   hospital	   were	   at	   nutritional	   risk,	   however,	   only	   a	   portion	   of	   these	   patients	   received	  
nutritional	  intervention.	  No	  more	  than	  33%	  of	  patients	  had	  a	  prescription	  for	  a	  nutritional	  intervention	  
and	   merely	   18%	   of	   the	   patients	   reached	   the	   given	   goals.16	   Another	   questionnaire-­‐based	   study	   with	  
doctors	   and	   nurses	   in	   Denmark	   showed	   that	   only	   20%	   of	   them	   conducted	   a	   nutritional	   screening	   or	  
assessment.	  Neither	  the	  body	  weight	  nor	  the	  dietary	   intake	  was	  recorded.	  The	  most	  common	  reasons	  
for	  inadequate	  nutritional	  practice	  are	  insufficient	  knowledge,	  low	  priority,	  unclear	  responsibility,	  lack	  of	  
time,	   material,	   techniques	   and	   guidelines.17,18	   This	   was	   also	   shown	   in	   our	   study	   (see	   Chapter	   4,	  
Publications).19	   A	   study	   conducted	   in	   Brazil	   in	   an	   intensive	   care	   unit	   confirmed	   that	   education	   in	  
nutritional	  management	  alone	  is	  inadequate	  for	  medical	  students,	  doctors	  and	  nursing	  staff.	  Therefore,
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it	   is	   very	   important	   to	   implement	   educational	   programs	   to	   improve	   the	   nutritional	   management	   in	  
hospitals.	   Tools	   such	   as	   bedside	   teaching,	   short	   conferences	   incorporating	   active	   participation,	  
discussion	   rounds,	   use	   of	   educational	   media	   and	   the	   participation	   of	   a	   multi-­‐professional	   NST	   are	  
proposed.20	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2.2 Clinical	  nutrition	  
The	   term	   ‘clinical	   nutrition’	   includes	   all	   nutritional	   measures	   provided	   to	   people	   under	   medical	   or	  
nursing	   care	   and	   involves	   preventive	   and	   therapeutic	   aspects.	   Four	   criteria	   determine	   nutritional	  
support:	   expected	   duration	   of	   inadequate	   oral	   intake,	   nutritional	   status	   of	   the	   patient,	   severity	   of	  
disease,	   specific	   conditions	   and	   stress	   factors,	   e.g.	   burns,	   sepsis,	   etc.	   The	   goals	   of	   clinical	   nutritional	  
support	   are	   the	   improvement	   of	   body	   mass	   and	   composition,	   wellbeing	   and	   QoL,	   the	   reduction	   of	  
complications,	   morbidity,	   mortality	   and	   faster	   recovery	   from	   illness.	   Nutritional	   support	   should	   be	  
individually	  implemented	  in	  patients	  with	  malnutrition	  or	  at	  nutritional	  risk.21	  There	  are	  different	  types	  
of	  nutritional	  support:	  ONS,	  EN	  and	  PN	  but	  in	  this	  thesis,	  the	  focus	  will	  be	  on	  PN.	  
	  
2.2.1 Enteral	  nutrition	  
The	   term	   EN	   includes	   feeding	   via	   nasogastric/enteral	   or	   percutaneous	   tube	   (tube	   feeding)	   and	   ONS.	  
Consequently,	  EN	  comprises	  all	  forms	  of	  nutritional	  support	  that	   indicate	  the	  use	  of	  “dietary	  foods	  for	  
special	   medical	   purposes”	   as	   defined	   in	   the	   European	   legal	   regulation	   of	   the	   commission	   directive	  
1999/21/EC	  of	  25	  March	  1999.22	  
	  
2.2.1.1 Oral	  nutritional	  supplements	  
If	   the	   patient	   is	   able	   to	   eat,	   nutritional	   support	   should	   be	   started	   using	   this	   most	   physiological	   oral	  
route.	  When	   the	   food	   intake	   of	   a	   patient	   is	   <75%	   of	   required	   intake	   over	   a	   period	   of	   five	   days,	   oral	  
supplementation	   must	   be	   started.23,24	   Upon	   diagnosis	   of	   DRM	   ONS	   containing	   macro-­‐	   and	  
micronutrients	  are	  used.	  These	  contain	  different	  enrichments/fortifications	  with	  protein,	  carbohydrate	  
powders	  or	  fat,	  come	  in	  a	  variety	  of	  flavors	  (vanilla,	  cappuccino,	  strawberry,	  etc.),	  with	  various	  energy	  
and	  protein	  contents,	  e.g.	  low	  (1	  kcal/mL)	  to	  high	  (2.5	  kcal/mL)	  caloric	  value,	  or	  enriched	  with	  proteins	  
(15-­‐20%)	  or	  without	  proteins.	  There	  are	  also	  ONS	  with	  or	  without	  dietary	  fibres	  and	  with	  disease	  specific	  
compositions,	   e.g.	   immune	   enhancing	   products,	   products	   based	   on	   short-­‐chain	   peptides	   or	   diabetes	  
specific	  products.	  ONS	   can	  enable	  patients	   to	   cover	   their	  nutritional	   requirements	  when	  normal	   food	  
intake	  is	  insufficient.	  To	  encourage	  the	  compliance	  of	  ONS	  intake,	  the	  ONS	  can	  be	  prescribed	  like	  other	  
medications	  and	  they	  can	  also	  be	  diluted	  or	  combined	  with	  ice	  cream,	  juices	  or	  fruits.25,26	  
	  
2.2.1.2 Tube	  feeding	  
When	  normal	  eating	  and	  ONS	  are	  insufficient	  to	  cover	  the	  nutritional	  requirement,	  EN	  with	  tube	  feeding	  
is	  indicated,	  provided	  that	  the	  gastrointestinal	  function	  is	  sufficient.	  The	  principal	  indication	  for	  EN	  is	  a	  
(partly)	   functional	   and	   accessible	   gastrointestinal	   tract	   (GIT)	   and	   the	   incapability	   or	   unwillingness	   to	  
cover	  the	  nutritional	  need	  orally.	  Possible	   indications	  for	  EN	  are	  disorientation,	  e.g.	  coma,	  depression,	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apoplexy;	  mechanical	  impairment	  when	  eating	  or	  swallowing,	  e.g.	  tumor	  in	  ear,	  nose	  and	  throat	  or	  GIT	  
area;	  neuromuscular	   impairment,	  e.g.	  dysphagia;	   increased	  nutritional	  need,	  e.g.	  sepsis,	  anorexia;	  and	  
inflammation	  processes,	  e.g.	  stomatitis,	  esophagitis.27	  
	  
The	  indication	  for	  EN	  should	  be	  regularly	  controlled	  and	  continually	  assessed.	  Compared	  to	  PN,	  enteral	  
tube	  feeding	  shows	  several	  advantages28:	  
-­‐ Lower	  complication	  rates	  
-­‐ More	  cost-­‐effective	  
-­‐ Increased	  patient	  safety	  and	  easy	  practicability	  
-­‐ High	  acceptance	  by	  the	  patients	  
-­‐ Structural	   and	   functional	   maintenance	   of	   gastrointestinal	   function	   (prevention	   of	   mucosal	  
atrophy	  and	  mucosal	  barrier	  against	  pathogens;	  intestinal	  immune	  system)	  
When	  the	  gastrointestinal	  function	  is	  insufficient	  or	  not	  accessible,	  or	  the	  patient	  has	  severe	  metabolic	  
and	  circulatory	  instability,	  EN	  should	  not	  be	  used	  or	  should	  be	  stopped.29	  
	  
2.2.2 (Home)	  Parenteral	  nutrition	  
PN	   is	   indicated	  when	  the	  gut	   is	  not	   functioning	  or	  accessible.	  The	  American	  Society	  of	  Parenteral	  and	  
Enteral	  Nutrition	   (ASPEN)	  defines	  PN	  as:	   the	   intravenous	   administration	  of	   nutrients,	   either	  delivered	  
through	   a	   central	   vein,	   usually	   the	   superior	   vena	   cava,	   or	   through	   a	   peripheral	   vein.	   Thus,	   water,	  
nutrients	  such	  as	  amino	  acids,	  glucose,	  lipids,	  electrolytes,	  vitamins	  and	  trace	  elements	  are	  administered	  
intravenously.24,30	  
	  
Comparing	  EN	  with	  PN,	  PN	  provides	   standardised	  administration	  of	   substrates	   ready	   for	   intermediate	  
metabolism	  into	  the	  blood	  stream	  in	  gastrointestinal	  dysfunction	  (digestion,	  absorption).	  However,	  this	  
intravenous	  nutrition	   is	   less	   physiological	   than	   EN	   and	   there	   is	   a	   higher	   complication	   rate	   due	   to	   the	  
parenteral	   administration.	   Last	   but	   not	   least,	   PN	   is	   more	   expensive	   and	   requires	   a	   higher	   level	   of	  
instruction	   and	   monitoring.31,32	   Advances	   in	   (H)PN	   regarding	   nutritional	   products	   and	   their	   delivery	  
(catheters),	  monitoring	  and	  care	  enable	  many	  patients	   to	   live	  at	  home	  and	   to	  have	  a	  good	  or	  almost	  
reasonable	   QoL	   in	   their	   normal	   environment	   instead	   of	   prolonged	   hospital	   stays.	   (H)PN	   can	   be	   a	  
lifesaving	  or	  life	  extending	  therapy.33	  
	  
2.2.2.1 Prevalence	  of	  home	  parenteral	  nutrition	  
It	   is	   difficult	   to	   estimate	   the	   prevalence	   of	   HPN	   patients,	   because	   there	   are	   global	   differences	   in	   the	  
organisation	   of	   care,	   the	   inclusion	   and	   management	   of	   the	   patients.	   A	   European	   survey	   reported	   a	  
2.2	  	  CLINICAL	  NUTRITION	  
8	  
prevalence	  of	  2-­‐40	  HPN	  patients	  per	  million	  inhabitants	  and	  an	  incidence	  of	  4-­‐6	  per	  million	  per	  year	  for	  
HPN	  patients	  with	  benign	  underlying	  diseases.34,35	  Since	  its	  beginning	  in	  the	  1970’s,	  the	  prevalence	  and	  
incidence	  of	  HPN	  usage	  in	  Europe	  has	  been	  continually	  increasing	  and	  is	  approaching	  US	  values.	  This	  is	  
mainly	  due	  to	  shorter	  HPN	  in	  patients	  with	  terminal	  diseases,	  e.g.	  cancer.33,36	  A	  recent	  study	  conducted	  
in	  Switzerland	  showed	  a	  prevalence	  of	  four	  HPN	  patients	  per	  one	  million	  inhabitants	  in	  Switzerland	  and	  
is	  therefore	  comparable	  with	  other	  European	  countries.37	  
	  
2.2.2.2 Indications	  for	  (home)	  parenteral	  nutrition	  in	  adults	  
PN	  is	  indicated	  when	  oral	  and/or	  EN	  is	  not	  possible	  for	  more	  than	  three	  days	  or	  contraindicated	  because	  
of	   a	   partial	   or	   totally	   non-­‐functional	   GIT.	   Consequently,	   it	   is	   not	   possible	   or	   insufficient	   to	   cover	   the	  
nutritional	  requirements	  by	  the	  enteral	  route	  and	  to	  treat	  or	  prevent	  malnutrition.38	  If	  the	  patient	  can	  
cover	  <75%	  of	  his	  energy	  requirement	  through	  EN,	  the	  commencement	  of	  PN	  should	  be	  evaluated.24	  For	  
example,	   in	   patients	   with	   intestinal	   failure	   and	   an	   impaired	   liquid,	   electrolytes	   or	   micronutrients	  
balance,	  who	  are	  not	  able	  to	  cover	  their	  protein-­‐energy	  requirement	  by	  enteral	   intake,	  total	  or	  partial	  
PN	   is	   indicated.	  Reasons	   for	  an	   intestinal	   failure	  are	  obstruction,	  dysmotility,	   surgical	   resection	   (Short	  
Bowel	  Syndrome),	  a	  congenital	  defect	  or	  disease	  associated	  with	  impaired	  absorption.39	  Indications	  are	  
severe	   diarrhea	   or	   vomiting,	   high-­‐output	   fistula,	   perforation	   or	   obstruction	   of	   the	   GIT,	   after	   surgical	  
interventions	   (e.g.	   after	   bariatric	   surgery),	   patients	   with	   cancer,	   inflammatory	   bowel	   diseases	   like	  
Crohn`s	   disease	   or	   severe	   neurological	   disorders.	   In	   particular,	   a	   further	   increase	   in	   cases	   following	  
bariatric	  surgery	  are	  expected	  in	  the	  future.37	  On	  the	  other	  hand,	  indications	  such	  as	  AIDS	  will	  disappear	  
because	  of	  the	  improved	  treatment	  possibilities	  in	  the	  recent	  years.	  	  
	  
HPN	  support	   is	   indicated	   in	  patients	  who	  cannot	  meet	  their	  nutritional	  requirement	  by	  oral	  or	  enteral	  
intake	   but	   are	   able	   to	   receive	   their	   therapy	   outside	   the	   hospital.11	   The	   indication	   for	   HPN	   should	   be	  
checked	  monthly	  in	  the	  first	  three	  months	  and	  thereafter	  quarterly.3	  
	  
2.2.2.3 Contraindications	  for	  parenteral	  nutrition	  
When	  a	   functioning	  GIT	   can	   absorb	   adequate	  macro-­‐	   and	  micronutrients,	   PN	   is	   not	   allowed.	  Another	  
contraindication	  for	  PN	  is	   impossible	  venous	  access	  (technical	  problems)	  or	  when	  the	  risks	  exceed	  the	  
benefits	  of	  PN.	  Absolute	  contraindications	  are	  life	  threatening	  situations	  where	  survival	  measures	  have	  
priority	  over	  nutritional	  needs,	  e.g.	  state	  of	  shock,	  severe	  acidosis	  pH	  <7.2,	  hypercapnia	  pO2	  >75	  mmHg,	  
hypoxia	  -­‐	  pO2	  <50	  mmHg,	  ethical	  considerations	  or	  refusal	  by	  the	  patient.21	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2.2.2.4 Parenteral	  nutrition	  substrates	  and	  requirements	  	  
Depending	  upon	  the	  patient’s	  additional	  food	  intake	  (oral	  and/or	  enteral),	  the	  correct	  and	  individualised	  
PN	   formulation	   has	   to	   be	   chosen:	   total	   or	   complete	   PN	   including	   all	   nutrient	   requirements	   in	   the	  
absence	   of	   significant	   oral	   or	   enteral	   intake	   or	   partial	   PN,	   in	   which	   only	   the	   absent	   portions	   are	  
administered	   parenterally	   to	  meet	   optimal	   requirements.	   Complete	   PN	   is	   composed	   of	   amino	   acids,	  
carbohydrates,	  fat,	  water,	  electrolytes,	  vitamins	  and	  trace	  elements.	  The	  exact	  nutritional	  requirements	  
of	  a	  patient	  have	  to	  be	  determined,	  taking	  into	  consideration	  the	  metabolic	  situation	  (stress	  situation)	  
and	   the	  nutritional	   status.	  The	   following	   subchapters	   refer	   to	  general	   recommendations	  of	   substrates	  
and	  their	  requirements	  in	  adults.	  
2.2.2.4.1 Carbohydrates	  
Carbohydrates	   are	   a	   vital	   substrate	   improving	   the	   nitrogen	  balance	   through	   an	   anabolic	   and	   protein-­‐
saving	   effect.	   In	   most	   PN	   for	   adults,	   they	   cover	   50-­‐60%	   of	   the	   non-­‐protein-­‐energy	   during	   artificial	  
nutrition,	  comparable	  to	  normal	  food.	  Four	  kcal,	  resp.	  16	  kJ	  are	  obtained	  per	  gram	  of	  carbohydrates.	  In	  
general,	  high	  concentrated,	  hypertonic	  glucose	  solutions	  (up	  to	  50%,	  respectively	  500	  g/L)	  are	  used	  to	  
provide	  the	  physiological	  substrate	  and	  are	  now	  the	  only	  form	  used	  in	  PN.	  The	  energy	  requirement	  for	  
an	   adult	   depends	  upon	  his	   specific	  metabolic	   situation,	   disease-­‐specific	   aspects	   and	  activity	   level	   and	  
amounts	  to	  25-­‐35	  kcal/kg	  of	  body	  weight	  per	  day	  (basal	  energy	  requirement).	  The	  basal	  metabolic	  rate	  
is	  then	  multiplied	  by	  an	  activity	  or	  stress	  factor.	  The	  energy	  expenditure	  must	  be	  considered	  in	  relation	  
to	   the	   parenteral	   administration	   of	   glucose,	   because	   there	   are	   limits	   of	   glucose	   oxidation.	  
Carbohydrates	  can	  be	  stored	  only	  in	  limited	  amounts	  as	  glycogen	  in	  the	  liver	  or	  in	  the	  musculature.40	  
	  
The	  gluconeogenesis	   is	   elevated	   in	   stress	   situations,	   e.g.	   critically	   ill	   patients.	   The	   initial	   ebb	  phase	  of	  
post-­‐aggression	   metabolism	   with	   hyperinflammation	   and	   high	   glucose	   energy	   consumption	   is	  
characterised	   by	   catabolic	   processes	   (proteolysis)	   caused	   by	   the	   massive	   increase	   of	   catecholamine	  
release	   and	   other	   stress	   factors.	   During	   the	   post-­‐aggression	   phase	   (parenteral)	   nutrition	   is	   mainly	  
indicated	  as	  protein-­‐saving	  measure.	  In	  the	  following	  anabolic	  phase	  (flow	  phase),	  the	  needed	  synthesis	  
process	   is	   increased	   and	   the	   exogenous	   glucose	   recovery	   is	   used	   again.	   In	   adults,	   the	   recommended	  
max.	  daily	  glucose	  dose	  is	  3-­‐4	  g/kg	  body	  weight	  infused	  over	  24	  hours	  or	  max.	  5-­‐7	  mg/kg	  body	  weight	  
per	  minute.	  Accordingly,	  the	  glucose	  dose	  in	  PN	  determines	  the	  administration	  rate	  or	  the	  duration	  of	  
daily	  PN.	  Greater	  amounts	  of	  exogenously	  administered	  glucose	  are	  metabolised	  into	  fat,	  resulting	  in	  a	  
fatty	   liver	  because	  the	  high	  administration	  of	  glucose	   is	  too	  high.	  The	  administration	  of	  carbohydrates	  
together	  with	  amino	  acids	  (and	  lipid	  emulsion)	  is	  the	  most	  effective	  way	  to	  enhance	  protein	  saving.	  This	  
mixed	  infusion	  is	  the	  most	  common	  type	  in	  hospitals.40	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2.2.2.4.2 Lipids	  
Lipids,	   administered	   as	   lipid	   emulsions	   in	   PN	  
admixtures,	   are	   an	   energy	   source	   contributing	   20-­‐40%	  
to	   the	   non-­‐protein-­‐energy	   requirement.	   They	   are	   also	  
essential	   nutrients	   as	   components	   of	   cell	   membranes	  
(phospholipids,	   glycolipids	   and	   cholesterol	   as	   the	  main	  
structural	   components	   of	   cell	   membranes),	   precursors	  
for	   hormone	   build-­‐up	   and	   for	   eicosanoids	   and	   their	  
kinin	  derivatives.	  Parenteral	  lipid	  emulsions	  are	  10-­‐20%	  
oil	  in	  water	  (O/W)	  emulsions	  containing	  a	  different	  fatty	  
acids	   profile.	   Quantitatively,	   the	   most	   important	   fatty	  
acids	   compound	   in	   EN	   and	   PN	   are	   triglycerides,	  which	  
are	   stabilised	   with	   lecithin	   emulsifiers	   (important	  
phosphate	   source	   of	   ca.	   15	   mM	   in	   commercial	   lipid	  
emulsions).	  The	  phosphoric	  acid	  and	  the	  choline	  build	  the	  polar	  part	  of	  lecithin,	  which	  is	  hydrophilic	  and	  
serves	   to	   increase	   the	  solubility	  of	   the	   lipids	  and	   thus	  guarantees	   the	  emulsification	  of	   the	   fatty	  acids	  
(Table	  1).41	  	  
	  
In	  contrast	  to	  the	  glucose	  solutions,	  lipid	  emulsions	  have	  a	  high	  energy	  density	  (9	  kcal/g	  lipid)	  and	  a	  low	  
osmolarity	   (ca.	   300	   mosm/L),	   are	   almost	   pH	   neutral,	   and	   can	   therefore	   also	   be	   administered	  
peripherally.	  As	  a	   consequence,	  high	   infusion	   rates	  of	  glucose	  can	  be	  avoided	  and	  hyperglycemia	  and	  
hepatic	  steatosis	  can	  be	  prevented.	  Moreover,	   these	  are	   important	   for	  the	  provision	  of	  essential	   fatty	  
acids	  as	  PN	  without	  lipids	  can	  lead	  to	  subnormal	  serum	  levels	  of	  essential	  fatty	  acids	  within	  one	  week.	  
The	  recommended	  daily	  dose	  for	  parenteral	   lipid	  emulsions	   in	  adults	   is	  0.7-­‐1.3	  g	  triglycerides/kg	  body	  
weight	  (max.	  1.5	  g/kg	  body	  weight	  in	  post-­‐aggression	  metabolism	  with	  impaired	  glucose	  tolerance).	  An	  
excessive	   lipid	   intake	   can	   lead	   to	   fat	   overload	   syndrome,	   accompanied	   by	   fever,	   icterus,	  
hepatosplenomegaly,	   thrombocytopenia,	   metabolic	   acidosis	   and	   hypoalbuminemia.	   Therefore,	   the	  
concentration	  of	  triglycerides	  should	  be	  monitored	  and	  controlled	  at	  <400	  mg/dL	  (4.6	  mmol/L).41	  
	  
There	   are	   various	   types	   of	   fatty	   acids	   emulsions,	   such	   as	   long-­‐chain-­‐triglycerides	   (LCT;	   16	   carbons	   or	  
more),	  medium-­‐chain-­‐triglycerides	  (MCT;	  8-­‐14	  carbons),	  structured	  lipids,	  olive	  oil	  or	  mixed	  emulsions.	  
Saturated,	  monounsaturated	  (MUFA)	  and	  polyunsaturated	  (PUFA)	  fatty	  acids	  are	  distinguished	  by	  their	  
metabolic	   behavior	   and	   physiologic	   effects.	   Saturated	   fatty	   acids	   contribute	   as	   energy	   source,	   while	  
PUFAs	  are	  part	  of	  structural	  lipids.	  Omega-­‐6-­‐fatty	  acids	  and	  Ω-­‐3-­‐fatty	  acids,	  belong	  to	  the	  essential	  fatty	  




à	  in	  egg	  yolk,	  soya	  beans	  
à	  antioxidative,	  emulsifying	  
à	  component	  of	  the	  cell	  membranes	  
à	  amphiphilic	  
Table	  1:	  Lecithin	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administration	  of	   lipid	   emulsions	   containing	  oleic	   acid	   (Ω-­‐9-­‐MUFA),	   a	  high	   administration	  of	  Ω-­‐6-­‐fatty	  
acids	  (and	  the	  related	  risk	  of	  an	  increased	  lipid	  peroxidation)	  can	  be	  reduced	  and	  the	  PUFA	  profile	  can	  
be	  modulated.	  Oleic	  acid	   is	  present	   in	  high	  concentrations	   in	  olive	  oil.	  Olive	  oil	  and	  soya	  oil	  emulsions	  
contain	  biologically	  active	  vitamin	  E	   (α-­‐tocopherol)	  as	  an	  anti-­‐oxidative	  protection.	  An	  additional	  need	  
for	  vitamin	  E	  is	  necessary	  to	  protect	  the	  lipids	  (principally	  PUFAs)	  from	  lipid	  peroxidation	  and	  to	  deliver	  
supplementary	  vitamin	  E.	  According	  to	  dietary	  guidelines	  0.5	  mg	  α-­‐tocopherol	  is	  needed	  to	  protect	  1	  g	  
of	  PUFA	  from	  peroxidation.42	  More	  about	  the	  lipid	  peroxidation	  is	  detailed	  in	  Chapter	  2.3.1.1.	  
	  
	  	  Table	  2:	  Characteristics	  of	  Ω-­‐6-­‐	  and	  Ω-­‐3-­‐PUFAs	  
Ω-­‐6-­‐PUFA	  







à	  mostly	  in	  sunflower,	  rape,	  and	  soya	  oils	  
à	  arachidonic	  acid	  (C20-­‐4)	  
à	  proinflammatory	  	  
à	  prostaglandins	  and	  thromboxanes	  (n-­‐2-­‐serie)	  
	  	  	  	  	  leukotrienes	  (n-­‐4-­‐serie)	  









à	  mostly	  in	  rape,	  soya,	  linseed,	  and	  fish	  oils	  
à	  eicosapentaenoic	  acid	  (EPA;	  C20-­‐5)	  
à	  anti-­‐inflammatory	  	  
à	  prostaglandins	  and	  thromboxanes	  (n-­‐3-­‐serie)	  
	  	  	  	  	  leukotrienes	  (n-­‐5-­‐serie)	  
à	  e.g.	  vascular	  tone	  ê,	  platelet	  aggregation	  ê	  
	  
LCT	  emulsions	  are	  manufactured	  on	  a	  base	  of	  soya	  oil	  and	  contain	  a	  high	  ratio	  of	  pro-­‐inflammatory	  Ω-­‐6-­‐
fatty	  acids.	  The	  ratio	  of	  Ω-­‐6-­‐PUFA	  to	  Ω-­‐3-­‐PUFA	  is	  8:1.	  MCTs	  are	  better	  tolerated	  in	  patients	  because	  they	  
do	  not	  serve	  as	  a	  source	  for	  the	  synthesis	  of	  pro-­‐inflammatory	  mediators	  and	  also	  because	  they	  can	  be	  
oxidised	  directly	   in	  the	  mitochondria,	   independent	  from	  carnitine.	  Often,	  MCTs	  and	  soya	  oil	  are	  mixed	  
(MCT/LCT	  emulsions).	  The	  available	  olive	  oil-­‐based	  lipid	  emulsions	  contain	  olive	  oil	  and	  soya	  oil	  (ration	  
4:1)	  and	  show	  a	  high	  ratio	  of	  MUFA.	  The	  ratio	  of	  Ω-­‐6-­‐PUFA	  to	  Ω-­‐3-­‐PUFA	  is	  9:1.	  Additionally,	  there	  are	  
fish	   oil-­‐based	   emulsions,	   containing	   Ω-­‐3-­‐PUFA,	   mainly	   as	   eicosapentaenoic	   acid	   (EPA)	   and	  
docosahexaenoic	  acid	  (DHA).41	  Omega-­‐3-­‐PUFAs	  are	  part	  of	  the	  cellular	  membrane	  and	  can	  influence	  the	  
membrane	   fluidity,	   regulate	   ion	   channels,	  modulate	   hormonal	   activity,	   have	   immunologic	   effects	   and	  
influence	   the	  gene	  expression.43	  Apart	   from	   these	  physical	   admixtures,	   there	  are	  also	   structured	   lipid	  
emulsions,	   containing	  mixed	   triglycerides	  with	  Ω-­‐6	   and	  Ω-­‐3	   LCTs	   and	  MCTs.	   For	   example,	   SMOFlipid®	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containing	  Soya	  oil	  (30%),	  MCT	  (30%),	  Olive	  oil	  (25%)	  and	  Fish	  oil	  (15%),	  resulting	  in	  an	  optimal	  ratio	  of	  
Ω-­‐6-­‐PUFA	  to	  Ω-­‐3-­‐PUFA	  of	  2.5:1.	  The	  addition	  of	  EPA	  and	  DHA	  to	  lipid	  emulsions	  has	  positive	  effects	  on	  
the	   cell	  membrane	   and	   inflammatory	   processes.	   It	   is	   also	   likely	   that	   fish	   oil	   enriched	   lipid	   emulsions	  
decrease	  LOS	  in	  critically	  ill	  patients.44	  
2.2.2.4.3 Amino	  acids	  
Amino	   acids	   can	   be	   divided	   into	   essential,	   unessential	   and	   semi-­‐essential	   amino	   acids	   (Table	   3).	  
Solutions	  of	  crystalline	  amino	  acids	  are	  difficult	  to	  handle	  because	  of	  the	  bad	  solubility	  of	  some	  amino	  
acids,	  e.g.	  tyrosine,	  cysteine,	  or	  the	  instability	  in	  aqueous	  solutions.	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Table	  3:	  Classification	  of	  amino	  acids45	  






















In	   adult	   patients	   with	   normal	   organ	   function	   and	   a	   balanced	   metabolism	   0.8-­‐1.0	   g	   protein/kg	   body	  
weight	  is	  recommended	  daily;	  and	  in	  an	  altered	  metabolic	  situation	  1.2-­‐1.5	  g/kg	  body	  weight,	  resp.	  15-­‐
23	  mg	  N	  (nitrogen)/kg	  body	  weight	  per	  day	   (100	  g	  amino	  acids	  ≈	  6.4	  g	  N).	  Patients	  with	  chronic	  renal	  
insufficiency	  (without	  hemodialysis)	  should	  receive	  more	  than	  0.6	  g/kg	  body	  weight	  of	  amino	  acids	  per	  
day.	  In	  a	  normal	  anabolic	  metabolic	  situation,	  a	  nitrogen-­‐energy-­‐ratio	  of	  1:130	  to	  1:170	  (g	  N/kcal)	  resp.	  
1:20	  to	  1:27	  (g	  amino	  acids/kcal)	   is	  recommended.	   In	  PN	  admixtures,	  the	  proportion	  of	  amino	  acids	   is	  
around	  20-­‐150	   g/L.45	   The	  protein	   turnover	   in	   stress	   situations	   (trauma,	   burns,	   infections)	   is	   increased	  
(10-­‐30%),	   indicating	  an	  increased	  protein	  breakdown	  and	  synthesis,	  but	  resulting	  in	  a	  negative	  protein	  
balance.46	  
2.2.2.4.4 Water	  and	  electrolytes	  
The	  water-­‐electrolyte	  balance	  includes	  the	  physiological	  system	  of	  absorption	  and	  release	  of	  water	  and	  
the	   closely	   related	   regulation	   of	   electrolytes.	   The	   calculation	   of	   the	   appropriate	   requirements	   is	  
important	   and	   their	   provision	   should	   be	   adjusted	   to	   the	   clinical	   situation.	   Calculation	   of	   the	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administration	  of	  fluids	   in	  patients	  with	  PN	  should	   include	  the	  PN	  itself,	  oral	  and	  enteral	  administered	  
fluids	  as	  well	  as	  other	  infusions	  and	  fluid	  loss	  from	  diarrhea,	  severe	  vomiting,	  fistula,	  severe	  burns,	  etc.	  
The	   normal	   fluid	   requirement	   of	   adults	   amounts	   to	   about	   30-­‐40	  mL/kg	   body	   weight	   per	   day,	   but	   is	  
higher	  in	  the	  case	  of	  extrarenal	  or	  renal	  fluid	  losses	  or	  in	  fever	  (10	  mL/kg	  body	  weight	  per	  1	  °C	  increase	  
of	   temperature	   >37	   °C).	   Daily	   weighing	   is	   the	   only	   way	   to	   monitor	   the	   external	   water	   balance;	   and	  
examination	  of	  the	  patient	  for	  evidence	  of	  dehydration,	  oedema,	  etc.	  can	  support	  it.47	  
	  
In	  multichamber	  bags,	  electrolytes	  are	  already	  included	  at	  standard	  doses	  in	  the	  amino	  acid	  solution	  of	  
a	  PN	  admixture.	  Before	  starting	  PN,	  the	  serum-­‐electrolyte-­‐concentration	  of	  sodium,	  potassium,	  calcium,	  
magnesium	  and	  phosphate	  must	  be	  determined.47	  A	  patient	  with	  a	  normal	  fluid	  and	  electrolyte	  balance	  
receives	  standardised	  amounts	  of	  electrolytes	  in	  PN48:	  
-­‐ 60-­‐150	  mmol	  sodium	  
-­‐ 40-­‐100	  mmol	  potassium	  
-­‐ 4-­‐12	  mmol	  magnesium	  
-­‐ 2.5-­‐7.5	  mmol	  calcium	  
-­‐ 10-­‐30	  mmol	  phosphate	  
In	   special	   indications,	   e.g.	   renal	   insufficiency,	   electrolyte-­‐free	   solutions	   are	   required.	   Higher	   need	   of	  
specific	   electrolytes	   has	   to	   be	   discussed	   with	   the	   pharmacist	   and	   stability	   and	   compatibility	   related	  
questions	  have	  to	  be	  considered	  (see	  Chapter	  2.3.1.2).	  Additional	  venous	  access	  (as	  separate	  infusions)	  
would	  make	  sense.	  Multivalent	  cations,	  e.g.	  calcium,	  can	  precipitate	  in	  the	  presence	  of	  a	  high	  amount	  of	  
anorganic	   phosphate.	  Organic	   salts	   can	   prevent	   such	   complications	   (more	   details	   in	   Chapter	   2.3.1.2).	  
Certain	  amino	  acids	  can	  chelate	  multivalent	  cations,	  reducing	  chemical	  reaction.47	  
2.2.2.4.5 Vitamins	  and	  trace	  elements	  
All	  lipid	  and	  water-­‐soluble	  vitamins	  and	  trace	  elements	  have	  to	  be	  substituted	  parenterally	  in	  a	  total	  PN	  
therapy	   (duration	   >1	   week).	   The	   recommended	   daily	   allowance	   (RDA)	   has	   to	   be	   reconsidered	   when	  
adjusting	  the	  dosage,	  except	  in	  special	  risk	  situations,	   in	  which	  an	  increased	  demand	  is	  needed,	  e.g.	   in	  
patients	   with	   trauma,	   burns,	   liver	   diseases,	   etc.47	   Ready-­‐made	   vitamin	   products	   (with	   lipid	   or	   water-­‐
soluble	  vitamins)	  like	  Soluvit®,	  Vitalipid®	  or	  Cernevit®	  or	  trace	  elements	  products	  such	  as	  Addaven®	  are	  
available.	  The	  estimated	  daily	  requirement	  for	  adults	  is	  shown	  in	  Table	  4.	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Soluvit®	   Vitalipid®	   Cernevit®	  
Vitamin	  B1	  	  Thiamin	   6	  mg	   3.1	  mg	   -­‐	   3.51	  mg	  
Vitamin	  B2	  Riboflavin	   3.6	  mg	   4.9	  mg	   -­‐	   4.14	  mg	  
Vitamin	  B6	  Pyridoxin	   6	  mg	   4.9	  mg	   -­‐	   4.53	  mg	  
Vitamin	  B12	  Cobolamin	   5	  µg	   5	  µg	   -­‐	   6	  µg	  
Pantothenic	  acid	   15	  mg	   16.5	  mg	   -­‐	   17.25	  mg	  
Niacin	   40	  mg	   40	  mg	   -­‐	   46	  mg	  
Biotin	   60	  µg	   60	  µg	   -­‐	   69	  µg	  
Folic	  acid	   600	  µg	   400	  µg	   -­‐	   414	  µg	  
Vitamin	  C	   200	  mg	   113	  mg	   -­‐	   125	  mg	  
*Vitamin	  A	  Retinol	   3300	  IU	   -­‐	   3300	  IU	   3500	  IU	  
*Vitamin	  D	  Calciferol	   200	  IU	   -­‐	   200	  IU	   220	  IU	  
*Vitamin	  E	  Tocopherol	   10	  IU	   -­‐	   10	  IU	   11.2	  IU	  




Addaven®	   	   	  
Chromium	   10-­‐20	  µg	   10	  µg	   	   	  
Copper	   0.3-­‐1.2	  mg	   0.38	  mg	   	   	  
Iodine	   70-­‐140	  µg	   130	  mg	   	   	  
Iron	   1-­‐1.5	  mg	   1.1	  mg	   	   	  
Manganese	   0.2-­‐0.8	  mg	   0.05	  mg	   	   	  
Selenium	   20-­‐80	  µg	   79	  µg	   	   	  
Zinc	   2.5-­‐4	  mg	   5	  mg	   	   	  
	  
2.2.2.5 Methods	  for	  administration	  of	  parenteral	  nutrition	  
The	  composition	  of	  the	  PN	  admixture	  (osmolarity)	  defines	  the	  central	  venous	  or	  the	  peripheral	  access.	  
PN	   can	  also	  be	  administered	  via	   an	  arteriovenous	   shunt,	   as	  used	   for	  haemodialysis.	  Complete	   (total),	  
long-­‐term	   PN	   requires	   central	   venous	   access	   because	   of	   the	   high	   osmolarity	   (≥800	   mosmol/L);	   a	  
commercialised	   total	   PN	   admixture	   has	   an	   osmolarity	   of	   about	   1500	  mosmol/L	   (Smofkabiven®).	   The	  
right	   internal	   jugular	   vein	   or	   the	   right	   subclavian	   vein	   are	   the	  most	   frequently	   chosen	   access	   points;	  
subclavian	  access	  being	  preferred.	  Mostly,	  the	  catheter	  tip	  is	  located	  in	  the	  lower	  third	  of	  the	  superior	  
vena	  cava,	  at	  the	  atriocaval	  junction	  or	  in	  the	  upper	  third	  of	  the	  right	  atrium.	  The	  catheter	  tip	  has	  to	  be	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located	   under	   fluoroscopic	   or	   ultrasound	   guidance	   or	   the	   position	   has	   to	   be	   checked	   by	   x-­‐ray	   after	  
insertion.	  This	  reduces	  the	  risk	  for	  local	  complications	  significantly.49	  	  
	  
For	  short-­‐term	  PN	  in	  the	  hospital,	  non-­‐tunneled	  central	  venous	  catheters	  (CVCs)	  or	  peripherally	  inserted	  
central	  catheters	  (PICCs)	  are	  used.	  A	  PICC	  is	  another	  type	  of	  catheter	  with	  a	  smaller	  diameter	  and	  has	  
the	   advantage	   of	   the	   elimination	   of	   the	   risk	   of	   complications	   of	   direct	   jugular	   or	   subclavian	  
catheterisation	   and	   the	   more	   facilitated	   insertion,	   but	   the	   patient’s	   physical	   activity	   and	   self-­‐
management	  is	  limited.	  For	  long-­‐term	  PN	  (>3	  weeks)	  and	  especially	  for	  HPN	  patients,	  tunneled	  CVCs	  like	  
Hickman	   or	   Broviac	   catheters	   or	   totally	   implanted	   ports	   are	   used.	   Port	   systems	   are	   often	   used	   for	  
patients	   with	   chemotherapy	   and	   requiring	   PN	   simultaneously	   in	   order	   to	   increase	   the	   safety	   and	  
comfort	   of	   the	   patient	   and	   for	   financial	   aspects.	   These	   are	   usually	  made	   of	   polyurethane	   or	   silicone.	  
There	  are	  catheters	  with	  a	  single,	  double	  or	   triple	   lumen;	   for	  patients	   in	   the	  hospital,	  a	  double	   lumen	  
catheter	  is	  often	  used	  in	  order	  to	  avoid	  mixing	  of	  PN	  admixtures	  and	  other	  infused	  medications.49	  
	  
Indications	  for	  peripheral	  PN	  are	  short-­‐term	  PN	  for	  less	  than	  seven	  days	  with	  low	  osmolar	  preparations	  
(600(-­‐800)	   mosmol/L).	   Hypertonic	   solutions	   are	   irritants	   to	   the	   veins	   resulting	   in	   phlebitis	   and	  
thrombosis.	  Addition	  of	   fat	  emulsions	   increases	  the	  volume	  and	  reduces	  the	  osmolarity.	  Furthermore,	  
isotonic	   fat	   emulsions	   have	   a	   protective	   effect	   on	   the	   vascular	   endothelium.50	   Ideally,	   the	   cannula	   is	  
inserted	  in	  a	  peripheral	  vein	  on	  the	  dorsum	  of	  the	  hand	  or	  at	  the	  forearm.	  Catheters	  with	  a	  caliber	  of	  18	  
to	   22	   gauge	   are	   normally	   used	   in	   adults.	   Along	   with	   phlebitis,	   complications	   of	   peripheral	   PN	   also	  
include	  thrombosis	  and	  infections.51	  
	  
2.2.2.6 Complications	  of	  parenteral	  nutrition	  and	  prevention	  
PN	  is	  not	  only	  lifesaving,	  but	  can	  also	  be	  accompanied	  by	  different	  complications.	  Mechanical,	  technical,	  
catheter-­‐related	  or	  metabolic	  complications	  can	  occur.	  Furthermore,	  medication	  errors	  can	  also	  occur,	  
which	  can	  be	  prevented	  by	  a	  pharmaceutical	  check.	  In	  this	  chapter,	  only	  catheter-­‐related	  and	  metabolic	  
complications	  with	  a	  pharmaceutical	  aspect	  will	  be	  discussed.	   Incompatibilities	  and	   instabilities	  of	   the	  
PN	  admixture	  will	  be	  discussed	  in	  the	  next	  chapter.	  	  
	  
Most	  of	  these	  complications	  arise	  from	  inadequate	  amounts	  of	  nutrients	  or	  from	  incorrect	  composition	  
or	   administration	  of	   PN	   formulations.	   Individual	  monitoring	   and	  assessment	  of	   nutrient	   requirements	  
and	   administration	   are	   inevitable	   to	   prevent	   such	   administration	   errors	   and	   complications.	   The	  
pharmacist	  has	  an	  advisory	  function	  regarding	  the	  correct	  choice,	  composition,	  and	  administration	  of	  PN	  
and	  the	  additives.	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Catheter-­‐related	  complications	  
Catheter-­‐related	  complications	  are	  divided	   into	  early	   (local	  hematoma	  or	  abscess,	   catheter	  embolism,	  
arrhythmias,	   pneumothorax	   central	   venous	   thrombosis),	   insertion-­‐related	   (arterial	   puncture	  or	   injury)	  
or	  late	  complications.	  Additionally,	  complications	  can	  also	  occur	  as	  a	  result	  of	  poor	  management	  or	  care.	  
Technical	  complications	  include	  insertion	  problems,	  dislocation	  of	  the	  catheter	  or	  wrong	  position	  of	  the	  
catheter	  tip.52	  Another	  complication	  with	  CVCs	  are	   intraluminal	  occlusions	  (0.07	  episodes	  per	  catheter	  
year),53,54	   which	   can	   occur	   because	   of	   lipid	   aggregates,	   precipitates	   of	   drugs/electrolytes	   or	   blood	  
clotting	   and	   can	   be	   prevented	   by	   appropriate	   nursing	   measures.	   To	   prevent	   such	   mechanical	  
complications,	  a	  CVC	  not	   in	  use	  should	  be	  flushed	  and	  blocked	  with	   isotonic	  sodium	  chloride	  solution.	  
Heparin	   should	   not	   be	   used	   as	   a	   flushing	   or	   locking	   solution	   because	   of	   numerous	   incompatibilities.	  
Should	   an	   occlusion	   occur,	   a	   first	   corrective	   measure	   is	   aspiration	   with	   0.9%	   NaCl,	   followed	   by	   an	  
injection.	  Where	  a	   suspected	  occlusion	   is	   caused	  by	  blood	  clots,	  urokinase	   is	  used,	  and	   in	   the	  case	  of	  
lipid	  aggregates	  (developed	  slowly	  over	  days),	  sodium	  hydroxide	  (0.1	  N	  NaOH)	  is	  used,	  always	  injected	  
with	  a	  10	  mL	  syringe	  or	  bigger	  so	  there	  is	  not	  too	  much	  pressure.49,55	  Physicochemical	  precipitates,	  e.g.	  
unsoluble	   crystals,	   caused	   by	   drugs	   or	   electrolytes	   such	   as	   calcium	   or	   phosphate,	   can	   be	   formed	   by	  
incompatibilities	  between	  these	  components.	  Important	  are	  the	  calcium	  phosphate	  precipitates,	  which	  
can	  be	   influenced	  by	   the	  amino	  acid	   composition	  of	   the	  PN	  admixture,	   relative	   calcium	  or	  phosphate	  
content,	   temperature,	   pH,	   etc.	   In	   such	   instances,	   occlusions	   like	   this	   can	   try	   to	  be	  dissolved	  with	  pH-­‐
changes	  (using	  0.1	  N	  NaOH	  or	  0.1	  N	  HCl)	  (more	  details	  in	  Chapter	  2.3.2.1).56,57,58	  
	  
Catheter-­‐related	   bloodstream	   infections	   are	   the	  most	   common	   and	   severe	   complications	   in	   patients	  
with	  PN.	  In	  hospitalised	  patients,	  0.45-­‐1	  infections/catheter	  year	  appear	  and	  HPN	  patients	  show	  0.1-­‐0.5	  
infections/catheter	  year.59	  In	  the	  case	  of	  a	  bacterial	  or	  fungal	  colonisation	  of	  the	  catheter,	  patients	  show	  
clinical	   symptoms	   such	  as	   local	   redness,	   swelling,	   pain,	   fever,	   and/or	   an	   increase	   in	   serum-­‐CRP.	  Most	  
common	   infections	  are	  caused	  by	  gram-­‐positive	  bacteria,	  primarily	  by	  staphylococcus	  epidermidis	  and	  
staphylococcus	   aureus,	   also	   known	   as	   physiological	   skin	   bacteria.60	   The	   best	   prevention	  method	   is	   a	  
strict	   asepsis,	   particularly	   regarding	   catheter	   management.	   Proper	   education	   and	   specific	   training	   of	  
staff,	  an	  adequate	  hand	  washing	  procedure,	  choice	  of	  type	  of	  device	  and	  insertion	  site,	  aseptic	  handling,	  
wearing	   of	   sterile	   gloves	   and	   coats,	   and	   correct	   local	   disinfection	   with	   2%	   chlorhexidine	   have	   been	  
shown	  to	  be	  effective	  in	  reducing	  the	  risk	  of	  catheter-­‐related	  infections.	  The	  catheter	  exit	  site	  has	  to	  be	  
dressed	  appropriately	  with	  sterile	  gauze	  or	  foil.	  Moreover,	  no	  blood	  sampling	  should	  be	  done	  using	  the	  
CVC	  and	  neither	   in-­‐line	   filters	   nor	  prophylactic	   antibiotics	   show	  positive	   effects	  on	   the	   infection	   rate.	  
Flushing	  the	  CVC	  after	  each	  use	  with	  0.9%	  NaCl	  is	  the	  best	  preventive	  measure	  against	  blood	  backflow	  
and	  subsequent	  infections.55	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Metabolic	  complications	  	  
These	  complications	  can	  be	  divided	  into	  three	  categories:	  deficiency	  states,	  acute	  and	  chronic	  metabolic	  
complications.	  To	  prevent	  such	  complications,	  a	  detailed	  and	  regular	  lab	  assessment	  of	  the	  patient,	  e.g.	  
glycemic	   control,	   and	   a	   balanced	   nutritional	   intake	   (composition	   of	   PN)	   are	   necessary.	   Deficiencies	  
(electrolytes,	   vitamins,	   trace	   elements,	   essential	   fatty	   acids)	   have	   to	   be	   corrected	   prior	   to	   the	  
prescription	  of	  PN	  in	  order	  to	  prevent	  more	  problematic	  and/or	  acute	  complications.	  Further	  acute	  or	  
chronic	   metabolic	   complications	   are	   hyperglycemia,	   hypertriglyceridemia,	   liver	   steatosis,	   hepatic	  
dysfunctions,	  cholestasis,	  cholecystitis	  or	  bone	  disease.	  The	  latter	  complications	  occur	  mainly	  in	  patients	  
with	   long-­‐term	  PN.	  For	  prophylaxis	  and	  therapy,	  calcium,	  phosphate	  and	  vitamin	  D	  dosages	  should	  be	  
adjusted.	   Bisphosphonates	   can	   be	   given	   to	   patients	   with	   low	   bone	   density.61	   Hepatic	   complications	  
occur	   in	   15-­‐40%	   of	   patients	   with	   PN.	   The	   risk	   for	   developing	   a	   Parenteral	  Nutrition-­‐Associated	   Liver	  
Disease	  (PNALD)	  increases	  in	  patients	  with	  short	  bowel	  syndrome	  (small	  bowel	  <150	  cm),	  absence	  of	  a	  
continual	  colon,	  impaired	  bile	  circulation,	  frequent	  catheter	  infections,	  bacterial	  overgrowth	  of	  the	  small	  
intestine,	  and	  lack	  of	  any	  EN	  or	  hypercaloric	  feeding.11	  
	  
Another	   potentially	   life	   threatening	   metabolic	   complication	   is	   the	   refeeding	   syndrome	   (RFS).	   This	  
syndrome	   occurs	   as	   a	   result	   of	   too	   fast	   or	   inadequate	   refeeding	   in	   patients	   at	   risk	   of	   malnutrition	  
(catabolic).	   The	   most	   important	   clinical	   symptoms	   of	   a	   RFS	   are	   hypophosphatemia	   (<0.32	   mmol/L),	  
tachycardia,	  tachypnea	  and	  oedema.24,62	  Hypophosphatemia	  shows	  symptoms	  such	  as	  rhabdomyolysis,	  
hemolysis,	   respiratory	   insufficiency	   and	   musculoskeletal	   and	   neurological	   impairments.63	   Risk	  
constellations	   leading	   to	   a	   high	   risk	   for	   RFS	   at	   the	   beginning	   of	   refeeding	   are	   patients	  with	   anorexia	  
nervosa,	  those	  who	  have	  gone	  on	  a	  hunger	  strike	  for	  several	  days,	  already	  malnourished	  patients	  with	  
temporarily	  reduced	  nutritional	  intake,	  tumour	  patients	  (heavy	  weight	  loss),	  alcoholic	  and	  patients	  after	  
bariatric	   surgery.	   An	   interdisciplinary	   and	   well-­‐educated	   NST	   is	   inevitable	   for	   prevention,	   early	  
identification	   and	   management	   of	   the	   RFS.	   Also	   in	   the	   sense	   of	   a	   safe	   treatment	   quality	   and	  
maintenance	  of	  the	  patient	  safety.64	  
	  
2.2.2.7 Systems	  for	  parenteral	  nutrition	  
At	  the	  beginning	  of	  PN,	  most	  nutrients	  including	  amino	  acids,	  glucose,	  electrolytes	  and	  lipids	  are	  given	  in	  
parallel	  with	   or	   in	   sequence	   through	   a	   single	   intravenous	   line	   using	   different	   bottles.	   This	  method	   is	  
called	  the	  multiple	  bottle	  system.	  The	  advantage	  of	  this	  system	  is	  the	  possibility	  and	  the	  flexibility	  of	  a	  
dose	  adjustment	  for	  patients	  with	  rapidly	  changing	  needs.	  Disadvantages	  of	  the	  multiple	  bottle	  system	  
are	  the	  numerous	  (6-­‐8)	  bottle	  changes	  every	  day	  with	  different	  flow	  rates.	  As	  a	  consequence,	  solution	  
compounding	   and	   administration	   errors	   are	   common,	   implying	   more	   frequent	   septic	   and	   metabolic	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complications.65	   This	   system	   is	   no	   longer	   state	   of	   the	   art,	   indicating	   too	   many	   handling	   errors,	  
inconvenience	  and	  not	  being	  appropriate	  for	  the	  home	  environment.	  
	  
In	  the	  1970’s,	  Solassol	  introduced	  a	  new	  system	  to	  administer	  PN.	  This	  so	  called	  all-­‐in-­‐one	  system	  (AiO)	  
showed	  improvements	  in	  safety,	  effectiveness,	  tolerance	  and	  convenience	  for	  PN.	  This	  system	  allows	  for	  
administration	   of	   all	   nutrients	   (daily	   requirements),	   water,	   lipids,	   glucose,	   amino	   acids,	   electrolytes,	  
trace	   elements	   and	   vitamins	   from	  one	  bag	   via	   one	   infusion	   line.66	   Advantages	   of	   this	   AiO	   system	  are	  
listed	  below67,68:	  
-­‐ Cost-­‐effective	  (reduced	  manpower	  costs	  in	  preparation,	  handling	  and	  delivery;	  reduced	  costs	  of	  
material)	  
-­‐ Efficient	   and	   safe	   (simultaneous	   administration	   of	   all	   required	   nutrients,	   documented	  
compounding,	  storage	  and	  administration)	  
-­‐ Regular	   and	   continuous	   administration	   (increased	   tolerance	   and	   stability,	   reduced	   risk	   of	  
metabolic	  complications)	  
-­‐ Reduced	  risk	  of	  contamination	  (fewer	  manipulations,	  aseptic	  compounding,	  closed	  system)	  
-­‐ Only	  one	  intravenous	  access	  needed	  
-­‐ Simple	   and	   convenient	   administration	   (standardisation,	   clear	   instructions,	   suitable	   for	   HPN	  
patients)	  
-­‐ Individual	   compounding	   is	   possible	   (patients	   with	   rapid	   changes	   of	   metabolic	   and	   energy	  
requirements,	  e.g.	  intensive	  care,	  volume	  restriction	  or	  long-­‐term	  HPN)	  
The	   advantage	   of	   a	   tailor-­‐made	   compounded	   PN	   AiO	   admixture	   is	   that	   it	   can	   be	   adapted	   per	   the	  
patient’s	  need	  (energy,	  volume,	  substrates).	  This	  personalised	  regimen	  is	  based	  on	  an	  actual	  nutritional	  
assessment	  and	  can	  be	  adapted	  according	  to	  the	  requirements	  of	  acute	  illness.	  These	  formulations	  are	  
prepared	  aseptically	  in	  the	  hospital	  pharmacy	  and	  are	  ready	  to	  use.	  More	  about	  this	  aspect	  is	  discussed	  
in	   Chapter	   2.3	   (Pharmaceutical	   tasks).	   Because	   of	   the	   limited	   stability,	   the	   shelf	   life	   is	   short	   (ca.	   one	  
week)	   and	   requires	   cold	   storage	   (2-­‐8	   °C).	   Additionally	   these	   O/W	   emulsions	   are	   thermodynamically	  
unstable,	   making	   a	   final	   sterilisation	   after	   preparation	   impossible.	   Therefore,	   AiO	   admixtures	   are	  
susceptible	   to	  microbial	   risk.	  Furthermore,	   this	  system	   is	  not	  suitable	  as	  a	  drug	  vehicle,	  because	  of	   its	  
complex	   formulation.	   Last	   but	   not	   least,	   AiO	   systems	   with	   their	   multiple	   components	   show	   many	  
potential	   physicochemical	   instabilities	   (see	   Chapter	   2.3.1).	   Regarding	   some	   pharmaceutical	   quality	  
aspects,	   AiO	   formulations	   demonstrate	   a	   safe,	   effective,	   convenient	   and	   low-­‐risk	   (microbial	  
contamination)	   mode	   of	   PN	   and	   are	   now	   the	   standard	   for	   PN	   formulation.	   They	   are	   individually,	  
aseptically	   compounded	   for	   immediate	   use	   or	   they	   are	   available	   as	   industrially	   manufactured,	  
standardised	  multi-­‐compartment	  containers	  or	  multichamber	  bags	  (Table	  5).	  In	  the	  latter	  instance,	  the	  
different	   components	   (glucose,	   amino	   acids	   and	   lipids)	   are	   contained	   in	   separate	   compartments	   and	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mixed	   just	   before	   administration	   by	   mechanical	   pressing	   by	   hand	   on	   the	   PN	   container	   to	   break	   the	  
individual	   seals.	   Industrial	   multichamber	   bags	   allow	   the	   admixing	   of	   stable	   components	   in	   a	   closed	  
system	   (asepsis)	   directly	   before	   administration.	   The	   ready	   admixture	   is	   then	  homogenised	  by	   turning	  
the	  bag	  several	  times.	  There	  are	  two-­‐chamber	  bags	  without	  lipids	  and	  three-­‐chamber	  with	  them.67,68	  	  


























	   	  
Ready-­‐to-­‐use	   (-­‐)	   (+)	   +	   ++	  
	  
The	   special,	   multilayer	   plastic	   container	   and	   the	   cover	   wrapping,	   which	   also	   serve	   as	   light	   and	   air	  
protection	  (oxygen)	  and	  guarantee	  heat	  sterilisation,	  extend	  the	  shelf	  life	  of	  these	  admixtures.	  The	  shelf	  
life	   of	   these	   commercialised	   (unmixed)	  multichamber	   bags	   is	  more	   than	   12	  months	   and	   they	   can	   be	  
stored	  at	  room	  temperature.	  Commercial	  multichamber	  bags	  are	  compounded	  without	  micronutrients	  
and	  have	  almost	  only	  low	  electrolyte	  content	  because	  of	  high	  incompatibility	  risk	  and	  reduced	  stability.	  
Therefore,	   vitamins,	   trace	   elements	   and	   additional	   electrolytes	   should	   be	   added	   to	   the	   AiO	   directly	  
before	   the	   infusion	   or	   are	   infused	   separately	   at	   the	   end	   of	   the	   PN	   treatment.	   After	  mixing,	   the	   bag	  
should	   be	   stored	   at	   2-­‐8	   °C	   and	   administered	   within	   24	   hours.	   It	   is	   not	   possible	   to	   adapt	   these	  
standardised	   PN	   admixtures	   to	   the	   specific	   individual	   requirements	   of	   patients	   but	   in	   most	   cases,	  
patients	   needing	   PN	   can	   be	   treated	  
initially	   (short-­‐term)	   with	   such	   industrial	  
multichamber	   bags.	   For	   long-­‐term	   HPN,	  
neonates	   or	   critically	   ill	   patients	   in	  
particular,	   such	   standardised	   PN	  
admixtures	   do	   not	   cover	   the	   correct	  
requirements	  and	  the	  compounding	  of	  an	  
individual	  AiO	  admixture	  is	  necessary.69	  	   	  
AiO 
Figure	  1:	  Industrial	  multichamber	  (3-­‐chamber)	  bag	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2.3 Pharmaceutical	  tasks	  in	  the	  nutrition	  team	  –	  with	  focus	  on	  PN	  admixtures	  
Total	   PN	   admixtures	   contain	   more	   than	   50	   individual	   dissolved	   and	   therefore,	   potentially	   reactive	  
components,	   including	  glucose,	  amino	  acids,	   lipids,	  triglycerides	  with	  PUFAs,	  electrolytes,	  vitamins	  and	  
trace	   elements.	   Therefore,	   the	   potential	   physicochemical	   interactions	   between	   the	   components,	   the	  
container	   or	   admixes	   are	   numerous.	   The	   handling	   and	   preparation	   of	   this	   complex	   O/W	   emulsion	  
requires	   pharmaceutical	   expertise	   to	   guarantee	   the	   quality	   of	   the	   product,	   but	   also	   the	   safe	  
administration.70	  
	  
According	  to	  the	  DGEM	  guidelines,	  the	  tasks	  of	  a	  pharmacist	  include	  the	  following69:	  
-­‐ Providing	  pharmaceutical	  advice	  for	  health	  care	  products,	  material	  and	  equipment	  for	  PN	  
-­‐ Checking	   and	   preventing	   potential	   interactions/incompatibilities	   between	   components	   and	  
other	  additives,	  e.g.	  drugs	  
-­‐ Providing	  instructions	  on	  the	  stability	  and	  handling	  of	  PN	  admixtures	  (storage,	  light	  protection,	  
administration,	  etc.)	  
-­‐ Checking	   and	   verifying	   the	   prescription	   of	   a	   PN	   admixture	   for	   individual	   patients,	   their	  
preparation,	  distribution	  and	  final	  inclusion	  in	  the	  treatment	  protocol	  (drugs!)	  
-­‐ Documenting	   and	   checking	   of	   the	   individual	   preparation	   of	   AiO	   admixtures	   (and	   possible	  
additives)	  
-­‐ Advising	  on	  the	  selection,	  composition	  and	  administration	  of	  PN	  
-­‐ Advising	   on	   drug-­‐related	   aspects	   such	   as	   potential	   admixing,	   the	   stability,	   compatibility	   and	  
bioavailability	  
-­‐ Maintaining	  quality	  assurance	  and	  increase	  of	  quality	  and	  drug	  safety	  
-­‐ Advising	  of	  adverse	  reactions	  and	  allergies	  due	  to	  drugs	  or	  nutritional	  components	  
-­‐ Providing	  education	  and	  training	  (health	  care	  professionals,	  patient,	  relatives)	  
Pharmaceutical	  expertise	  is	  necessary	  in	  an	  NST	  to	  guarantee	  the	  quality,	  safety	  and	  effectiveness	  of	  PN	  
(Figure	  2).	  A	  pharmacist’s	  responsibilities	  and	  activities	  include:	  education	  of	  health	  care	  professionals,	  
patients	  and	  their	  relatives;	  adherence	  to	  good	  pharmaceutical	  practice	  principles,	  as	  well	  as	  definition	  
of	   standards	   and	   coordinative	   and	   administrative	   functions;	   quality	   control	   and	   documentation;	  
research	  activities;	  selection	  and	  instruction	  of	  the	  safe	  handling	  of	  nutritional	  products;	  and	  last	  but	  not	  
least,	   the	   formulation	   and	   compounding	   of	   PN	   admixtures	   including	   stability	   and	   compatibility	  
assessments.	   Usually,	   PN	   product	   preparation	   takes	   place	   in	   a	   hospital	   pharmacy,	   ensuring	   the	   best	  
possible	   aseptic	   conditions	   and	   pharmaceutical	   expertise.70,71	   Adequate	   training	   of	   an	   NST	   reduces	  
catheter-­‐related	   complications,	   e.g.	   sepsis,	   or	   other	   mechanical	   or	   metabolic	   complications	   and	  
therefore	   also	   re-­‐admission	   into	   hospital.11	   Pharmaceutical	   advice	   is	   also	   necessary	   to	   avoid	  
incompatibilities	   and	   instabilities,	   especially	   in	   the	   compounding	   process,	   because	   they	   are	   seen	   as	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preventable	   medication	   errors.72	   As	   an	   important	   example	   the	   correct	   dosing	   and	   administration	   of	  
calcium	  and	  phosphate	  is	  shown	  in	  Chapter	  2.3.1.2.	  Also	  errors	  in	  preparation	  (especially	  multiple	  step	  














According	  to	  the	  guidelines,	  an	  AiO	  admixture	  must	  be69:	  
-­‐ “Therapeutically	  and	  pharmaceutically	  suitable	  for	  the	  patient”	  
-­‐ “Free	  of	  microbiological	  impurities	  and	  pyrogenes”	  
-­‐ “Correctly	  dosed	  and	  admixed	  (compatible)”	  
-­‐ “Correctly	  labelled,	  stored	  and	  administered”	  













• Patient (name, date of birth, body weight) 
• Administration date 
• Product details 
- Composition (concentration, daily dosage) 
- Energy and protein content 
- Storage instructions 
- Administration instructions 
- Expiry date (storage and administration 
period) 
• Manufacture identification 
- Date of manufacture 
- Lot number 
- Manufacturer 






ONS,	  EN,	  PN	  
Admixing	  control	  -­‐	  Quality,	  safety	  
GMP	  	  
Pharmacist	  
Figure	  2:	  NST	  -­‐	  Multiprofessional	  process	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Appropriate	  (manufacturing)	  conditions,	  e.g.	  laminar	  air-­‐flow,	  and	  a	  trained	  and	  skilled	  pharmaceutical	  
staff	  are	  preconditions	  for	  a	  strict	  aseptic	  and	  correct	  compounding	  or	  ready-­‐to-­‐use	  preparation	  of	  PN	  
admixtures.	  Good	  Manufacturing	  Practice	  (GMP)	  as	  a	  standard	  of	  quality	  is	  compulsory	  (materials,	  room	  
and	   airflow	   conditions,	   equipment,	   employees	   (training),	   process	   definition,	   documentation,	  
distribution)	   for	   manufacturing	   AiO	   admixtures.	   The	   manufacturing	   process	   needs	   to	   be	   validated	  
regularly	  according	  to	  GMP	  and	  supplementary	  guidelines.74	  Furthermore,	  as	  AiO	  admixtures	  cannot	  be	  
sterilised	  at	   the	  end	  of	  preparation,	  a	   strict	  aseptic	   technique	  and	  sterile	  and	  pyrogene-­‐free	   infusions	  
are	   mandatory	   as	   part	   of	   the	   compounding	   procedure.	   Additionally,	   the	   compounding	   of	   the	   AiO	  
admixture	   after	   a	   defined	   admixture	   sequence	   should	   be	   carried	   out	   as	   close	   as	   possible	   to	   the	  
administration	  time	  because	  of	  stability	  problems.	  Finally,	  pharmaceutical	  evaluation/documentation	  is	  
required	  for	  the	  ready-­‐to-­‐use	  manufacture	  of	  a	  PN	  admixture.	  The	  most	  important	  factors	  are	  shown	  in	  











Figure	  4:	  Important	  factors	  for	  the	  pharmaceutical	  assessment	  of	  a	  PN	  admixture68	  
	  
2.3.1 Compatibility	  and	  stability	  of	  AiO	  admixtures	  
Compatibility	  and	  stability	   tests	  are	  part	  of	   the	  major	  duties	  of	  a	  pharmacist.	  Stability	  means	   that	   the	  
ingredients	   in	   a	   PN	   admixture	   do	   not	   change	   in	   excess	   of	   given	   specs	   over	   a	   period	   of	   time.	  
Compatibility	   indicates	   the	   circumstance	   in	   which	   the	   ingredients	   of	   a	   PN	   admixture	   do	   not	   interact	  
together	   over	   a	   given	   period	   of	   time.	   To	   evaluate	   these	   reactions,	   specific	   knowledge	   and	   adequate	  
methods	  are	  crucial.72	  Possible	  physicochemical	  reactions	  are	  shown	  in	  Table	  6.70	  	  
	  
	  
Deﬁned	  stardng	  materials	  
Manufacturing	  procedures	  	  
Admixing	  sequence	  
Lot-­‐speciﬁc	  documents	  
Process	  control/condions,	  involved	  staﬀ	  
Suitable	  ﬁnal	  product	  analyses	  
Colour	  changes,	  pH,	  concentraon,	  precipitates,	  etc.	  
Stability-­‐documented	  storage	  and	  applicadons	  guidelines	  
Tests	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Table	  6:	  Physicochemical	  reactions70	  
Chemical	  reactions	   Physical	  reactions	  
Oxidation	   and	   reduction	   (amino	   acids,	   PUFA,	  
vitamins)	  
Precipitation	  (solubility	  product)	  
Hydrolysis	  (triglycerides)	   Sorption,	   permeation,	   extraction	   phenomena	  
(oxygen,	  lipophilic	  compounds)	  
Condensation	   and	   polymerisation	   (Maillard	  
reaction)	  
Disruption	  of	  emulsion	  (divalent	  cations)	  
Elimination	  reactions	  (decarboxylation,	  water)	   Thermal	  processes	  (oiling	  out)	  
Racemisation	  (optical	  active	  compounds)	   Photo-­‐induced	  processes	  (vitamin	  K1)	  
Complex	  formation	  (trace	  elements)	   	  
	  
Physical	  interactions	  among	  PN	  components	  are	  often	  dependent	  on	  their	  solubility	  products	  or	  on	  the	  
electrical	   interactions	   of	   charged	   solutes	   with	   the	   lipid	   emulsifier.	   These	   incompatibilities	   can	   be	  
prevented	   by	   adequate	   dose	   administration	   because	   they	   are	   concentration	   dependent.	   Chemical	  
reactions	   are	   influenced	   by	   co-­‐factors,	   which	   have	   to	   be	   controlled.	   The	   different	   reactions	   can	   be	  
influenced	  by	  the	  material	  of	  the	  bag,	  oxygen	  or	  light	  exposure,	  temperature,	  pH	  or	  other	  additives,	  e.g.	  
catalysts.	  These	  reactions	  can	  end	  in	  a	  mechanical	  catheter	  occlusion,	  wherein	  modified	  bioavailabilities	  
of	  drugs	  or	  nutrients	  can	  also	  induce	  adverse	  effects	  such	  as	  microvascular	  pulmonary	  emboli,	  etc.	  The	  
most	  critical	  component	  in	  an	  AiO	  admixture	  is	  the	  lipid	  emulsion.69	  
	  
2.3.1.1 Lipid	  emulsion	  stability	  
An	   O/W	   emulsion	   which	   mostly	   uses	   lecithin	   as	   the	   emulsifier	   is	   the	   primary	   factor	   leading	   to	   an	  
unstable	   PN	   admixture.	   Lecithin	   as	   the	   amphoteric	   emulsifying	   agent	   is	   responsible	   for	   homogenous	  
distribution	  of	   lipid	  droplets	  and	  the	  zeta	  potential.	  The	  non-­‐polar	  fatty	  acid	  tails	  orient	  toward	  the	  oil	  
phase,	  whereas	  the	  ionised	  polar	  phosphate	  groups	  extend	  into	  the	  aqueous	  phase.	  The	  mechanical	  and	  
electrostatic	  repulsive	  forces	  prevent	  a	  coalescence	  of	  the	  small	  lipid	  droplets	  and	  a	  formation	  of	  large-­‐
diameter	  fat	  globules,	  coating	  each	  oil	  droplet	  with	  a	  layer	  of	  phospholipids,	  which	  provides	  a	  negative	  
surface	  charge	  (zeta	  potential	  (ideal	  -­‐30	  to	  -­‐50	  mV)).	  The	  zeta	  potential	  is	  the	  electrical	  potential	  which	  
acts	  on	  the	  shear	  plane	  of	  a	  particle	  and	  determines	  the	  strength	  of	  electrostatic	   interaction	  between	  
particles.	   It	   is	   strongly	   pH	   dependent	   and	   in	   a	   pH	   of	   ca.	   2.5	   attains	   the	   value	   0.	   The	   stability	   of	   an	  
emulsion	   as	   a	   function	   of	   the	   pH	   can	   be	   predicted	   from	   the	   zeta	   potential.	   Using	   a	   lower	   pH	   value	  
(standard	   pH	   of	   range	   between	   6.0-­‐9.0)	   reduces	   the	   zeta	   potential	   thus	   destabilising	   the	   emulsion.75	  
Positively	  charged	  cations	  (divalent	  cations)	   impair	  this	  surface	  charge	  by	  modifying	  the	  zeta	  potential	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by	   adsorbing	   to	   the	   negative	   charged	   droplet	   surface,	   neutralising	   the	   negative	   charge	   and	   allowing	  
formation	  of	  larger	  droplets.76	  Commercially	  available	  lipid	  emulsions	  show	  a	  mean	  particle	  size	  of	  0.25-­‐
0.5	   µm,	   similar	   to	   natural	   chylomicrons.	   Fat	   globules	   bigger	   than	   5	   µm	   may	   occlude	   the	  
microvasculature,	   e.g.	   pulmonary	   capillaries,	   leading	   to	   embolic	   syndrome	   or	   have	   pathological	  
consequences	  to	  the	  reticuloendothelial	  system.77	  
	  
Additives,	  electrolytes,	  trace	  elements	  and	  the	  surrounding	  pH	  are	  able	  to	  reduce	  the	  repulsive	  forces	  
(zeta	  potential)	  between	  the	  lipid	  droplets	  by	  reducing	  the	  stabilising	  negative	  charge	  of	  the	  emulsifier	  
(less	   ionised),	   leading	   to	   aggregation	  or	   even	   coalescence.	   The	  pH	  of	   a	   lipid	   emulsion	  decreases	   over	  
time	   because	   of	   the	   hydrolysis	   of	   the	   triglycerides.	   Additionally,	   the	   addition	   of	   glucose	   (acidic)	  
decreases	  the	  pH.	  A	  pH	  <5.0	  implies	  an	  unstable	  lipid	  emulsion.	  Furthermore,	  amino	  acid	  solutions	  have	  
a	  protective	  effect	  on	   the	  emulsion	  by	  enhancing	   the	  electrostatic	  barrier,	   the	  buffering	   capacity	   and	  
electrolyte	   complexing.	   Therefore,	   an	   amino	   acid	   solution	   should	   always	   be	   added	   first	   to	   the	   AiO	  
admixture,	  preserving	  the	  lipid	  stability.	  Positively	  charged	  cations	  (especially	  divalent	  cations	  like	  Mg2+	  
or	   Ca2+)	   have	   a	   destabilising	   power	   on	   the	   repulsive	   forces.	   The	   zeta	   potential	   falls	   with	   increasing	  
electrolyte	   concentrations	   (asymptotes	   to	   zero	   at	   high	   electrolyte	   concentrations).	   With	   falling	   zeta	  
potential,	   the	   repulsive	   forces	   become	   weaker,	   until	   at	   a	   critical	   point	   they	   are	   no	   longer	   able	   to	  
overcome	   the	  attractive	  Van	  der	  Waals	   force.	  At	   this	  point,	   the	   forces	  become	  mostly	  attractive,	   and	  
flocculation	  occurs.	  The	  electrolyte	  concentration	  required	  to	  achieve	  this	  critical	  point	  is	  called	  critical	  
flocculation	  concentration	   (à	   zeta	  potential	  as	  a	   function	  of	  electrolyte	  concentration).	  Consequently	  
the	  concentration	  of	  monovalent	  cations	  like	  Na+	  or	  K+	  should	  not	  exceed	  130	  mmol/L,	  and	  of	  divalent	  
cations	  8	  mmol/L.78	  
	  
Figure	   5	   shows	   the	   different	   phases	   of	   lipid	   emulsion	   instability.	   The	   first	   sign	   of	   destabilisation	   is	  
flocculation,	   in	  which	   the	   emulsion	   droplets	   build	   coherent	   globules,	   retaining	   their	   individual	   forms.	  
Creaming	   can	  occur	  without	   relevant	  change	   in	  particle	   size	  and	   is	   reversible	  by	  shaking.	  Thereby	   the	  
electrical	   charge	   on	   the	   emulsion	   droplets	   is	   reduced,	   causing	   them	   to	   drift	   to	   the	   surface	   of	   the	  
emulsion	  and	  alter	  its	  homogeneity.	  According	  to	  Stokes’	  law,	  the	  upward	  drift	  of	  these	  droplets	  occurs	  
because	  the	  density	  is	  lower	  in	  the	  dispersed	  oil	  phase	  compared	  to	  the	  continuous	  water	  phase	  of	  the	  
emulsion.	   The	   first	   irreversible	   phase	   of	   lipid	   instability	   is	   coalescence,	   in	   which	   the	   individual	   small	  
droplets	   lose	   their	   mechanical	   and	   electrostatic	   barriers	   and	   form	   large	   droplets.	   Over	   time	   these	  
growing	  lipid	  droplets	  can	  be	  measured	  using	  a	  light	  microscope.	  As	  this	  process	  continues,	  the	  growing	  
lipid	   droplets	   expand	   until	   the	   oil	   begins	   to	   separate	   from	   the	   dispersed	   phase,	   or	   so	   called	   oiling	  
out.76,79	  Methods	  to	  detect	  these	  instabilities	  are	  discussed	  in	  Chapter	  2.3.1.3.	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Another	   important	   point	   to	   consider	   is	   lipid	   peroxidation.	   PUFAs	   are	   susceptible	   to	   oxidation	   in	   the	  
presence	  of	  oxygen.	  They	  can	  form	  reactive	  radicals	  and	  aldehydes,	  leading	  to	  oxidative	  stress	  reactions	  
and	   toxicity.	   Daylight,	   oxygen,	   temperature,	   trace	   elements	   and	   other	   additives	   can	   increase	  
peroxidation.	  This	  is	  in	  contrast	  to	  correctly	  dosed	  anti-­‐oxidative	  additives	  such	  as	  water-­‐soluble	  vitamin	  
C	  and	  the	  lipid	  soluble	  vitamin	  E	  which	  can	  reduce	  this	  risk.	  Measures	  to	  prevent	  peroxidation	  include	  
more	  airtight	  and	  multilayered	  bags,	   light	  protection,	  storage	   in	  the	  fridge,	  addition	  of	  trace	  elements	  
shortly	  before	  the	  infusion,	  and	  covering	  the	  bags	  including	  orange	  or	  yellow	  administration	  sets.80,81,82	  
	  
2.3.1.2 Stability	  of	  other	  additives	  (electrolytes,	  vitamins,	  trace	  elements,	  calcium	  and	  phosphate)	  
The	  addition	  of	  additives	  such	  as	  electrolytes,	  trace	  elements	  and	  vitamins	  to	  PN	  admixtures	  can	  result	  
in	  precipitation,	  leading	  to	  physical	  incompatibilities	  and	  chemical	  degradation.	  Therefore,	  simultaneous	  
administration	  of	  trace	  elements	  and	  vitamins	   is	  not	  recommended;	  but	  must	  be	  administered	  shortly	  
before	  the	  infusion.	  Monovalent	  electrolytes	  don’t	  show	  any	  significant	  physical	  compatibility	  problems	  
(high	   concentrations	   are	   generally	   well	   tolerated	   in	   PN	   admixtures).	   Di-­‐	   or	   trivalent	   ions	   interactions	  
(especially	  calcium	  and	  phosphate)	  can	   lead	  to	  precipitation.	  This	   is	  especially	  a	  problem	  when	  higher	  
daily	  needs	  have	  to	  be	  administered	  (higher	  concentrated	  admixtures).	  When	  electrolytes	  are	  added	  to	  
a	  lipid	  emulsion,	  the	  electrostatic	  field	  emanating	  from	  a	  negatively	  charged	  lipid	  droplet	  gives	  rise	  to	  a	  
repulsive	  force	  on	  a	  neighboring	  droplet,	  and	  is	  partially	  screened.	  This	  allows	  Van	  der	  Waals	  attractive	  
forces	  between	  the	  droplets	  to	  gain	  influence	  and	  form	  agglomerations.	  The	  reaction	  between	  calcium	  
and	  phosphate	   is	  the	  most	   important	  aspect	  because	  they	  are	  a	  daily	  requirement	  (high	  requirement)	  
It	   is	  prohibited	   to	   infuse	  AiO	  admixtures	  with	  signs	  of	   coalescence	  or	  
oiling	  out	  to	  the	  patient!	  	  
Figure	  5:	  Phases	  of	  lipid	  emulsion	  instability79	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and	  indicate	  compatibility	  problems.	  Their	  instability	  depends	  on	  several	  factors	  including	  pH	  (high),	  low	  
concentration	  of	  amino	  acids	  and	  glucose,	  nature	  of	  calcium	  and	  phosphate	  salts,	   temperature	   (high),	  
high	  concentration	  of	  lipids	  and	  slow	  infusion	  rates,	  etc.	  The	  solubility	  of	  the	  two	  phosphate	  anions	  and	  
their	  calcium	  salts	   is	  an	   important	  aspect	  of	   the	  safety	  of	  an	   intravenous	  therapy.	  Monobasic	   (H2PO4-­‐)	  
and	  dibasic	  (HPO42-­‐)	  phosphate	  salts	  (inorganic)	  can	  form	  a	  salt	  with	  calcium,	  but	  the	  calcium	  dihydrogen	  
phosphate	   is	  60	   times	  more	  soluble	   than	   the	  dibasic	   salt,	   the	  calcium	  monohydrogen	  phosphate	   (less	  
dissociated).	   At	   a	   pH	   of	   7.4	   (physiological	   pH),	  
approximately	   60%	   of	   the	   phosphate	   is	   in	   the	  
poorly	   soluble	   dibasic	   form	   (based	   on	  
Henderson-­‐Hasselbach	   equation),	   enhancing	  
the	   possibility	   of	   calcium	   phosphate	  
precipitation.	   The	   lower	   the	   pH,	   the	   more	  
phosphate	   is	   in	   the	   monobasic	   form,	   which	   is	  
more	  soluble.	  Therefore,	  the	  pH	  of	  the	  final	  PN	  admixture	  is	  an	  important	  factor	  regarding	  this	  aspect.57	  
The	   concentrations	   of	   calcium	   (as	   gluconate	   salt)	   should	   be	   ≤2.5	   mmol/L	   and	   phosphate	   (as	   the	  
inorganic	  combination	  of	  sodium	  mono-­‐	  and	  dibasic	  phosphate	  injection)	  ≤15	  mmol/L.	  To	  prevent	  such	  
precipitation,	   an	   organic	   salt	   of	   phosphate,	   e.g.	   glucose-­‐1-­‐phospahte,	   glycerol	   phosphate,	   should	   be	  
used.78	  	  
	  
The	   three	  most	  prevalent	   vitamin	   instabilities	   in	  PN	  are	  photodegradation,	  oxidation	  and	   interactions	  
with	   the	   storage	   material.	   On	   the	   other	   side,	   solutions	   of	   trace	   elements	   have	   a	   very	   sour	   pH	   and	  
contain	   di-­‐	   or	   trivalent	   cations,	   e.g.	   iron,	   copper,	   selenium,	   chromium,	   zinc,	   which	   can	   influence	   the	  
emulsion	  stability	  depending	  on	   the	  concentration.	  Manganese,	   zinc,	   ferric	   ions	  and	  especially	  copper	  
catalyse	  the	  oxidation	  of	  ascorbic	  acid	  into	  dehydroascorbic	  acid	  and	  the	  production	  of	  oxalic	  acid	  and	  
threonic	  acid.	  Vitamin	  C	  is	  oxidised	  with	  copper	  causing	  the	  concomitant	  reduction	  of	  copper	  from	  the	  
cupric	  (II)	  to	  the	  cuprous	  (I)	  form.	  Cysteine	  in	  the	  amino	  acid	  solution	  can	  inhibit	  the	  catalytic	  effect	  of	  
copper,	  slowing	  down	  the	  degradation	  of	  vitamin	  C.	  Also	  high	  temperature	  and	  a	  pH	  >4.0	  can	  increase	  
the	  degradation/oxidation	  of	  ascorbic	  acid.	  The	  products	  of	  ascorbic	  acid	  degradation	   (oxalic	  acid	  and	  
threonic	  acid)	  can	  impair	  the	  stability	  of	  the	  emulsion	  by	  increasing	  the	  acidity.	  Additionally,	  oxalic	  acid	  
interferes	   with	   free	   calcium,	   resulting	   in	   calcium	   oxalate	   precipitates	   which	   are	   dangerous	   for	  
neonates.83	  Other	  vitamins	  are	  chemically	  unstable	  and	  are	  degraded	  by	  ultraviolet	  light	  (vitamin	  A	  and	  
B2)	  or	  diffuse	   into	  the	  semipermeable	  membrane	  of	  polyvinyl	  chloride	  containers	   (vitamin	  A).	  Another	  
important	  chemical	  degradation	  is	  the	  reduction	  of	  thiamine.	  Lipid	  soluble	  vitamins	  (vitamin	  A,	  D,	  E,	  K)	  
can	   be	   added	   to	   a	   lipid	   containing	   PE	   admixture	   and	   are	   therefore	   protected	   from	   ultraviolet	   light	  
degradation.	  There	  are	  some	  pharmaceutical	  aspects	  that	  minimise	  interactions	  between	  nutrients	  and	  
Ca2+	  +	  H3PO4	  	   à	  Ca(H2PO4)2	   	   130	  mM	  
	   	   à	  CaHPO4	  	   	   	  2.1	  mM	  
	  
	  Figure	  6:	  Influence	  of	  pH	  on	  the	  calcium	  x	  phosphate	  solubility	  
product	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the	  infusion	  bags:	  the	  effects	  of	  artificial	  or	  daylight	  can	  be	  reduced	  by	  protecting	  the	  bag	  or	  through	  the	  
presence	  of	  a	  fat	  emulsion	  and	  use	  of	  multilayered	  or	  oxygen	  impermeable	  bags	  can	  lessen	  oxidation	  of	  
vitamins.57	  
	  	  
2.3.1.3 	  (Analytical)	  Methods	  to	  detect	  physical	  and	  chemical	  instabilities	  
Guidelines	  and	   regulatory	   requirements	   (production	   licence)	   recommend	  preparing	  AiO	  admixtures	   in	  
specialised	   facilities,	   e.g.	   hospital	   pharmacy,	   under	  pharmaceutical	   supervision	   for	   parenteral	   product	  
manufacturing	   or	   preparing,	   adhering	   to	   validated	   procedures	   for	   types	   and	   amounts	   of	  macro-­‐	   and	  
micronutrients,	  admixing	  order	  and	  the	  quality	  control	   (standard	  operating	  procedures,	  GMP).	  The	  PN	  
admixtures	  should	  be	   inspected	  prior	  to	  and	  during	   infusion	  for	  signs	  of	   instability	  and	   incompatibility	  
such	  as	  precipitation,	  discoloration,	  gas	  formation,	  aggregation,	  creaming	  and	  coalescence.	  A	  visual	  and	  
instrumental	  inspection	  of	  the	  end	  product	  is	  inevitable	  to	  guarantee	  an	  effective,	  safe	  and	  high	  quality	  
treatment	   to	   the	   patient.3	   Organoleptic,	   especially	   visual	   inspection,	   is	   a	   first,	   very	   important	  
assessment	   in	   order	   to	   detect	   separations	   of	   phases	   or	   color	   changes.	   Further	   investigations	   are	  
necessary	  to	  detect	  any	  changes	  in	  particle	  size,	  signs	  of	  lipid	  peroxidation	  or	  changes	  in	  concentration	  
of	  glucose,	  amino	  acids	  and	  electrolytes	  (and	  to	  detect	  their	  degradation	  products).84	  The	  United	  States	  
Pharmacopeia	  determined	  that	  the	  volume-­‐weighted	  percent	  of	  fat	  greater	  than	  5	  µm	  (PFAT5),	  has	  to	  be	  
<0.05%.85	   It	   should	   be	   noted,	   that	   this	   monograph	   applies	   to	   manufacturers	   of	   lipid	   injectable	  
emulsions.	   Given	   the	   anticipated	   changes	   in	   stability	   during	   the	   AiO	   compounding	   process,	  
specifications	   have	   to	   be	   adjusted	   upwards	   to	   account	   for	   the	   qualitative	   difference	   in	   preparing	  
emulsions	   for	   industry	   vs.	   clinicians.	   There	   are	   different	   methods	   to	   test	   the	   physical	   stability	  
determined	  by	  the	  particle	  size,	  size	  distribution,	  surface	  potential	  or	  aggregation	  state.	  The	  coalescence	  
of	   lipid	   globules	   indicates	   the	   instability	   of	   a	   lipid	   emulsion,	   therefore	   assessments	   of	   changes	   in	   the	  
globule	  size	  distribution	  are	  essential.	  As	  part	  of	  a	  clinical	  routine,	   it	   is	   important	  that	  simple,	  fast	  and	  
sensitive	   methods	   are	   available.	   They	   should	   be	   validated,	   e.g.	   indicate	   reproducibility,	   robustness,	  
precision,	   etc.,	   to	   provide	   an	   acceptable	   result.	   Two	   key	   parameters	   are	   required	   in	   a	   critical	  
pharmaceutical	  assessment	  of	  an	  intravenous	  lipid	  emulsion	  to	  characterise	  the	  globule	  size	  distribution	  
and	  to	  meet	  pharmacopeial	  standards:	  1.	  Mean	  droplet	  size	   (statistical	  value)	  and	  2.	  A	   large	  diameter	  
(>5	   µm)	   measurement	   for	   characterisation	   of	   the	   globule.	   Most	   important	   is	   the	   size	   limit	   of	   an	  
individual	  particle	  as	  this	  has	  the	  greatest	  implications	  for	  safety	  issues	  (infusion	  safety).86,87	  
	  
The	  United	   States	   Pharmacopeia	   recommends	   the	   dynamic	   light	   scattering	   (DLS)	  method,	   also	   called	  
photon	   correlation	   spectroscopy	   (PCS)	   to	  determine	   the	  mean	  droplet	   size.	  Other	  methods	   to	  detect	  
lipid	   particle	   size	   and	   distribution	   are	   called	   laser	   diffraction	   or	   light	   obscuration.	   The	   latter	  method	  
uses	  a	   single-­‐particle	  optical	   sensing	   technique	   to	  count	  a	   large	  number	  of	  particles	  and	  can	  measure	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particles	  in	  the	  range	  of	  1-­‐150	  µm.	  Therefore,	  a	  small	  number	  of	  large	  particles	  in	  the	  emulsions	  can	  be	  
detected.	  A	  disadvantage	  is	  that	  the	  samples	  have	  to	  be	  diluted	  before	  measuring.	  The	  laser	  diffraction	  
method	   can	   detect	   particles	   in	   the	   range	   of	   0.05-­‐3500	   µm.	   Because	   the	   light	   beam	   illuminates	   the	  
particles	  simultaneously,	  this	  method	  is	  not	  adapted	  to	  count	  the	  number	  of	  particles;	  it	  only	  provides	  
the	  distribution	  of	   particle	   sizes.	   This	  method	   is	   not	   sensitive	   enough	   to	  determine	   small	   numbers	  of	  
larger	  particles	  in	  a	  mass	  of	  smaller	  particles.	  Therefore,	  to	  detect	  unstable	  intravenous	  lipid	  emulsions,	  
the	  light	  obscuration	  method	  is	  superior	  to	  the	  laser	  diffraction	  method.75	  The	  PCS	  method	  is	  based	  on	  
the	  detection	  of	  a	  laser	  light	  scattered	  on	  a	  particle’s	  bulk.	  Advantages	  of	  the	  PCS	  method	  are	  the	  simple	  
and	   fast	   sample	   preparation	   and	   the	   statistical	   sample	  measurement.	   The	   PCS	  measuring	   range	   is	   3-­‐
3000	  nm.	  Disadvantages	  include	  the	  very	  small	  sample	  volume,	  the	  sample	  dilution	  and	  the	  impossibility	  
to	  detect	   larger	  and	  therefore	  physiological	  more	  critical	  particles	  which	  are	  over	  the	  detection	  range.	  
This	  method	  also	  doesn’t	  allow	  a	  single	  particle	  statistic.	  Another	  method	  to	  test	  the	  emulsion	  is	  to	  use	  a	  
light	  microscope.	  With	   light	  microscopy,	  1000-­‐fold	  magnification	  and	  oil	   immersion,	  particles	  of	  1	  µm	  
are	  detectable.	  Larger	   lipid	  droplets	  or	  aggregates	  can	  be	  measured.	  Compared	  to	  the	  other	  methods,	  
an	  advantage	  of	  the	  microscope	  method	  is	  that	  one	  can	  distinguish	  between	  solid	  particles	  (impurities,	  
precipitation)	  and	   lipid	  droplets.	   Further	  advantages	  are	   that	  no	   sample	  predilution	   is	  necessary,	   that	  
only	   small	   samples	  are	  used	  and	  also	   that	  particles	  up	   to	  20	  µm	  can	  be	  detected.	  Additionally,	   it	   is	   a	  
validated,	   fast,	   simple	   and	   cost-­‐effective	   method,	   applicable	   in	   the	   clinical	   routine,	   e.g.	   hospital	  
pharmacy88	   The	  microscopic	   assessment	   form,	   including	   the	   specific	   procedure,	   is	   shown	   in	   Figure	   7.	  
Another	   important	   factor	   influencing	   the	   stability	   of	   the	   AiO	   admixture	   is	   the	   pH.	   Therefore,	   a	  
supplementary	  method	  to	  test	  the	  stability	  of	  the	  formulation	   is	  a	  pH	  measurement.	  The	  pH	  of	  a	   lipid	  
emulsion	   is	   in	   the	   range	  of	   6-­‐8.	   The	  pH	  of	   an	  AiO	   admixture	   (containing	   lipids)	   decreases	   because	  of	  
additives	  like	  glucose,	  amino	  acids	  and	  electrolytes.	  The	  pH	  of	  a	  lipid	  emulsion	  also	  depends	  on	  the	  age	  
of	   the	   emulsion	   (pH	   decreasing	   over	   time)	   because	   of	   the	   hydrolysis	   of	   fat	   triglycerides.	   A	   pH	   <5.0	  
indicates	  an	  unstable	  emulsion.	  The	  effect	   (zeta	  potential)	   responsible	   for	   this	   is	  described	   in	  Chapter	  
2.3.1.1.78	   Liquid	   chromatography	   (LC)	   is	   often	   used	   for	   pharmaceutical	   analyses	   and	   is	   frequently	  
indicated	  in	  many	  official	  drug	  monographs.86	  A	  LC	  fractionates	  the	  substances	  on	  an	  analytical	  column	  
and	   the	   detection	   of	   the	   substances	   is	   done	   by	   mass	   spectrometry	   (MS).	   A	   tandem	   MS	   (MS/MS)	  
increases	   the	   selectivity.	   LC-­‐MS/MS	   investigations	   are	   state	  of	   the	   art,	   representing	   a	   highly	   sensitive	  
identification	  and	  quantification	  method.	  A	  drug	  (or	  vitamin)	  specific	  detection	  is	  possible	  and	  such	  an	  
analysing	   instrument	   is	   nearly	   available	   in	   all	   bigger	   hospital	   medical	   labs	   (also	   for	   therapeutic	   drug	  
monitoring).	  The	  analysis	   is	  possible	   in	  different	  biological	  matrixes	  such	  as	  blood,	  plasma	  or	  also	   lipid	  
containing	  emulsions.	  A	  further	  advantage	  is	  the	  small	  sample	  preparation	  and	  the	  short	  pre-­‐treatment	  
of	  the	  samples.	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Sample:____________________________	   	   Date	  evaluation:________________________	  
Lot:_______________________________	   	   Date	  preparation:_______________________	  
Storage	  temperature:________________	   	  	   Storage	  duration:________________________	  
Microscope:_______________________________________________________________________	  
All	  samples	  are	  turned	  upside	  down	  2x.	  10µl	  of	  the	  sample	  are	  transferred	  with	  a	  manual	  pipette	  to	  	  	  	  
a	  microscope	   slide	   and	  covered	  with	   a	   coverslip,	  with	  oil	   immersion	   and	   a	  magnification	  of	   1000x.	  
Lens	  opening	  closed.	  Five	  visual	  fields	  of	  each	  of	  the	  three	  samples.	  
	  
Visual	  evaluation:	  	   ☐	  no	  changes	   ☐	  creaming	   ☐	  oil	  droplets	  
pH-­‐value:_______________________	  
Specification	   LLDmax	   LLD	  >5µm	   LLD≥2µm	   Crystals	   Aggregates	  
Visual	  field	   [µm]	   [n]	   <20	  [X]	   20-­‐50	  [X]	   >50	  [X]	   [µm]	   [n]	  
1	   	   	   	   	   	   	   	  
2	   	   	   	   	   	   	   	  
3	   	   	   	   	   	   	   	  
4	   	   	   	   	   	   	   	  
5	   	   	   	   	   	   	   	  
6	   	   	   	   	   	   	   	  
7	   	   	   	   	   	   	   	  
8	   	   	   	   	   	   	   	  
9	   	   	   	   	   	   	   	  
10	   	   	   	   	   	   	   	  
11	   	   	   	   	   	   	   	  
12	   	   	   	   	   	   	   	  
13	   	   	   	   	   	   	   	  
14	   	   	   	   	   	   	   	  
15	   	   	   	   	   	   	   	  
1-­‐15:	  LLDmax:___________µm	  	  	  	  MLLDmax:_________±_________µm	  	  	  	  LLD>5µm:__________	  
Commentary:	  
 
Figure	  7:	  Microscope	  assessment	  form	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2.3.2 Drugs	  and	  AiO	  admixtures	  
Critically	  ill	  patients	  or	  patients	  with	  a	  severe	  functional	  or	  anatomical	  failure	  of	  the	  GIT	  often	  use	  long-­‐
term	   PN.	  Quite	   often,	   simultaneous	   administration	   of	   one	   or	  more	  medications,	   or	   additives	   such	   as	  
micronutrients,	   is	   necessary	   or	   convenient.	   On	   one	   hand,	   it	   is	   possible	   that	   the	   decreased	   intestinal	  
absorption	  influences	  the	  bioavailability	  of	  orally	  administered	  drugs,	  which	  requires	  a	  parenteral	  drug	  
administration	   to	   maintain	   an	   effective	   drug	   concentration	   in	   the	   body.	   Particularly	   the	  
pharmacotherapy	   of	   patients	   in	   the	   intensive	   care	   unit,	   requires	   control	   of	   the	   efficacy	   of	   drug	  
treatments.	  On	  the	  other	  hand,	   it	   is	  possible	   that	  a	  patient	  with	  PN	  has	   limited	  access	   to	   intravenous	  
lines	  or	  difficult	  venous	  access,	  e.g.	  neonates,	  or	  a	  volume	  restriction	  to	  administer	   intravenous	  drugs,	  
requiring	   PN	   admixtures	   as	   a	   drug	   vehicle.	   Additionally,	   fewer	   catheter	   manipulations	   decrease	   the	  
infection	   risk,	   simplify	   the	   treatment	   and	  are	  more	   convenient,	   especially	   for	  patients	  with	   long-­‐term	  
HPN.	  However,	  such	  a	  situation	  can	  be	  problematic	  because	  sparse	   information	   is	  available	  about	   the	  
compatibility	  and	  stability	  of	  drugs	  with	  AiO	  admixtures	  and	  the	  therapeutic	  outcome.	  When	  a	  drug	  or	  
another	   additive	   is	   admixed	   to	   a	   commercialised	   PN	   formulation,	   a	   new	   formulation	   with	   changed	  
properties	   is	   created	  and	   the	  associated	  manufacturer’s	  quality	   can	  no	   longer	  be	  guaranteed.	  The	  PN	  
formulation	   can	   influence	   the	   bioavailability	   of	   the	   drug	   or	   vice	   versa.	   Furthermore,	   there	   are	  many	  
different	  drug,	  including	  generics,	  and	  PN	  formulations	  and	  different	  manufacturers,	  rendering	  it	  almost	  
impossible	  to	  test	  and	  document	  all	  possibilities	  of	  mixing.89	  
	  
	  
Figure	  8:	  Algorithm	  for	  drugs	  and	  PN	  delivery	  
Before	  admixing	  a	  drug	  to	  a	  PN	  formulation,	   it	   is	   important	  to	  consider	  the	  algorithm	  in	  Figure	  8.	  This	  
requires	   pharmaceutical	   know-­‐how,	   especially	   in	   the	   prescription	   and	   administration	   process,	   drug	  
formulation	   and	   physicochemical	   characterisation	   of	   the	   drug.	   Regarding	   step	   one,	   alternative	  
need	  for	  i.v.	  
medicaon
	  
• Is	  this	  medicaon	  necessary?	  




• Is	  there	  alternave	  i.v.	  access	  available?	  
• Is	  an	  intermient	  administraon	  possible?	  
proﬁle	  of	  the	  
drug	  
• What	  is	  the	  therapeuc	  index	  of	  the	  acve	  ingredient	  (crical	  dose	  drug)?	  
• What	  is	  the	  physicochemical	  characterisaon	  (pH,	  pK,	  excipients)?	  
• Is	  an	  incompability	  ancipated?	  
documentaon	  
&	  insepcon	  of	  
the	  admixture	  
• Is	  an	  incompability	  or	  interacon	  already	  reported	  in	  the	  literature?	  
• Is	  easy	  tesng	  possible	  (pH	  changes,	  visual	  insepcon,	  lipid	  droplets	  measurement)	  ?	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formulations	  have	  to	  be	  used,	  e.g.	  sublingual	  tablets,	  if	  they	  are	  available.	  If	  it	  is	  possible,	  a	  multi-­‐lumen	  
catheter	  should	  be	  used	  in	  patients	  at	  the	  hospital.	  Otherwise,	  patients	  with	  cyclic	  HPN	  can	  administer	  
intermittent	   intravenous	  medication	   after	   rinsing	   the	   catheter	  with	   sufficient	   rinsing	   fluid.	   In	   the	   last	  
step	   of	   the	   algorithm,	   admixing	   can	   be	   considered	   if	   all	   the	   previous	   questions	   do	   not	   create	   an	  
obstacle.	  An	  aseptic	   admixing	   in	   the	  appropriate	   sequence	  of	   admixing	  and	  dilution	   is	   inevitable.	   The	  
assessment	   and	   documentation	   of	   compatibility	   and	   stability	   of	   a	   drug	   in	   an	   AiO	   admixture	   is	   a	  
prerequisite	   for	   admixing	   it	   into	  a	  PN	   formulation.	  Appropriate	  methods	  and	   tests	   should	  be	  used	  by	  
pharmacists	   in	  daily	   practice	   to	  prevent	   incorrect	   handling	   and	  medication	  errors	   and	   to	   guarantee	   a	  
safe	  and	  efficient	  treatment	  (see	  also	  Chapter	  2.3.1.3).69,73	  
	  
Firstly,	   the	   emulsion	   character	   of	   the	  PN	   formulation	   can	   change	  when	   a	   drug	   is	   admixed	   to	   the	  AiO	  
admixture.	  Drug	  formulations	  with	  a	  low	  pH	  (like	  midazolam	  or	  vancomycin)	  or	  a	  high	  pH	  (like	  acyclovir,	  
metoclopramide,	  phenytoin	  or	  barbiturates)	  can	  reduce	  the	  repulsion	  forces	  between	  the	  lipid	  droplets	  
in	   the	   PN	   formulation,	   leading	   to	   creaming	   or	   oiling	   out	  which	   is	   irreversible.89	   Drugs	  with	   a	   logP	   ≥3	  
(highly	   lipophilic),	   dissolved	  with	   the	   aid	   of	   cremophors	   or	   tweens,	   e.g.	   cyclosporine	   in	   Sandimmun®,	  
can	  interact	  with	  the	  lipid	  emulsions	  resulting	  in	  an	  increased	  stability.	  Hence,	  the	  bioavailability	  of	  the	  
drug	   and	   the	   triglycerides	   is	   changed.90	   Additionally,	   reactions	   of	   the	   drug	   with	   the	   container	   or	  
administration	  material	  of	  the	  AiO	  admixture	  can	  occur.	  Lipophilic	  drugs	  like	  diazepam	  and	  nitroglycerin	  
can	   be	   absorbed	   into	   the	   plastic	   of	   administration	   sets,	   which	   is	   mostly	   polyvinyl	   chloride.	   Other	  
substances	   such	   as	   insulin,	   albumin	   or	   vitamin	   A	   can	   be	   absorbed	   on	   the	   container	   surface.	   An	  
inactivation	   of	   drugs	   or	   PN	   components	   can	   also	   occur.	   Short	   acting	   drugs	   often	   show	  high	   chemical	  
reactivity	  and	  therefore	  should	  not	  be	  added	  to	  a	  PN	  admixture	  because	  of	  the	  rapid	  inactivation.	  Trace	  
elements	  (iron,	  copper,	  selenium)	  can	  catalyse	  oxidation	  or	  reduction	  of	  drugs	  or	  nutrients	  (epinephrine,	  
vitamin	  C).	  The	  formation	  of	  precipitates	  can	  lead	  to	  potentially	  toxic	  reactions.	  This	  can	  be	  induced	  by	  
drugs	  dissolved	  at	   pH	  <5	  or	   >7.	  Weak	  acids	  or	  weak	  bases	  need	  a	  high	   resp.	   low	  pH	   to	  be	  dissolved.	  
When	  these	  salts	  are	  added	  to	  a	  buffered	  PN	  formulation,	  precipitates	  can	  be	  built.89	  	  
	  
In	  general,	  admixing	  with	  the	  AiO	  formulation	  is	  not	  allowed	  when:	  	  
-­‐ Solubilisers	  are	  present	  to	  dissolve	  lipophilic	  drugs	  
-­‐ Drugs	  are	  chemically	  instable	  
-­‐ Drugs	  have	  a	  narrow	  therapeutic	  range	  
-­‐ Drugs	  have	  short	  elimination	  half-­‐lives	  
	  







In	  the	  guidelines	  it	   is	  written	  that	  AiO	  admixtures	  should	  not	  be	  used	  as	  a	  drug	  vehicle	  because	  of	  the	  
complex	   interaction	   potential.	   If	   it	   is	   possible,	   for	   therapeutic	   and	   practical	   reasons,	   stability	   and	  
effectiveness	   must	   be	   examined	   and	   documented	   appropriately.	   The	   same	   is	   also	   relevant	   for	  
medications	   infused	   into	   the	   same	   line	   via	   Y-­‐connector.	   This	   situation	   can	   be	   eased	   by	   extrapolation	  
from	  well-­‐investigated	  to	  unknown	  drugs	  by	  defining	  their	  pharmaceutical	  profile	  (see	  Chapter	  4.4	  -­‐	  the	  
levetiracetam	   example).	   Nevertheless,	   a	   strict	   aseptic	   process	   according	   to	   the	   GMP	   protocol	   and	  
pharmaceutical	  expertise	  should	  be	  adhered	  to.69	  
	  
Only	  selected	  drugs	  with	  acceptable	  extended	  administration	  
time,	  a	  large	  therapeutic	  index,	  and	  appropriate	  physico-­‐
chemical	  properties	  are	  candidates	  for	  admixing!	  
Figure	  9:	  Candidates	  for	  admixing90	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3 Overall	  summary	  of	  the	  thesis	  
The	   four	  different	  publications	   show	   the	  variety	  and	  also	  partly	   the	  new	  possibilities	  of	   activities	  of	  a	  
pharmacist	  in	  an	  NST.	  Best	  pharmaceutical	  practice	  includes	  not	  only	  the	  responsibilities	  taking	  place	  in	  
the	  pharmacy	  such	  as	  preparation,	  compounding,	  evaluation	  of	  the	  correct	  medication,	  treatment	  form,	  
logistics,	   etc.	   but	   also	   the	   education	   and	   training	   of	   other	   health	   care	   professionals,	   the	   care	   and	  
advising	   patients	   at	   home	   and	   monitoring	   of	   these	   patients;	   and	   last	   but	   not	   least,	   the	   handling	   of	  
industrialised	  multichamber	  bags,	  checking	  of	  possible	  additives,	  strict	  aseptic	  handling	  and	  appropriate	  
methods	  to	  test	  and	  ensure	  stability	  and	  compatibility.	  Though	  the	  role	  of	  the	  pharmacist	   in	  an	  NST	  is	  
not	  well	  established,	  specific	  education	  and	  training	  in	  the	  field	  for	  these	  activities	  as	  part	  of	  the	  basic	  
education	  of	  a	  pharmacist	  is	  necessary	  to	  promote	  and	  integrate	  the	  pharmacist	  as	  an	  important	  team	  
member	  in	  the	  nutritional	  process.	  	  
	  
The	  aim	  of	  this	  thesis	  was	  to	  provide	  insight	  into	  the	  different	  aspects	  of	  pharmaceutical	  expertise	  and	  
the	  contributions	  of	  a	  pharmacist	  to	   improve	  the	  quality	  of	  treatment,	  safety	  and	  patients’	  QoL	  based	  
on	  best	  pharmaceutical	  practice.	  	  
	  
(I)	   The	   specific	   aim	   of	   this	   first	   prospective	   educational	   study	   was	   to	   improve	   malnutrition	  
awareness	  and	  management	  in	  a	  tertiary	  hospital	   in	  the	  department	  of	   internal	  general	  medicine.	  The	  
objectives	   included	   the	   identification	  of	  patients	  with	  a	   risk	  of	  malnutrition	   (using	   the	  NRS	  2002)	  and	  
whether	  an	  online	  educational	   intervention	   leads	   to	  an	   increase	   in	  basic	  knowledge,	  measured	   in	   the	  
number	  of	  prescribed	  nutritional	  therapies.	  For	  this	  purpose,	  each	  of	  the	  300	  patients	  were	  screened	  in	  
the	   pre-­‐	   and	   post-­‐intervention	   phase	   and	   the	   prescribed	   therapies	   were	   recorded.	   The	   intervention	  
comprised	   an	   online	   education	   programme	   for	   the	   residents	   and	   a	   pocket	   card	   usable	   in	   the	   daily	  
routine.	   The	   number	   of	   patients	   with	   a	   risk	   for	   malnutrition	   was	   remarkable	   at	   54.1%	   resp.	   61.7%.	  
Despite	   these	   alarming	   statistics,	   the	   amount	   of	   nutritional	   prescriptions	   after	   the	   educational	  
intervention	  did	  not	  increase	  (18.7%	  vs.	  17%).	  The	  short	  (20-­‐30	  minutes)	  online	  educational	  intervention	  
was	  not	  enough	  to	  change	  the	  awareness	  of	  medical	  staff	  and	  the	  subsequent	  management	  of	  this	  risk	  
population.	  This	  study	  shows	  the	  necessity	  of	  education	  and	  postgraduate	  training	  in	  the	  field	  of	  clinical	  
nutrition:	   early	   identification	   of	   patients	   at	   risk	   for	   malnutrition	   or	   with	   malnutrition,	   prescribing	   of	  
adequate	  nutritional	   therapy	  and	   improvement	  of	  the	  nutritional	  knowledge.	  The	  pharmacist	  can	  play	  
an	  important	  role	  in	  the	  education	  and	  skills	  training	  of	  health	  care	  professionals.	  
	  
(II	  a)	   An	   optimal	   quality	   of	   treatment	   and	   a	   guarantee	   of	   patient’s	   safety	   is	   a	   central	   element	   in	  
patients	  at	  risk	  of	  malnutrition	  or	  depending	  on	  a	  nutritional	  device	  like	  HPN.	  There	  is	  very	  limited	  data	  
on	  the	  specific	  characteristics	  in	  Swiss	  HPN	  patients,	  a	  prerequisite	  to	  evaluate	  efficiency	  and	  QoL	  of	  the	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actual	   nutritional	   treatment.	   The	   second	   study	   aimed	   to	   collect	   representative	   nationwide	   data	   on	  
current	  HPN	  patients	  in	  Switzerland	  for	  international	  comparability	  and	  benchmarking	  and	  to	  define	  and	  
evaluate	   best	   practices.	   In	   this	   multicentre,	   nationwide,	   observational	   study,	   data	   were	   assessed	   at	  
baseline	  and	  followed	  up	  after	  three	  months	  with	  a	  questionnaire	  with	  thirty-­‐three	  adult	  HPN	  patients.	  
The	  underlying	  disease	  and	   indication,	   as	  well	   as	  problems	  and	   risks	   influencing	   the	  outcome	  of	  HPN	  
were	   identified.	   The	  most	   common	   underlying	   diseases	  were:	   cancer	   (42%),	   radiation	   enteritis	   (12%)	  
and	   obesity	   (after	   bariatric	   surgery)	   (12%).	   The	   most	   common	   indication	   for	   HPN	   was	   short	   bowel	  
syndrome	   (37%).	   HPN	   dependency	   and	   travel	   restrictions	   were	   of	   concern	   to	   most	   patients.	  
Anthropometric	  parameters	  and	  QoL	  improved	  during	  the	  observational	  interval	  of	  three	  months.	  As	  a	  
result	   of	   the	   Swiss	   HPN	   trial,	   for	   the	   first	   time	   there	   is	   the	   possibility	   to	   evaluate	   and	   compare	   HPN	  
recommendations,	   professional	   care	   instructions,	   related	   to	   quality	   of	   treatment	   and	   patient	   safety,	  
thus	  supporting	  the	  introduction	  of	  a	  Swiss	  HPN	  registry.	  A	  registry	  would	  allow	  for	  profound	  knowledge	  
about	  therapy	  recommendations,	  care	  instructions	  and	  ensure	  better	  treatment	  quality	  and	  respectively	  
greater	  patient	  safety.	  Monitoring	  and	  appropriate	  care	  and	  advice	  for	  patients,	  especially	  with	  HPN,	  are	  
part	  of	  the	  pharmaceutical	  activities	  in	  an	  NST.	  	  
	  
(II	  b)	   To	   focus	  more	  on	   the	  QoL	  of	  patients	  with	  HPN,	  a	   further	   study	  was	  conducted	  with	  patients	  
with	  systemic	  sclerosis	  and	  gastrointestinal	  dysfunction.	  Because	  the	  deterioration	  of	  the	  nutritional	  and	  
functional	   status	   has	   a	   severe	   impact	   on	   the	   prognosis	   of	   the	   underlying	   disease	   as	   well	   as	   on	   QoL,	  
concerned	  patients	  require	  adequate	  and	  early	  nutritional	  therapy	  including	  partial	  HPN.	  The	  purpose	  of	  
this	  study	  was	  to	  show	  the	  benefit	  of	  HPN	  on	  clinical	  outcome	  in	  terms	  of	   improvement	  of	  nutritional	  
state	  and	  QoL	  during	  one	  year	  of	  observation	  and	  to	  motivate	  physicians	  to	  consider	  this	  palliative	  care	  
with	   patients	   at	   later	   stages	   of	   systemic	   sclerosis.	   Five	   patients	   were	   included	   in	   this	   retrospective,	  
single-­‐centre	  pilot	  study.	  The	  data	  show	  that	  nutritional	  support	  by	  HPN	  is	  a	  feasible	  and	  safe	  method	  
leading	   to	   a	   health	   benefit	   in	   terms	   of	   improved	   anthropometric	   parameters	   and	   QoL	   in	   patients	  
severely	  affected	  by	  systemic	  sclerosis	  and	   late	  stage	  GIT	  dysfunction.	  Mean	  BMI	   increased	   from	  19.1	  
kg/m2	  (range	  17.4-­‐20.3)	  to	  21.0	  kg/m2	  (range	  18.3-­‐23.4).	  QoL	  improved	  in	  all	  patients	  receiving	  HPN	  over	  
12	  months	  as	  indicated	  by	  the	  summary	  of	  physical	  components	  (33.99	  vs.	  56.52)	  and	  the	  summary	  of	  
mental	   components	   (49.66	  vs.	  88.26).	  HPN	  should	  be	  considered	   for	  malnourished,	   catabolic	   patients	  
unable	   to	  maintain	   their	   nutritional	   state	   by	   other	  means.	  Monitoring	   of	   these	  patients,	   and	   thereby	  
providing	   safe	   and	   effective	   nutritional	   therapy	   with	   improved	   QoL,	   are	   contributions	   that	   the	  
pharmacist	  can	  provide.	  	  
	  
(III)	   A	  third	  aspect	  of	  the	  pharmaceutical	  tasks	  investigated	  was	  the	  assessment	  of	  compatibility	  and	  
stability	  of	  ready-­‐to-­‐use,	  compounded/prepared	  AiO	  PN	  admixtures	  and	  the	  potential	  as	  a	  drug	  carrier	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for	   selected	   drugs	   with	   useful	   and	   rapid	   tests.	   The	   aim	   of	   the	   completing	   study	   was	   to	   assess	   the	  
physicochemical	   stability	   and	   compatibility	   of	   the	   frequently	   used	   levetiracetam	   in	   commercialised	  
ready-­‐to-­‐use	  PN	  admixtures	  under	  conditions	  of	  practice	  using	  validated	  tools.	  The	  study	  showed	  that	  
levetiracetam	  was	  stable	  up	  to	  seven	  days	  in	  two	  different	  commercially	  available	  PN	  admixtures	  and	  at	  
usual	  handling/storage	  temperatures	  (4	  °,	  22	  °	  and	  37	  °C).	  The	  stability	  of	  lipid	  emulsion	  was	  observed	  
by	  light	  microscope	  and	  by	  visual	  inspection.	  No	  changes	  in	  pH	  occurred	  and	  no	  microscopic	  out-­‐of-­‐the-­‐
specs	   (MLLDmax	   2.4	   ±	   0.08	   μm)	   or	   visual	   changes	   were	   observed.	   Moreover,	   the	   concentrations	   of	  
levetiracetam	  were	   checked	  by	   LC-­‐MS/MS	  and	   ranged	  100	  ±	  15%	  of	   the	   theoretical	   value	  over	   seven	  
days.	  The	  results	  show	  a	  valuable	  approach	  how	  to	  determine	  pharmaceutical	  stability	  and	  compatibility	  
of	   drugs	   with	   PN	   in	   daily	   practice	   to	   support	   complex	   therapeutic	   schemes.	   This	   timely	   and	   cost-­‐
effective	   pharmaceutical	   support	   to	   document	   quality	   of	   complex	   therapeutic	   regimes	   increases	  
convenience	   and	   avoids	   medical	   errors	   in	   the	   clinical	   setting.	   Levetiracetam	   is	   hydrophil	   (logP	   -­‐0.6),	  
neutral,	   has	   a	  wide	   therapeutic	  window	  and	   linear	   kinetics,	   therefore	   indicating	   a	   drug	   candidate	   for	  
admixing.	   Physicochemical	   characterisation	   of	   drugs	   and	   PN	   admixtures,	   assessment	   of	   stability	   and	  
compatibility,	   compounding	   and	   recommendations	   for	   possible	   additives,	   correct	   administration	   and	  
right	  product	  are	  essential	  aspects	  of	  the	  pharmaceutical	  activities	  in	  an	  NST.	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a b s t r a c t
Objectives: To improve malnutrition awareness and management in our department of general
internal medicine; to assess patients’ nutritional risk; and to evaluate whether an online educa-
tional program leads to an increase in basic knowledge and more frequent nutritional therapies.
Methods: A prospective pre-post intervention study at a university department of general internal
medicine was conducted. Nutritional screening using Nutritional Risk Score 2002 (NRS 2002) was
performed, and prescriptions of nutritional therapies were assessed. The intervention included an
online learning program and a pocket card for all residents, who had to ﬁll in a multiple-choice
questions (MCQ) test about basic nutritional knowledge before and after the intervention.
Results: A total of 342 patients were included in the preintervention phase, and 300 were in the
postintervention phase. In the preintervention phase, 54.1% were at nutritional risk (NRS 2002 !3)
compared with 61.7% in the postintervention phase. There was no increase in the prescription of
nutritional therapies (18.7% versus 17.0%). Forty-nine and 41 residents (response rate 58% and 48%)
ﬁlled in the MCQ test before and after the intervention, respectively. The mean percentage of
correct answers was 55.6% and 59.43%, respectively (which was not signiﬁcant). Fifty of 84 resi-
dents completed the online program. The residents who participated in the whole program scored
higher on the second MCQ test (63% versus 55% correct answers, P ¼ 0.031).
Conclusions: Despite a high ratio of malnourished patients, the nutritional intervention, as assessed
by nutritional prescriptions, is insufﬁcient. However, the simple educational program via Internet
and usage of NRS 2002 pocket cards did not improve either malnutrition awareness or nutritional
treatment. More sophisticated educational systems to ﬁght malnutrition are necessary.
! 2015 Elsevier Inc. All rights reserved.
Introduction
Disease-related malnutrition (DRM) is deﬁned by the Euro-
pean Society of Clinical Nutrition and Metabolism (ESPEN) as a
condition that results from a lack of uptake or intake of energy
and nutrients, which leads to an altered body composition with
diminished function and a negative clinical outcome [1]. Many
studies have been performed in hospitals and have found a high
prevalence of DRM [2–4]. A multicenter survey conducted
between 2003 and 2006, which included 32,837 newly admitted
internal medicine patients of non-university Swiss hospitals,
indicated that 18.2% of the inpatients were either malnourished
or at severe nutritional risk [5].
DRM among hospital patients is a serious problem [6]. DRM
negatively inﬂuences the immune system and muscle strength
and is an independent risk factor for increased complication
rates (mainly infections) and extended length of hospital stay,
which results in a lower quality of life and higher healthcare
costs [7,8]. DRM is a largely treatable co-morbidity, which
makes rapid and simple identiﬁcation as well as effective
management essential. If nutritional risk is recognized early,
* Corresponding author. Tel.: þ41 31 632 42 46; fax: þ41 31 382 42 60.
E-mail address: carla.aeberhard@insel.ch (C. Aeberhard).
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then many patients with DRM can be treated uneventfully or
even the disease can be prevented [9–11]. The ESPEN guidelines
for good clinical nutrition management implied the screening
of patients on admission, examination of malnourished pa-
tients, and implementation of nutritional support [12].
According to a Swiss study, patients with a Nutritional Risk
Score 2002 (NRS 2002) of !3 should receive nutritional therapy
that consists of oral nutritional support (dietary fortiﬁcation,
snacks, and oral nutritional supplements) or artiﬁcial nutrition
(enteral or parenteral nutrition) [5,13].
Over the past decade, many surveys have evaluated the
knowledge about the management of DRM among hospital
physicians of different specialties. All of the surveys concluded
that the knowledge concerning DRM management among
physicians was poor, and consequently nutritional practice was
insufﬁcient; this circumstance results in a high prevalence of
undetected DRM within hospitals [14–16]. Physicians and also
medical students need more education and training in nutri-
tional assessment and intervention [17].
To date, no study has sequentially tested the potential
improvement of physicians’ nutritional management knowledge
and consequently increased the treatment of DRM after an online
educational program. The speciﬁc aims of this prospective pre-
post intervention study were to assess whether such a targeted
educational intervention (online learning program) leads to an
increase in basic knowledge in clinical nutrition and behavioral
changes toward better malnutrition management and therefore
to more frequent adequate nutritional therapies (measured by
an aimed 10% more prescriptions).
Materials and methods
Study design
We conducted a prospective pre-post intervention study with a follow-up
period. The study was conducted at the University Hospital of Bern from April
1, 2013, to July 31, 2014. The study was performed on three wards of the
Department of General Internal Medicine (GIM). The study ﬂow diagram and
duration are illustrated in Figure 1.
Residents and patient selection
All of the residents (n ¼ 84 [100%]) working at the GIM department were
included in the study. The majority (42.9% in the ﬁrst questionnaire and 53.7%
Fig. 1. Study ﬂow chart. NRS, Nutritional Risk Score 2002.
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in the second questionnaire) were third- or fourth-year residents. Only a few
were more experienced (6.1% and 7.3% with more than six years’ experience)
or ﬁrst- and second-year residents (16.3% and 19.5%). To prevent losing
participating residents because of the high changing and rotating number at
the GIM department, all of the new residents entering during the study phase
were included in the study, and all of the departing residents had to ﬁnish the
intervention program. The participation of the residents was voluntary, and
their data were encoded in such a way that the participants could not be
identiﬁed from the documents presented. Demographic and professional
characteristics of the physicians were collected.
Newly admitted (<48 h) adult patients (>18 y old) on the three wards were
selected to participate in this study. The principal investigator (C.A.), a pharmacy
PhD student, evaluated and included the patients in the study if the inclusion
criteria were met. In the pre- and postintervention phase, an identical patient
recruitment process was conducted, always by C.A. The exclusion criteria were as
follows: a palliative situation and/or life expectancy less than 30 d; foreign lan-
guage (except German, French, Italian, and English); isolated patients for infec-
tion reasons, uncontrolled pain, or reduced level of consciousness; patients with
dementia or mental disorders; and patients who refused or were not able to sign
the informed consent. Participation was voluntary. The participants could not be
identiﬁed from the collected material, and no plausible harm to the participating
individuals was identiﬁed.
Data collection
The included patients were screened with NRS 2002 by C A. [12,18]. The
international validated screening tool NRS 2002 is a fast and simple screening
method that is based on four variablesdweight loss, body mass index (BMI),
general condition, and amount of food intake in the preceding weekdin addition
to the patient’s age and the severity of the underlying disease. The total scorewas
calculated from the impaired nutritional status section (score 0 to 3), the score for
the severity of the disease (an indicator of stress metabolism and increased
nutritional requirements; score 0 to 3), and age adjustment (scoreþ 1 for>70 y),
and the total score ranged from 0 to 7. Patients are classiﬁed as being malnour-
ished (score "3) or not (score<3), according to the total score obtained [18]. The
length of stay and nutritional prescriptions were collected from the electronic
medical records.
Preintervention phase and online multiple-choice questions test
The patients’ data were collected on the GIM wards without the residents
knowing about the conducted study. In a further step, the baseline knowledge
of the residents on the nutritional management was tested using an online
multiple-choice questions (MCQ) test, which was created by three experienced
physicians and specialists in clinical nutrition and sent to all residents of the
GIM department by internal hospital e-mail. The test contained 16 multiple-
choice questions about the basics of clinical nutrition, nutritional manage-
ment, recognition of malnutrition, NRS 2002 scoring, and nutritional therapies.
Additionally, in a closed question, the residents were asked about their attitude/
barriers toward nutritional therapy (“Why do physicians pay little attention to
nutritional issues?”).
Educational intervention phase
The online educational program (easyLEARN) was based on theMCQ test (the
same topics in the MCQ test as in the online program) and contained basic details
about (clinical) nutrition; a detailed deﬁnition of DRM; its prevalence, causes,
and consequences; screening tool (NRS 2002); and treatment and management
of patients at nutritional risk. Information and online access to easyLEARN were
provided by internal e-mail to all of the residents (duration of the program: 20 to
30 min). The educational objectives included identiﬁcation of the causes and
consequences of malnutrition, the use of a nutritional screening tool for identi-
ﬁcation of malnourished patients, options and implementation of an adequate
nutritional therapy, and the correct monitoring. There were no interactive case
studies. The easyLEARN program was developed by the authors in collaboration
with the Institute of Medical Education of the University of Bern. Furthermore, a
pocket card that contained the NRS 2002 and nutritional therapy options was
created and handed out to all of the residents.
Postintervention phase
Two months after the intervention (education), a new evaluation of the pa-
tient data was performed in the postintervention phase using the same method
as in the preintervention phase. Additionally, the residents were asked to
participate in the online MCQ test again, using the same questions as in the
preintervention period.
Statistical analysis
All statistical analysis was performed with the software IBM SPSS Statistics
for Windows, Version 21.0 (IBM Corp., released 2012). Some of the data were
assessed using descriptive statistics only. Pearson two-sided chi-square test and
paired t test were conducted, and P values <0.05 were considered to be statis-
tically signiﬁcant.
Ethics approval
This study was conducted in accordance with the ethics guidelines of the
1957 Declaration of Helsinki. Ethics approval for the study was obtained from the
local ethics committee (Ethic Board Canton of Bern: Kantonale Ethikkommission
Bern KEK Study No. 029/13). The participants provided written informed con-
sent; the standard form of which was available on the ﬁle for each.
Results
Patient characteristics
When comparing the patients in the pre- and postintervention
phase, no signiﬁcant differences were found in the patients’
characteristics (Table 1). On average, patients who were at
nutritional risk were signiﬁcantly older, with a mean age # SD of
70.5 # 15.65 y compared with patients without risk, with a mean
age# SD of 63.9# 16.52 y. Overall, the patients with NRS 2002"3
stayed longer at the hospital, by 8.9 # 6.07 d (range 0–36),
compared with patients with NRS 2002<3, by 7.0# 5.79 d (range
0–61). Themean BMI of the patients at risk was 23.5# 5.67 kg/m2
(range 10.62–48.79, n¼ 262), whereas patientswith NRS 2002<3
had an average BMI of 28.0 # 5.45 kg/m2 (range 18.25–57.8,
Table 1
Comparison of characteristics between patient groups (pre- and postintervention)
Characteristic Preintervention Postintervention P
Total, n (%) 342 (100) 300 (100)
Sex, n (%) 0.625
Male 206 (60.23) 175 (58.33)
Female 136 (39.77) 125 (41.67)
Age (years; mean # SD) 66.45 # 16.91 66.92 # 15.97 0.717
Age groups, n (%) 0.668
<45 39 (11.40) 29 (9.66)
45 to 64 102 (29.82) 83 (27.67)
65 to 84 157 (45.91) 152 (50.67)
"85 44 (12.87) 36 (12.00)
BMI (kg/m2; mean # SD) 26.49 # 6.64* 25.66 # 5.07y 0.079
BMI groups, n (%) 0.053
<18.5 29 (8.68)* 21 (7.12)y
18.5 to 24.9 116 (34.73) 121 (41.02)
25 to 29.9 111 (33.23) 104 (35.25)
"30 78 (23.35) 49 (16.61)
NRS 2002 (mean # SD) 2.51 # 1.36 2.41 # 1.23 0.339
NRS 2002 groups, n (%) 0.053
NRS 2002 <3 185 (45.91) 185 (38.33)
NRS 2002 "3 157 (54.09) 115 (61.67)
Length of stay
(days; mean # SD)
7.78 # 6.39 7.86 # 5.49 0.478
Length of stay groups, n (%) 0.224
0 to <5 115 (34.80) 83 (27.76)z
5 to <10 136 (39.77) 136 (45.48)
10 to <15 48 (14.06) 50 (16.72)
15 to <20 21 (6.14) 13 (4.35)
20 to <25 8 (2.34) 11 (3.68)
"25 10 (2.92) 6 (2.01)
Reduced nutritional intake, n (%) 130 (38.01) 98 (32.67) 0.059
Weight loss, n (%) 132 (43.42)* 102 (35.79)y 0.158
BMI, body mass index; NRS 2002, Nutritional Risk Score 2002
Pearson chi-square 2-sided test
* n ¼ 304.
y n ¼ 285.
z n ¼ 299.
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n ¼ 367). The percentage of the patients at nutritional risk (NRS
2002 "3) with overweight was 8.6% and obesity 4.9%, versus
25.6% overweight and 15.3% obesity in patients with NRS
2002 <3. Remarkably, looking at patients with nutritional risk
only, one-third were overweight (20.6%) or obese (11.8%).
Nutritional therapy
Three-hundred forty-two patients were included in the
preintervention phase and 300 in the postintervention phase (n
¼ 642 [100%]). In the preintervention phase, 54.1% (n ¼ 157)
were at nutritional risk (NRS 2002 "3) versus 61.7% (n ¼ 115)
in the postintervention phase (c2[1, n ¼ 642] ¼ 3.75, P ¼ 0.053).
A nutritional intervention was performed on 18.7% (n ¼ 64) in
the preintervention phase and 17.0% (n ¼ 51) in the post-
intervention phase. Figure 2 shows the prescribed nutritional
therapies in both phases. No signiﬁcant difference regarding the
number of nutritional prescriptions between the pre- and
postintervention phases (c2[1, n ¼ 642] ¼ 0.319, P ¼ 0.572) was
observed; thus, the goal of 10% more prescriptions was not
reached. Focusing on the NRS 2002, 32.5% with NRS 2002 "3
had a nutritional intervention in the preintervention phase and
29.6% in the postintervention phase (c2[1, n ¼ 272] ¼ 0.263,
P ¼ 0.691). Furthermore, 7% with NRS 2002 <3 received a
nutritional therapy in the preintervention phase and 9.2% in the
postintervention phase (c2[1, n ¼ 370] ¼ 0.580, P ¼ 0.568).
Intervention and knowledge test
The ﬁrst MCQ test was completed by 49 of the 84 residents
(response rate 58%). The mean percentage of correct answers was
55.6 # 9.38 (min, 35.7%; max, 78.6%). Additionally, the residents
were asked, “Why do physicians pay little attention to nutritional
issues?” The two most frequently mentioned barriers were that
the manifest malnutrition of the individual patient was not
noticed and that there was insufﬁcient knowledge about malnu-
trition in general (see Fig. 3). In the intervention phase, 50
residents (response rate 60%) completed the easyLEARN program.
Forty-one residents ﬁlled in the postintervention MCQ test
(response rate 48%). The mean percentage of correct answers was
59.4 # 16.35 (min, 42.9%; max, 73.6%). There was no signiﬁcant
difference in the percentage of correct answers between the
pre- and postintervention MCQ test (c2[323, n ¼ 42] ¼ 326.04,
P ¼ 0.442). Only 26 residents completed the total intervention
procedure (ﬁrst MCQ test, easyLEARN program, and second MCQ
test; response rate 31%) (see Fig. 4). These participants demon-
strated improved results in the postintervention MCQ test
compared with the preintervention MCQ test (mean percent-
age of correct answers 63.0 # 10.43 versus 55.3 # 9.39)
(t [23] ¼ $2.30, P ¼ 0.031).
Discussion
This prospective pre-post intervention study aimed to assess
patients’ nutritional risks and whether an online learning
Fig. 2. Comparison of nutritional therapies given to patient groups (pre- and postintervention). EN, enteral nutrition; ONS, oral nutritional supplement; PN, parenteral
nutrition.
Fig. 3. Question of the multiple-choice questions (MCQ) test: “Why do physicians
pay little attention to nutritional issues?” PEM, protein-energy-malnutrition.
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program, together with a ready-to-use pocket card, for residents
enables an increase in their basic knowledge of nutritional
management and would lead to more prescriptions for nutri-
tional therapies for malnourished patients. The main ﬁnding was
that this intervention had no signiﬁcant effect on the number of
prescribed nutritional therapies. We had two almost comparable
patient groups in the pre- and postintervention phases, and we
found a high percentage of malnourished patients in both
groups. However, the percentage of prescribed nutritional sup-
port for these patients was remarkably low.
In teaching hospitals, 30% to 50% of GIM patients have been
found to be at risk for DRM [19–22]. This study conﬁrmed this
high prevalence in elderly people in a Swiss GIM referral center
along with the increased hospital stay of malnourished patients.
To ﬁght against DRM, the Public Health Committee of the Council
of Europe adopted a resolution for preventing and treating DRM
in hospitals [23], which outlined the importance of awareness of
DRM. Nutritional knowledge at all levels of physicians is insuf-
ﬁcient, and therefore DRM is not treated, as several studies have
demonstrated [24–28]. Our data showed that a very high pro-
portion, 42.4% of the patients (pre- and postintervention), suf-
fered from DRM. The awareness of DRM in patients with
overweight and obesity, a population per se at high risk of sar-
copenia, is very low. We found a large portion of malnourished
patients with normal body weight and malnourishment pre-
senting even in overweight (20.61%) or obesity (11.84%).
Considering that palliative patients and the patients with strong,
uncontrolled paindwho are even more prone to DRMdwere
excluded, the number of malnourished patients could well be
much higher. Furthermore, malnourished patients showed a
longer length of hospital stay, which was statistically signiﬁcant.
Imoberdorf et al. [5] found only 18.2% of newly admitted internal
medicine patients to be malnourished, probably because the
included hospitals were to a great extent peripheral hospitals
and not tertiary referral centers, such as the university hospital of
Berne in this case. Such referral hospitals usually have higher
rates of polymorbid patients with complex pathologies and
complications, which could explain the higher prevalence of
DRM found in our study.
Despite the high rates of malnourished patients, there is no
universal screening program for nutritional assessment in our
hospital that has been established to the extent necessary as
indicated by other international ﬁndings, which implies that 21%
to 73% of the hospital wards screen patients for nutritional risk
on admission to the hospital on a standard-of-care basis [29].
This ﬁnding conﬁrms the necessity of a routinely performed
nutritional risk screening upon admittance of the patients, to not
delay the necessary intervention.
The outcome in our study was measured with the prescribed
nutritional therapies: only 18.7% and 17%, respectively, of
malnourished patients (NRS 2002 !3) received nutritional sup-
port in the pre- and postintervention phases. The number of
nutritional prescriptions as a marker for malnutrition manage-
ment might be challenged, but the use of nutritional products
correlates with the nutritional support actions in the hospital
that inﬂuence the subsequent NRS 2002 monitoring of the pa-
tient. This low level of nutritional therapies correlates with the
poor awareness of the treating residents. They lack the basic
training of clinical nutrition during their medical traineeships,
which is again not speciﬁc to Switzerland [20,30,31]. The lack of
nutritional support measures was strengthened by the poor re-
sults in the nutrition knowledge test, even after the educational
intervention with online education and pocket cards (55.6%
versus 59.4% correct answers).
In our preintervention test, the residents were asked for the
reason “why physicians pay little attention to nutritional is-
sues.” The two most reported reasons were insufﬁcient
knowledge and that the manifest malnutrition of the patient
was overlooked or not recognized. The same reasons were also
identiﬁed by a Danish research group [32]. Interestingly, a
survey of Mowe et al. [33] in Scandinavia described that nearly
40% of the medical staff lacked techniques for identifying
malnourished patients, and more than 50% found it difﬁcult to
prescribe adequate nutritional therapy. Those who assumed
their nutritional knowledge to be good also showed better
nutritional management practice. Furthermore, Mowe et al.
[33] found that low knowledge was associated with difﬁculties
in performing nutritional risk screening and nutritional as-
sessments and in prescribing adequate nutritional therapies.
Clinical nutrition or nutrition in general is usually neglected
in medical schools. This ﬁnding was also conﬁrmed by Adams
et al. [17], who called for more and better training in nutritional
Fig. 4. Physicians’ intervention ﬂow chart and results of the multiple-choice questions (MCQ) test.
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assessment and intervention options for physicians, residents,
and medical students.
The same authors reported on a new initiative that offers a free
online education program for residents and other physicians. The
lessons are practice-based and can be completed in 15min or less.
The modules contain detailed recommendations for nutritional
assessments and appropriate therapies as well as practical ap-
plications and interactive case studies to reinforce the instructions
and allow the residents to apply the newly learned skills imme-
diately with patients [17]. Our study found that an online inter-
vention of 20 to 30 min with an easyLEARN educational program
did not cause a signiﬁcant increase in correct answers in the MCQ
knowledge test and in prescriptions of nutritional therapies. The
residents who completed the whole program showed better
scores in the second MCQ test, but this ﬁnding was not followed
by an increase in nutritional prescriptions. Only offering training
through a recommended e-learning tool and the distribution of
a memo card was not successful in signiﬁcantly changing the
behavior of the young residents to the point of resulting in better
malnutrition management.
An interdisciplinary nutrition team and different educational
strategies are needed for better education in clinical nutrition,
detection, and management [34]. A call for a multimodal and
more compulsory educational intervention arises. Rasmussen
et al. [35] conducted a study with a comprehensive nutritional
action plan in two internal medicine departments (e.g., intro-
duction of a screening system, nutrition sheet for physicians,
nutrition record for nurses, and implementation of guidelines),
which was able to increase the screening for nutritional risk from
3% to 50%, while 26% more patients (20%–46%) received a
nutrition intervention within 1 week [35]. A study conducted in
Brazil on the ICU concluded that a multifaceted educational
nutritional intervention improved the quality of nutritional
therapies. The intervention included nutritional therapy pro-
tocols, workshops for the physicians, and bedside clinical case
discussion [36].
To our knowledge, this study is the ﬁrst prospective pre-post
intervention study that uses the validated NRS 2002 as a
screening instrument. The study group of GIM residents from a
large tertiary hospital center represents also the national educa-
tional status for this physician group. The study was conducted in
a university hospital and addressed complex and multimorbid
patients. All of the patients were screened. Another strength of
this study is the use of a multifaceted intervention program: an
online learning tool, which was created on purpose by experts in
clinical nutrition and medical education, included a pre- and
postintervention knowledge test, and printed material was
distributed (a pocket card).
There are limitations to the study. Only half of the residents
completed the whole program (ﬁrst and second questionnaires
and the easyLEARN program), because of the high turnover of the
medical staff in a tertiary resident trainee center. Moreover, the
main clinical decision maker (the attending physician) was not
involved in the program. In addition, it was not possible to
correlate the prescribed nutritional therapies with the pre-
scribing physicians to obtain more information at the individual
physician level.
Conclusions
This study found that a recommended educational online
program together with the distribution of printed “pocket” ma-
terials alone was not effective at increasing the nutritional
knowledge that should be accompanied by improved
malnutrition management in a large university GIM clinic
despite the high rate of malnourished patients. Our simple online
educational intervention via Internet combined with a ready-to-
use pocket card of the NRS 2002 with information on malnutri-
tion management showed improvement in nutritional knowl-
edge in the subgroup of residents who participated in the whole
program. Nevertheless, there was no increase in the number of
nutritional interventions, as assessed by nutritional pre-
scriptions, which conﬁrms the insufﬁcient awareness and
behavioral changes of the involved physicians. More sophisti-
cated educational systems to ﬁght malnutrition are necessary.
Certainly, a compulsory multimodal training approach for resi-
dents in clinical nutrition is mandatory to successfully identify
and manage malnourished patients and to create awareness and
responsibility of the treating physicians. Further research is
needed to explore the speciﬁcs of the multifaceted educational
activities, including the format of the well-structured educa-
tional program, targeted at local circumstances, and interdisci-
plinary efforts to signiﬁcantly improve knowledge in nutritional
basics and malnutrition management skills of physicians and
other healthcare professionals.
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plaints.  Conclusion: Anthropometric parameters and QoL 
improved during the observational period in this HPN co-
hort. These Swiss HPN data are prerequisite for evaluation 
and comparison of HPN recommendations and best clinical 
practice, status of professional care instructions related to 
HPN effectiveness, quality of treatment and patient safety. 
 © 2015 S. Karger AG, Basel 
 Introduction 
 Parenteral nutrition (PN) is life saving and indicated 
when the gut is not functioning and due to oral or enter-
al intake not being sufficient to reach appropriate re-
quirement target. Advances in home parenteral nutrition 
(HPN) enable many patients to survive, to live at home 
and to have good or reasonably good quality of life (QoL) 
in their normal environment instead of prolonged hospi-
tal stays. Today it represents an established and common-
ly used procedure  [1] . Even in elderly patients with can-
cer, HPN has been shown to benefit nutritional status and 
QoL  [2] . Patients can be treated in an outpatient setting, 
resulting in reduced healthcare costs  [3] .
 Since the introduction of HPN in the 1970s, HPN 
prevalence and incidence have been steadily increasing in 
 Key Words 
 Home parenteral nutrition · Patient characteristics · 
Underlying disease · Quality of life · Complications 
 Abstract 
 Background: There are no specific Swiss home parenteral 
nutrition (HPN) data showing patient characteristics, quality 
of life (QoL) and complications. The goal of this study was to 
collect representative nationwide data on current adult HPN 
patients in Switzerland for international comparability and 
benchmarking.  Methods: This was a multicenter, nation-
wide, observational study. We conducted interviews for de-
mographics, PN characteristics, QoL and complications. The 
data were assessed at baseline and after a follow-up of 
3 months using a questionnaire.  Results: Thirty-three adult 
patients were included. The most common underlying dis-
eases were cancer, radiation enteritis and state after bariatric 
surgery, and the most prevalent indication was short bowel 
syndrome. During the 3-month observation period, signifi-
cant increase or stabilization of body weight occurred in the 
patients, physical activity scores improved from 34.0 to 39.4 
and mental scores improved from 41.9 to 46.4. HPN depen-
dency and traveling restrictions were of the greatest con-
cern. Diarrhea, xerostomia and/or thirst were frequent com-
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Europe, with a large multicentric survey showing an an-
nual incidence of 4–6 per 10 6 inhabitants and a preva-
lence of 2–40 per 10 6 inhabitants  [4–6] . The most com-
mon indications for long-term HPN in Europe are 
Crohn’s disease, mesenteric vascular disease, cancer and 
radiation enteritis  [7] . Other more recent studies confirm 
that malignancy is the single most common indication for 
HPN  [8, 9] .
 PN causes important restrictions in personal life, par-
ticularly, in social life, mainly due to the cyclic noctur-
nal HPN administration. These patients show reduced 
QoL, with physical problems, HPN dependency, social 
restrictions, sleeping problems and financial problems 
 [10] .
 Shaw et al.  [8] performed a first retrospective epide-
miological analysis of patients with home artificial nutri-
tion in Switzerland, based on data provided by the leading 
national insurance provider. Over the 5-year analysis pe-
riod, from 2005 to 2009, 433 HPN patients were recorded, 
showing increasing frequency of HPN.
 Data on HPN patients’ characteristics and living con-
ditions are scarce, and little is known about the challeng-
es and problems these patients face. The goal of this pro-
spective study was to collect representative nationwide 
data on the current Swiss adult HPN patient group for 
international comparability and benchmarking.
 Material and Methods 
 Study Design and Patient Selection 
 This multicenter, nationwide, observational study started in 
April 2013 and ended in March 2014. General practitioners and 
hospital physicians taking care of HPN patients were contacted. 
Their names were accessible through the Swiss Association for 
Common Tasks of Health Insurers (SVK). The physicians ad-
dressed were requested to obtain written consent from their pa-
tients to participate in the study. Inclusion criteria were the follow-
ing: age >18 years, receiving HPN, life expectancy >30 days and 
signed written consent. Patients fulfilling the inclusion criteria 
were either visited at home for an interview or interviewed in their 
hospital’s outpatient clinic.
 Data Collection 
 Data were collected using an entry questionnaire and a follow-
up questionnaire 3 months later. Patients included in the study 
either filled out the questionnaire together with their interviewer 
or on their own. The mean interview duration was about 45 min. 
The following data were collected: personal and demographic data, 
social aspects, detailed nutrition regimes and QoL according to the 
validated Short Form 36 Health Survey version 2 (SF-36v2) TM 
questionnaire, anthropometric data over time, indications for PN, 
medical history and prevalence of complications. The documents 
were available in three languages: German, French and Italian.
 Body mass index (BMI) was calculated as weight in kilograms 
divided by height in meters squared (kg/m 2 ). To assess the effects 
of HPN on personal life, behavior and emotions, patients were in-
terviewed about the effects of HPN and asked to check all appli-
cable responses. HPN-related complaints could be evaluated by 
the patients in the questionnaire by choosing from 3 options: ‘a 
little’, ‘medium’ or ‘strong’. To assess physical performance and 
mental health status at different time points (before disease, just 
before starting HPN and during HPN), the patients could choose 
between 4 different options (‘very good’, ‘good’, ‘bad’ and ‘very 
bad’). The QoL of the patients on HPN was assessed using the SF-
36v2 TM  questionnaire at the time of entry in the study and at the 
time point when the patients had to answer the follow-up ques-
tionnaires.
 The SF-36v2 TM is a multipurpose health survey with 36 ques-
tions. It yields an 8-scale profile of functional health and well-
being scores as well as psychometrically based physical and men-
tal health summary measures and a preference-based health util-
ity index  [11] . These 8 scales are reduced to a physical component 
summary (PCS = physical functioning + physical role + bodily 
pain + general health) and to a mental component summary 
(MCS = vitality + social functioning + emotional role + mental 
health)  [12] .
 Statistical Analysis 
 The statistical assessment was performed with IBM SPSS sta-
tistics for Windows, version 19.0 (IBM Corp., Released 2010, 
 Armonk, N.Y., USA). The Wilcoxon test was used for continuous, 
non-parametric data. Results are reported as means with SD or as 
numbers and percentages. A p value of <0.05 was considered sta-
tistically significant.
 Ethical Approval 
 This study was conducted in accordance with the ethical guide-
lines of the 1957 Declaration of Helsinki, and written informed 
consent was obtained from all participants. Ethical approval for 
the study was obtained from the Bernese Cantonal Ethics commit-
tee (KEK Bern, study no. 068/13), Bern, Switzerland.
 Results 
 Forty-one patients were recorded during the 1-year in-
vestigation ( fig. 1 ). Eight of the patients who were com-
parable to the study population did not consent to par-
ticipate, while 33 participated (n = 100%) and filled in the 
entry questionnaire. The follow-up questionnaire was 
filled in by 24 patients. In 3 patients, the loss of follow-up 
was because they died during the study period due to the 
underlying disease (cancer), 4 patients ceased HPN and 
2 patients had no more interest in the further participa-
tion of the study. This corresponds to about 4 patients per 
1 million inhabitants in Switzerland and is comparable 
with other European countries. All tertiary university 
hospitals and all important referral centers of different 
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are familiar with HPN therapies, were contacted but not 
all of them had patients to contribute. The patients’ char-
acteristics are listed in  table 1 . The mean age on starting 
HPN was 53.8 ± 17.8 years. At the time of the initial in-
terview, HPN treatment had been initiated on an average 
of 3.44 years previously, with a wide range from 2 days to 
30.75 years. The mean BMI before disease was 28.5 ± 11.4 
kg/m 2 and decreased significantly before starting HPN to 
a BMI value of 19.6 ± 6.7 kg/m 2 (p < 0.001). At the time 
point of the first interview, the mean BMI had increased 
significantly with HPN treatment to 22.0 ± 6.1 kg/m 2 (p < 
0.001). The BMI could be kept stable at 21.5 ± 3.2 until 
the follow-up interview ( fig. 2 ).
 Underlying Diseases and Indications for HPN 
 The underlying diseases and the indications for HPN 
of the 33 patients are reported in  table 2 . As underlying 
disease cancer was predominant (n = 14, 42%), followed 
by post-bariatric surgery and post-radiation enteritis (n = 
4 each, 12%). In 13 (39%) of the cases, a short bowel syn-
drome (SBS) was the indication for HPN.
 Central Venous Catheter-Related Complications 
 Most patients (n = 32, 97%) used tunneled catheter 
systems like the Hickman or the Port-a-cath. Only 1 pa-
tient was fed through a dialysis arteriovenous fistula. In 
45% of the patients (n = 15), there was at least one central 
venous catheter (CVC) replacement during the nutri-
tional treatment, primarily due to infections, CVC occlu-
sions or displacement. Eleven patients (33%) reported at 
least one infection during the HPN period. Intervention-
related CVC complications (e.g. arterial lesions, fixation 
problems) occurred in 5 patients (15%) and CVC occlu-
sions in 5 patients (15%). During the present observa-
tional period (follow-up questionnaire after 3 months 
from baseline), 6 patients (18%) had to have the CVC re-
placed due to infectious complications.
 Effects of HPN on QoL 
 Regarding the employment, 85% (n = 28) of the HPN 
patients were no longer employed, either because of phys-
ical impairment or because they had already retired (n = 
13). Nine percent (n = 3) had an employment with me-
dium physical activity or were students. Less than half of 
the patients (39%, n = 13) were able to do the housekeep-
ing themselves; 58% (n = 19) were dependent on family 
help. Personal care was performed themselves by 88% 
(n = 29). For attaching and removing the PN, 76% (n = 
25) relied on external help, such as a homecare service or 
a nurse.
Table 1.  Patient characteristics
Data Results
Patients, gender, n (%)
Male 12 (36)
Female 21 (64)
Age at start of HPN, years
Age, mean ± SD 53.76±17.75
Age, median 59
Age, n (%), (f:m)
<40 8 (24), (5:3)
41–60 11 (33), (9:2)
61–70 10 (30), (5:5)
≥71 4 (12), (2:2)
Geographical distribution (Switzerland), n (%)
East part 1 (3)
North part 2 (6)
South part 3 (9)
Central part 5 (15)
West part 10 (30)






Living situation, n (%)
Partner 15 (45)
With children <18 years or with the parents 3 (9)
Alone 8 (24)
Nursing home 4 (12)
Catheter types, n (%)
Hickman 18 (55)
Port-a-cath 14 (42)








n = 3, death
n = 4, ceased HPN
n = 2, withdrawal from study
Follow-up (3 months)
n = 24
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 Performance level and mental health status are shown 
in  figure 3 . Before the disease, 52% (n = 17) of patients 
were very active. During the disease, but just before be-
ginning HPN, 58% (n = 19) were not active at all. This 
improved during treatment with HPN, with 52% (n = 17) 
of patients reporting they were a little active. The mental 
health status was rated very bad in 30% (n = 10) during 
the disease, just before starting HPN. During HPN treat-
ment, only 3% (n = 1) described their mental status as 
very bad. Almost all patients showed improved physical 
and mental QoL after 3 months (PCS 34.02 vs. 39.37; 
MCS 41.91 vs. 46.35), as shown in  figure 4 . Only 2 patients 
(6%) considered themselves healthy, while 7 (21%) de-
scribed themselves as fairly healthy. Most patients report-
ed in the QoL questionnaire that their health was not ex-
cellent at all (n = 12, 36%).
 Aspects of HPN treatment that were reported as most 
disturbing were the restricted ability to travel and the im-
possibility to participate in social events (n = 21, 64%) and 
the dependency on the treatment (n = 19, 58%). Sleep 
Table 2.  Underlying diseases and indication for HPN
Diagnosis n (%)
Cancer 14 (42)
Complications of surgery 5 (15)
Post-bariatric 4 (12)
Others 1 (3)
Radiation enteritis 4 (12)
Crohn’s disease 3 (9)
Systemic sclerosis 2 (6)
Congenital bowel disease (Hirschsprung disease) 1 (3)
Motility disorders 1 (3)
Caecum perforation 1 (3)
Mesenteric infarction 1 (3)
Glycogenosis type Ia (–> severe inappetence) 1 (3)
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disturbances because of noise generated by the mechani-
cal infusion pump were mentioned 8 times (n = 8, 24%). 
Fear of further health complications (n = 5, 15%) and 
problems in partnership/family life (n = 3, 9%) were also 
listed. The HPN-related complaints are shown in the  fig-
ure 5 . The complaint cited most often was by far fatigue 
(n = 31, 94%). Rarely occurring complaints were pains, 
spasms, difficulty in controlling blood sugar level, night 
sweats and post-prandial health problems.
 Discussion 
 The present prospective study is the first detailed anal-
ysis of HPN patients in Switzerland. We consider this sur-
vey as representative for the population of HPN patients 
in our country. Of the 41 HPN patients identified, 33 were 
included. The University Hospital of Berne provided 36% 
of the recruited patients, far more than any other site, 
which may be due to the long lasting clinical experience 
with this population. HPN is prescribed not only by im-
portant referral centers, but also by general practitioners 
taking care of these patients. There are no regular follow-
ups, aspects or guidelines for HPN prescriptions and care 
in Switzerland.
 The age and gender distribution in our study are com-
parable to those of other surveys, which also showed a 
much higher rate of female HPN patients  [4, 13–15] . This 
is influenced by the underlying diseases, for example, 
post-radiation enteritis occurring in patients with gyne-
cological malignancies. SBS may also be more likely to 






























































































 Fig. 4. QoL follow-up. 
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intestine  [16] . A final reason is the increasing number of 
bariatric patients in Switzerland, of which 75% are wom-
en  [17] .
 Compared to other studies, the mean duration of HPN 
in our cohort is slightly lower (mean 3.44 years), but with 
a broader range (0.1–31 years)  [10, 18] . There was also 
greater variation in our study due to the inclusion of a 
patient with Hirschsprung disease requiring HPN since 
birth and due to the inclusion of a patient with SBS since 
more than 30 years, corresponding to almost 9 times the 
mean duration of HPN.
 Approximately, half of our patients have had at least 
one CVC replacement during HPN treatment. The com-
plication mentioned most often was CVC infection. 
This corresponds with the results of previous studies: 
28.6% had at least one catheter sepsis and 50% had at 
least one catheter change. CVC infection rate ranged be-
tween 0.38 and 4.58 episodes per 1,000 catheter days  [19, 
20] . To prevent infections and other catheter-related 
complications, good clinical practice and an experi-
enced multidisciplinary team are mandatory  [21] . Six 
patients (18%) needed a catheter replacement because of 
infectious complications in the 3 months of follow-up. 
This rate has to be interpreted with caution, because of 
the short follow-up period and because many patients 
just had started with the HPN therapy. The procedure 
in case of suspected CVC-related infection and subse-
quent removal is managed in a similar way throughout 
Switzerland. When a catheter infection is suspected, pe-
ripheral blood culture samples and culture samples from 
each catheter lumen are taken. If there is a definitive sign 
of local infection, for example, purulent secretion at the 
exit site, or a catheter-induced sepsis, the CVC is re-
moved immediately and an antibiotic therapy is started 
 [22] .
 In a European multicenter study, Van Gossum et al. 
 [4] showed almost the same distribution of underlying 
diseases (cancer 42%, Crohn’s disease 15%, vascular dis-
eases 13%). Recently, the ESPEN HPN-Chronic Intesti-
nal Failure Special Interest Group (European Society of 
Clinical Nutrition and Metabolism) created a survey to 
describe the use of HPN in post-bariatric surgery, includ-
ing the indications and outcome. An interesting finding 
in our study is that 4 patients (nearly 15%) of our study 
population need HPN after bariatric surgery. Patients un-
dergoing malabsorptive procedures are at risk of develop-
ing nutritional deficiencies and protein-energy malnutri-
tion (PEM). A small number of patients will develop PEM 
and will therefore require HPN months to years after bar-
iatric surgery. Bariatric surgery has increased significant-
ly in the last years in Switzerland, with 750 bariatric inter-
ventions in 2001 compared with 4,000 in 2013  [17] . Not 
much is known about this group of patients requiring 
HPN to compensate for complications or side effects after 
bariatric surgery  [23, 24] . Given the proportion of mor-
bidly obese people in the Swiss population (in 2012: 11% 
men and 9% women)  [25] , post-bariatric PEM will be an 
emerging problem in the future.
 On the other hand, other indications have dramati-
cally decreased, noticeably, the 4% proportion of AIDS 
patients in earlier years, most of who died of wasting 
syndromes due to the lack of effective therapies  [4, 26] . 
New treatments, better outcome and prevention strate-
gies have increased survival and decreased the need for 
HPN in such patients  [27] . This was also reflected in the 
fact that there were no AIDS patients in the cur-
rent study. In the study of Van Gossum et al.  [4] , cancer 
was in first place (39%) at almost the same rate like in 
our survey. The proportion of HPN patients with onco-
logical tumors has increased over the past years in 
 Europe  [28] . Previous Swiss data about the indications 
for home artificial nutrition demonstrated that neo-
plasms were the most frequent underlying disease (51%), 
diseases of the digestive system on the second place 
(10.4%) and diseases of the nervous system in third 
place (9.6%)  [8] . In our study, there were no patients 
with underlying neurological disorders. This is probably 
due to the fact that patients with neurological disorders 
can mostly be treated with enteral nutrition, including 
PEG  [29] . Another important fact is the change in offi-
cial recommendations for HPN over the last years, re-
positioning HPN as a palliative treatment in cancer pa-
tients because of the relatively small proportion of PN-
associated comorbidity risk factors  [14, 30] . Regarding 
the indications for HPN, we found that SBS is the most 
frequent indication (37%), consistent with other pub-
lished data  [31, 32] .
 Our investigation also focused on the QoL of HPN pa-
tients. Both physical and mental QoL, assessed by the 
non–disease-specific SF-36v2, improved over time in our 
patients. Many other studies determined the QoL using 
the Karnofsky score, the SF-36 or a new specific question-
naire for HPN patients. Overall, patients with HPN have 
poorer QoL than healthy people or patients with chronic 
illnesses  [13, 19, 32–34] . An earlier study with only 13 
participants showed that none of those HPN patients had 
a regular employment, but 46% did most of the house-
keeping  [35] . Our data showed that 85% of patients had 
no employment, and only 39% were able to do the house-
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 The additional subjective definition of physical perfor-
mance and mental health status were also investigated by 
Winkler et al.  [36] , who achieved greater insight into the 
lives of HPN patients and their definition of QoL. In our 
study, most of the patients reported that they were ‘very 
active’ or ‘active’ before disease, comparable with healthy 
individuals. In the immediate period before starting 
HPN, most of the patients felt very tired, adynamic and 
‘not active’. Fortunately, after initiation of HPN, the per-
formance level increased after weeks in most patients, 
showing the positive effects of HPN on well-being, body 
function and performance levels. The results concerning 
mental health were similar, with ‘poor’ mental health re-
ported before starting HPN and ‘good’ mental health af-
ter initiation of HPN.
 We conclude that our population profits by HPN from 
a better health status. Other studies confirm our findings 
showing improved QoL with HPN in both patients with 
benign and malignant underlying disease  [37–39] .
 Restricted travel options, limited social interaction 
and activities as well as loss of independence were the 
most frequent complaints related to HPN. Other studies 
showed similar results, mostly evaluated in surveys: the 
lack of freedom, being dependent and limitations in so-
cial life  [40, 41] . Moreover, Huisman-de Waal et al.  [42] 
showed social and somatic impacts of HPN therapy on 
daily life, which are comparable with our data (e.g. fa-
tigue, xerostomia, diarrhea;  fig. 5 ).
 Strengths and Limitations of the Study 
 This prospective study provides the first detailed 
analysis of HPN patients in Switzerland. It is intended 
to regularly follow-up (in longer time periods) this co-
hort. The presented data will form the basis for a na-
tional HPN registry, which is needed to evaluate the spe-
cific situation of this cohort in the national (healthcare) 
context.
 The fact that the follow-up of the study was only 
3 months, and 3 patients had just started HPN before in-
clusion in the study is a limitation. The short duration was 
chosen to minimize patients lost to follow-up. Second, it 
was difficult for most patients during the survey to distin-
guish between HPN-related side effects and side effects 
due to underlying disease, and it was very challenging to 
determine whether improved or worsened QoL was 
caused by the underlying disease or is a direct conse-
quence of the HPN. A disadvantage of our study is that 
we do not have the information about how many patients 
were eligible for the present study, but did not give their 
consent to the physicians in charge.
 Conclusion 
 We conclude that PN is life saving and shows physical 
and mental benefit for HPN patients, but there are also 
negative implications for QoL, especially in terms of so-
cial and emotional aspects and loss of autonomy. The 
number of patients after bariatric surgery seems to in-
crease steadily, and PN is effective in this population. This 
first prospective analysis of Swiss HPN patients, focusing 
on anthropometric parameters and QoL, shows major 
improvements over the 3 months study period. These pa-
tients should be monitored over the long term to evaluate 
and compare outcomes and the impact of HPN on the 
underlying disease and HPN-associated complications. A 
national registry is a prerequisite for international com-
parability and benchmarking and can help to improve 
treatment quality and safety as well as to define best prac-
tices of HPN.
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Home parenteral nutrition is beneﬁcial in systemic sclerosis patients
with gastrointestinal dysfunction
Z Stanga1*, C Aeberhard1*, P Schärer2, A Kocher2, S Adler2, PM Villiger2
Departments of 1Endocrinology, Diabetes and Clinical Nutrition, and 2Rheumatology, Immunology and Allergology, Bern University
Hospital and University of Bern, Switzerland
Objectives: To assess 12-month changes in nutritional status and quality of life (QoL) in systemic sclerosis (SSc)
patients requiring home parenteral nutrition (HPN).
Method: We conducted a retrospective, single-centre database analysis of SSc patients regarding a 12-month period of
HPN at an interdisciplinary University Unit/team for nutrition and rheumatic diseases. Nutritional status was analysed
by nutritional risk screening (NRS) and body mass index (BMI). QoL was evaluated using Short-Form Health Survey
(SF-36) questionnaires.
Results: Between 2008 and 2013, daily nocturnal HPN was initiated in ﬁve consecutive SSc patients (four females and
one male, mean age 62.2 years) suffering severe malnutrition due to gastrointestinal tract (GIT) involvement. After
12 months of HPN, the mean NRS score decreased from 4.4 (range 4–5) to 1.4 (range 1–2), the mean BMI increased
from 19.1 (range 17.4–20.3) to 21.0 kg/m2 (range 18.3–23.4). QoL improved in all patients, reﬂected by the summary
of physical components with 33.92 points before vs. 67.72 points after 12 months of HPN, and the summary of mental
components with 49.66 points before vs. 89.27 points after 12 months of HPN. Two patients suffered one catheter-
related infection each with subsequent surgical removal and reinsertion.
Conclusions: HPN is a feasible method for improving anthropometric parameters and QoL in SSc patients severely
affected by GIT dysfunction. We recommend HPN in malnourished, catabolic SSc patients unable to otherwise
maintain or improve their nutritional status.
Systemic sclerosis (SSc) is a rare connective tissue disease
characterized by increased ﬁbroblast activity and resulting
in multiple organ ﬁbrosis (1). The gastrointestinal tract
(GIT) can be affected in up to 90% of SSc patients.
Nevertheless, GIT involvement is rarely reported, mostly
because of other more prevalent organ complications, and
is therefore diagnosed at late stages leading to
malnourishment in about 29% of patients (2). The main
GI manifestations are gastro-oesophageal reﬂux,
gastroparesis, intestinal pseudo-obstruction, bacterial
overgrowth, and malabsorption resulting in protein–energy
malnutrition (PEM). Deterioration of nutritional and
functional status has a severe impact on the prognosis
and quality of life (QoL) of these SSc patients with GIT
involvement (3–5).
As early recognition of PEM is crucial, screening of
nutritional status should be implemented in every physi-
cian consultation (6). Nutritional counselling and oral
nutritional supplements, between-meal snacks and for-
tiﬁed food should be recommended as a ﬁrst-line
approach (6). From our experience, this ﬁrst-line
strategy is effective at early stages of GI dysfunction.
At energy intake below 75% of the requirements, com-
plementary artiﬁcial nutrition should be considered; as
soon as the resorptive capacity of the intestine is too
low, the only possible option is life-sustaining, long-
term home parenteral nutrition (HPN) (7).
At present, there is a scarcity of literature on mal-
nourished SSc patients and the effectiveness and safety
of HPN. Over the past 20 years, several authors have
seen beneﬁcial, and sometimes striking, effects of com-
plementary HPN in this population. The aim of our pilot
study was to show improvement in nutritional state and
QoL during 1 year of HPN and to motivate physicians to
discuss this palliative option with SSc patients suffering
from severe GIT involvement.
Method
Patients
We conducted a retrospective, single-centre database
analysis of SSc patients regarding a 12-month
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period of HPN at an interdisciplinary University
Unit/team for nutrition and rheumatic diseases. Data
were extracted from paper and electronic medical
records. We documented medical history relevant
to the topic, demographics, HPN regime, and anthro-
pometric and clinical data during the observational
period.
Nutritional status
Energy intake measured in kilocalories (kcal) was
estimated by a dietician according to recall protocols.
Body mass index (BMI) was calculated as weight
in kilograms divided by height in metres squared
(kg/m2). Nutritional risk was assessed based on the
internationally validated Nutritional Risk Screening
(NRS 2002) system to predict outcomes based on
identiﬁed risk parameters (8). Scores range from 0
to 7, classifying patients as malnourished (score ≥ 3)
or not (score < 3).
QoL
QoL scores were assessed by the Short-Form Health
Survey (SF-36) questionnaire comprising 36 ques-
tions regarding physical and mental status, as
described previously (9). Evaluation leads to a phy-
sical component summary (PCS) score and a mental
component summary (MCS) score (10).
Ethics
The study was conducted in accordance with the ethical
standards of the local ethics committee on human experi-
mentation and with the Helsinki Declaration of 1975, as
revised in 1983 (Ref. no. KEK-BE 035/12).
Statistics
Descriptive statistics are expressed by mean values and
their respective standard deviations (sd) where applic-
able.
Results
Between 2008 and 2013, HPN was initiated in ﬁve
consecutive SSc patients (four females and one male,
mean age 62.2 years) suffering severe malnutrition due
to GIT involvement (for a patient overview, see
Table 1). Speciﬁc anti-Scl70 antibodies were present in
one patient, anticentromere antibodies were found in
another, both anti-Scl70 and anticentromere antibodies
were positive in one, and no speciﬁc antibodies were
found in another two patients. The maximum modiﬁed
Rodnan skin score ranged from 13 to 34 (mean 23).
Organ involvements were cardiac in three patients
with one lethal outcome, interstitial lung disease (ILD)
in three patients, with associated pulmonary arterial
hypertension (PAH) being oxygen dependent in one
female patient. Muscle weakness was moderate to
severe in all patients. Kidney involvement was found
Table 1. Demographic and anthropometric outcome data.
Parameter Patient 1 Patient 2 Patient 3 Patient 4 Patient 5
Gender (female or male) Female Male Female Female Female
Age (years) 64 41 76 58 72
Age at SSc diagnosis (years) 58 39 74 50 69
SSc subtype Diffuse Limited Limited Diffuse Diffuse
Time between diagnosis of SSc and HPN (years) 6 2 2 8 3
Energy requirements before HPN (kcal) 2300 2600 1700 1600 1700
Energy intake before HPN (kcal) 1000 200 500 750 800
Height (cm) 178 194 162 157 152
Weight loss since SSc diagnosis until start
of HPN (kg/year)
41/5 23/1 12/2 17/3 23/2
BMI at SSc diagnosis (kg/m2) 32.5 25.3 22.9 24.3 30.3
BMI at start of HPN (kg/m2) 19.6 19.9 18.3 17.4 20.3
BMI 6 months after start HPN (kg/m2) 22.4 19.9 19.0 19.9 22.5
BMI 1 year after start of HPN (kg/m2) 23.4 20.7 18.3 19.5 22.9
NRS 2002 score at start of HPN 4 4 5 4 5
NRS 2002 score 1 year after HPN 1 1 2 1 2
Percentage of energy intake before HPN
(=oral intake) compared to the requirements
43 8 30 47 47
PCS score 17.4/40.8 11.2/87.8 12.2/66.2 44.2/58.2 84.6/85.6
MCS score 50.2/82.4 5.2/78.7 8/83.8 68.9/73.4 116/128
SSc, Systemic sclerosis; HPN, home parenteral nutrition; BMI, body mass index; NRS, nutritional risk screening; PCS, physical
component summary; MCS, mental component summary.
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in two patients, one with acute renal failure. The most
prevalent GIT symptoms were: feeling of fullness,
pseudo-obstruction, abdominal distension, constipa-
tion, dysphagia, heartburn, regurgitation, and diarrhoea
as signs of malabsorption. In case of suspected bacter-
ial overgrowth of the small intestine (SIBO), we per-
formed a hydrogen breath test to conﬁrm or exclude
the diagnosis. Upon suspicion of gastro-oesophageal
reﬂux, we performed an upper GI endoscopy and
manometry, and then by indication a 24-h pH test.
Motility disorders of the oesophagus were diagnosed
by cinematography. None of the patients suffered from
SIBO; however, all patients suffered reﬂux oesophagi-
tis and oesophageal motility disorders of the oesopha-
gus. The motility of the GI tract was assessed by
whole-gut transit with a radio-opaque marker, showing
generalized dysmotility in all patients.
According to the NRS 2002, all patients were severely
malnourished (Figure 1). The mean energy intake before
HPN was 35% of the calculated requirements, revealing
catabolic metabolism. Indications for complementary
HPN were low caloric intake (< 75%) and subsequent
deterioration of nutritional status. All patients received a
cyclical nocturnal parenteral nutrition infusion daily.
Commercial, standard three-chamber bag systems (all-
in-one) with the following components were used:
lipids, proteins, and carbohydrates (standard product:
StructoKabiven®, 1477 mL, Fresenius Kabi, Switzer-
land; content of 1000 mL (1115 kcal): 38.5 g structured
triglycerides, 51 g amino acids, and 127 g glucose). All
patients were given their full energy requirements within
the ﬁrst week.
The mean BMI increased from 19.1 kg/m2 (range
17.4–20.3) at the start of HPN to 20.8 kg/m2 (range
19.0–22.5) 6 months later and stabilized at 21.0 kg/m2
(range 18.3–23.4) after 12 months of HPN (Figure 2,
Table 1).
Analysis of SF-36 after 1 year yielded beneﬁts in all
parameters (Table 1). PCS and MCS scores both
improved (PCS: 33.92 before vs. 67.72 after; MCS:
49.66 before vs. 89.27 after) (Figure 1, Table 1).
Prior to HPN, patients were malnourished and in a
catabolic state, manifesting fatigue, asthenia, and
exhaustion, as well as lack of energy for daily activities
such as vacuuming, shopping, walking, or getting
dressed. Additionally, pain was reported as subordinate
in comparison to nutritional and digestive problems.
After starting HPN, all components of the SF-36 ques-
tionnaire showed amelioration.
As an example, the male patient aged 39 years at
diagnosis of SSc with a daily energy intake of
200 kcal reported difﬁculties in playing football with
his sons prior to HPN. After HPN, he reported rapid
mental and physical improvement leading to more phy-
sical activity and ﬁnally enabling cycling tours.
Three patients reported technical difﬁculties, such as
functional impairment of their hands, which made it
difﬁcult to administer the HPN. For example, they
experienced problems connecting the ﬁligree catheter
kits.
No further HPN-related complications were detected.
Two patients suffered one catheter-related infection
each, with subsequent surgical removal and reinsertion.
Discussion
There is scarce literature about SSc patients with GIT
dysfunction and the effect of complementary HPN on
QoL. Recent data show beneﬁts from long-term HPN
representing a safe and effective feeding method in
these patients (7, 11). In line with these reports, our
data show that administration of HPN over 1 year is
able to improve anthropometrical parameters, nutritional
state, and QoL.
Thus, HPN should be considered in malnourished,
catabolic patients unable to maintain their nutritional
status with subsequently declining body functions. In
our patients, nutritional goals were already reached
within 1 week of HPN, with maintained nutritional
status and body function after another year of treatment.
At present, there are no data on QoL assessment using






















Figure 2. Body mass index (BMI) follow-up (data shown as mean ± sd).








































Figure 1. Follow-up mental (MCS) and physical component summary
(PCS) and nutritional risk screening (NRS 2002) scores (data shown as
mean) at the start of home parenteral nutrition (HPN) and 1 year later.
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comparison. The beneﬁt of the parenteral nutrition on QoL
has been demonstrated in small case studies only (max-
imum of 15 cases) with assessment tools being different
from the SF-36 (7, 12). Only Jawa et al showed an insig-
niﬁcant effect of HPN on the functional state of SSc
patients (13).
In our pilot study, physical as well as mental health
categories of the QoL questionnaire increased considerably
after 1 year of HPN treatment. Of note, the mental charac-
teristics presented a slightly higher beneﬁt in comparison to
the physical ones (Figure 1). From our prior studies we
know that mental performance and mood do improve in
malnourished patients if adequate nutritional support is
ensured (14). Present-day application of HPN with all-in-
one bags is well accepted by patients and their relatives;
patients soon feel better with HPN, and are motivated to
participate in social events and family activities; nocturnal
infusions render patients independent and physically active
during the daytime. Our cohort reported havingmore energy
for daily activities, a better health situation, renewal of
participation in social events, and enjoyment of travel (data
not shown).
As also reported by Brown et al, our cohort experi-
enced technical difﬁculties, rendering HPN handling
difﬁcult (7). In this context, family members, relatives,
community nurses, and home care providers should be
trained in managing HPN by themselves. Sleep distur-
bance, as a consequence of pump-related noises, unfor-
tunately could not be overcome.
Overall, the severity and rate of medical complica-
tions can be kept low by correct and careful manage-
ment, hopefully eliminating catheter-related infections.
Study limitations are the retrospective nature and the
small number of patients hampering relevant statistical
tests, yet our cohort is the only one simultaneously assessed
for HPN and changes in nutritional status and QoL.
Conclusions
HPN in severely malnourished SSc patients is a fea-
sible option leading to improved anthropometric
parameters and QoL. We suggest that HPN should
be considered in malnourished, catabolic patients
unable to otherwise maintain their nutritional status.
The effects of HPN on organ function and survival
should be veriﬁed within a prospective study.
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Background: Parenteral antiepileptic drugs are frequently used in critically ill patients for seizure control therapy
or prevention. Many of these patients require additional parenteral nutrition (PN). Therefore, a parallel infusion
of the frequently used antiepileptic drug levetiracetam (LEV) is interesting in terms of the restricted i.v. lines
(e.g., neonates). The potential interactions of the complex PN admixturewith the drug product and the appropri-
ate admixing of a drug at effective dosages require physicochemical lab assessments to obtain speciﬁc and reli-
able pharmaceutical documentation for the intended admixing.
Aim: To assess the of compatibility and stability of LEV, a neutral and hydrophilic drug, in commercial all-in-one
(AiO) PN admixtures using simple validated tests to provide necessary data in a timelymanner and to allow con-
venient, documented and safe treatment with PN as the drug vehicle.
Methods:Different concentrations of LEVwere injected into two different AiO PN admixtureswith no further ad-
ditives. Stability and compatibility tests for the drug and the PN admixtures were performed over seven days at
+4 °C, +23 ± 1 °C and +37 °C without light protection. Stability and sample characteristics were observed by
visual inspection and the validated light microscope method. Moreover, the pH level of the admixture was
checked, as were the concentrations of LEV over time in the PN admixtures, using an established LC-MS/MS
method.
Results: The stability controls of LEV at different temperatureswerewithin absolute±20% of the theoretical value
in a concentration range of 98.91–117.84% of the initial value. No changes in pH occurred (5.55 ± 0.04) and no
microscopic out of speciﬁcation data or visual changeswere observed. Themean value of the largest lipid droplet
in each visual ﬁeld over seven days was 2.4 ± 0.08 μm, comparable to that of the drug-free AiO admixture. Sam-
ples stored at +37 °C showed yellowish discolorations after 96 h of storage.
Conclusion: LEV showed compatibility and stability over seven days in the selected PN admixtures, and the de-
scribed methods represented a valuable and timely approach to determine the stability and compatibility of
the highly hydrophilic, not dissociated LEV in AiO admixtures under conditions of use. Further studies with clin-
ically relevant and representative examples of physicochemically different drug classes are needed.
© 2016 Elsevier B.V. All rights reserved.
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Most hospitalized patients, especially critically ill patients requiring
parenteral nutrition (PN) require additional intravenous (i.v.) medica-
tions. To prevent or to treatmalnutrition, PN is necessary when the gas-
trointestinal feeding is inefﬁcient, nonfunctional or not possible
(Dudrick, 2009). All-in-one (AiO) admixtures represent the standard
for PN regimen and include an oil/water (o/w) emulsion containing ap-
proximately 50 individual and potentially reactive soluble components.
Therefore, the potential physicochemical interactions among the com-
ponents, the container and admixes, such as electrolytes, vitamins,
trace elements to individualize the regimen, or even i.v. medications,
are numerous. The formulation is too complex to be evaluated biblio-
graphically. Accordingly, a lab analysis of the speciﬁc composition is
needed. In principal, AiO PN admixtures donot represent suited vehicles
to carry drugs, but in certain situations they may be convenient or oth-
erwise beneﬁcial (e.g., with limited separate i.v. access, as in neonates,
or for compliance, in the home PN setting). Co-administering i.v. medi-
cations via Y-site together with PN or as added to AiO PN admixture,
without documented compatibility/stability as a prerequisite for both
drug and PN efﬁcacy and safety is deemed unacceptable and represents
an avoidable medication error. At a minimum, short-term physico-
chemical compatibility and stability data are required to guarantee
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quality and tolerance of such an individual pharmaceutical formulation.
In current nutrition practice commercial multichamber AiO PN admix-
tures are used at least in the short term. Documented stability of such
regimens are mandatory (Mühlebach, 2009). The most common insta-
bilities from the o/w emulsion are creaming and coalescence; physico-
chemical reactions may be visible by colour or pH changes and by the
formation of precipitates as a result of the degradation of components
or reactions between nutrients and/or drugs. These reactions depend
on various factors, including concentration, light exposure, temperature,
catalyst actions, trace elements, or other components, such as electroni-
cally charged ions (e.g., dissociated drugs, electrolytes) (Mühlebach,
2005). This can also lead tomajor, even fatal complications, such as a ve-
nous catheter occlusion or blood vessel obstruction due to precipitates or
enlarged lipid droplets (N5 μm) or deposits (Hill et al., 1996; Sobotka,
2011; Driscoll, 2006). The United States Pharmacopeia requires that the
mean droplet size (MDS) of a parenteral lipid emulsion has to be b5 μm
and the volume-weighted percent of fat globules ≥ 5 μm (PFAT5) has to
be b0.05% (globule size distribution) (United States Pharmacopeial Con-
vention, 2008). To assess lipid emulsion deteriorations, simple analytical
methods are mandatory to be used in a timely, reliable and cost-effective
manner in daily (pharmaceutical) hospital practice to ensure the stability
or compatibility of ready-to-use individual AiO PN admixtures.
There are many studies on the compatibility and stability of different
medications that are admixed in PN (Bullock et al., 1989; Cano et al.,
1988; Trissel et al., 1999;Husson et al., 2003a). However,most of these in-
vestigations are older (N10 years) and are done with analytical methods
and techniques, not more state of the art. Furthermore, the composition
of ready-to-use PN admixtures and the speciﬁc i.v. drug formulations
have not been tested or have changed over time, and they may differ be-
tween manufacturers (e.g., generic drugs or individually manufactured,
non- commercial hospital products). Therefore, it is very important to
evaluate and document individual admixtures to achieve the best impact
on medication practice and to avoid medication errors, especially when
evaluating drugs that are frequently used in patients with PN.
Antiepileptic drugs such as levetiracetam (LEV) i.v. are frequently
used in critically ill patients for seizure control therapy or prevention
and treatment of a status epilepticus (e.g., in patients after traumatic
or surgical brain injury, cancer patients or neonates) (DeWolfe &
Szaﬂarski, 2013). Such patients mostly receive multiple lifesaving and
potent parenteralmedications and often require simultaneous adminis-
tration with PN. LEV is a new-generation antiepileptic drug that is used
with a larger therapeutic range with linear kinetics, in contrast to older
antiepileptic drugs. There is a lack of published clinical data on the com-
parative efﬁcacy of LEV given separately or admixed to a daily PN por-
tion. In general, there is also limited literature about PN as a drug
carrier for LEV or other antiepileptics.
The aim of the present study was to evaluate the physicochemical
compatibility and stability of LEV, which is an almost neutral and hydro-
philic drug (see Fig. 1), admixed to commercialized PN AiO admixtures
under practice conditions. In addition, suitable tests for timely assess-
ment were proposed. Data are necessary to document this treatment
framework because the possibility using of PN as a drug carrier presents
a new formulation with associated individual pharmaceutical quality
responsibility.
2. Material and methods
The investigations were done from January to August 2015 in the
laboratory medicine unit of the Cantonal Hospital (Aarau). The LEV in-
jection solution of 500 mg/5 mL (Levetiracetam Sandoz® concentrate
for infusion; active pharmaceutical ingredient: Levetiracetam 100
mg/mL (Fig. 1) (AHFS, 2013), excipients: sodium acetate trihydrate, so-
dium chloride, water for injections for 1 mL) was obtained from Sandoz
Pharmaceuticals AG, (Rotkreuz, Switzerland).Water, acetonitrile (ACN)
and methanol (MeOH) were of LC-MS/MS grade and obtained from
Sigma (Buchs, Switzerland). All other chemicals used were from
Sigma (Buchs, Switzerland) andof analytical grade or otherwise indicat-
ed. Nutriﬂex® Lipid Special [NLS], 625 mL (lot:0333 F1) and Nutriﬂex®
Omega Special [NOS], 625 mL (lot:0679 F1) (B Braun, Medical AG,
Sempach, Switzerland), were used as PN admixtures (three-chamber-
bags with separate lipid, glucose and amino acids compartments,
Table 1). Three different LEV concentrations were used, representing a
commonly adapted dosage range (20mg/kg bodyweight) added to cur-
rent PN regimens/volumes yielding LEV concentrations in the PN ad-
mixture of 0.4 mg/mL (≈2.35 mmol/L), 1.6 mg/mL (≈9.40 mmol/L)
and 4.8 mg/mL (≈28.20 mmol/L). Stability and compatibility tests
were performed over seven days at 0, 24, 48, 72 and 168 h after
admixing LEV injection solution into a PN sample. To prepare the test
samples, the bag compartment seals were broken bymechanical press-
ing on the PN container. The bag was turned upside down ﬁve times for
homogenization. Three samples (5 mL of PN) of each homogenized PN
were transferred into 10 mL glass tubes using a 5 mL manual pipette.
LEV injection solution was dosed by admixing 20 μL, 80 μL or 240 μL to
the PN sample aliquots in the glass tubes, using manual pipettes. All pi-
pettes in the range of 20–10,000 μL used had to pass the lab-internal
testing within a speciﬁed accuracy of ±1.0% and a coefﬁcient of varia-
tion (CV) of ±0.50%. The glass tube samples were covered with an air-
tight seal to provide an air- and ﬂuid-tight seal. The test samples (PN
with LEV) were stored in a refrigerator at +4 °C; at room temperature
(23 ± 1 °C) in the laboratory; or at +37 °C (water bath). The samples
were stored in transparent normal glass tubes without additional light
protection. Samples stored and handled in the laboratory at room tem-
perature or in thewater bath at elevated temperatures were exposed to
Fig. 1. Formula for Levetiracetam (C8H14N2O2; MG = 170.2 g/mol; logP−0.6; pH 7.0)
(AHFS, 2013).
Table 1







Volume glucose solution mL 250 250
Glucose monohydrate g 99.0 99.0
Sodium dihydrogen phosphate dihydrate g 1.56 1.56
Zinc acetate dihydrate mg 4.39 4.39
Volume fat emulsion mL 125 125
Soya-bean oil g 10.0 12.5
Medium-chain triglycerides g 12.5 12.5
Omega-3 fatty acids g 2.5 –
Monounsaturated fatty acids % 11.4 13
Polyunsaturated fatty acids % 34.0 30.7
Ratio Ω-3:Ω-6 1:2.7 1:7
Essential fatty acids % 31.7 30.7
Volume amino acid solutiona mL 250 250
Amino acid content g 35.9 35
Nitrogen content g 5 5
Carbohydrate content g 90 90
Lipid content g 25 25
Non-protein energy kJ (kcal) 2505 (600) 2505 (600)
Total energy kJ (kcal) 3090 (740) 3088 (738)
Osmolality (mOsm/kg) 2170 2090
pH-value 5.0–6.0 5.0–6.0
a Not detailed.
450 C. Aeberhard et al. / European Journal of Pharmaceutical Sciences 96 (2017) 449–455
4.4	  	  ASSESSMENT	  OF	  PN	  STABILITY	  AND	  COMPATIBILITY	  OF	  MEDICATION	  IN	  AIO	  PN	  FORMULATIONS	  
62	  
	   	  
daylight or artiﬁcial light (practical condition); samples stored in the re-
frigerator were protected from light by the closed door (“in the dark”).
At each test time point, the samples in the tubeswere visually inspected
for discolorations, creaming, phase separation, or precipitates. Before
taking an analytical sample, the tubes were turned upside down and
back three times to guarantee a homogenous admixture. Three aliquots
of each sample were measured by LC-MS/MS and then statistically cal-
culated for drug concentration (mean ± SD for each sample). For the
identiﬁcation and quantiﬁcation of LEV, a Thermo Fischer Ultimate
3000 UHPLC system (Thermo Fisher, San Jose, CA, USA) coupled to an
ABSciex 4500 quadrupole mass spectrometer (ABSciex, Darmstadt,
Germany) was used with a commercial kit (AED MassTox panel,
Chromsystems, München, Germany). Mobile phases I and II were from
Chromsystems, München, Germany (AV 92921, 2012). The MS was
run in the multiple reactions monitoring (MRM) mode using two tran-
sitions for each analyte. The Turbo V ion source run in positive ESImode.
Preparation and clean-up of the samples was performed according to
the manufacturer's protocol for serum samples (AV 92111, 2014). Ma-
trix effects and extraction recoveries were determined for serum and
PN, as proposed by Matuszewski et al. (2003). Three aliquots of all
three concentrationswere used. Thereby, the stock solutionwas diluted
1 + 1 (1:2) and also 1 + 99 (1:100). Sample aliquots of 50 μL were put
into Eppendorf tubes, mixed with 25 μL of extraction buffer, vortexed
for 10 s and then incubated for 2min at room temperature. The internal
standard mix (250 μL, containing precipitation reagent) was added,
vortexed for 30 s and then centrifuged for 5 min at 13,000 rpm. 10 μL
of the supernatant wasmixedwith 1090 μL of dilution buffer. The injec-
tion volume was 10 μL, and the LC ﬂow rate was 0.6 mL/min. The injec-
tion was done by a thermo-controlled autosampler at room
temperature (Thermo Scientiﬁc, Dionex UltiMate 3000), and the quan-
tiﬁcation was done according to a calibration curve, normalized to the
corresponding internal standard.
Light microscope investigations for lipid droplet assessment and pH
measurements (Metrohm 744 pH Meter) were performed for NOS and
NLS as blanks andwith concentrations of 1.6 mg/mL LEV (9.40mmol/L)
at+4 °C,+23±1 °C and+37 °C. Before each pHmeasurement, a two-
point calibration of the pH meter was done, each with a buffer solution
of pH 9.00 and pH 4.00, respectively (Metrohm calibration buffer). The
pH 7.00 solution was used afterwards as a control. Between the calibra-
tion steps, the electrode was rinsed with distilled water and wiped dry.
The physical stability of lipid emulsion was assessed by lipid droplet
measuring in a lightmicroscope (BX51 Olympus)with an upper droplet
size of ≥1 μm. Eachmicroscopic sample (10 μL by amanual pipette) was
analysed with 100-fold magniﬁcation and oil immersion (Schmutz,
1993). Five individual visual ﬁeldswere inspected permicroscopic sam-
ple (15 total visualﬁelds/aliquot): four in the corner and one in themid-
dle of the preparation. The size of the lipid droplets in the visual ﬁeld
was determined using an ocular micrometre (0.01 mm). The diameter
of the largest lipid droplet (LLD) and the number of lipid droplets N
5 μmwere measured and counted in each of the 15 visual ﬁelds tested
per aliquot. The stability-indicating data were measured and calculated
according to Schmutz (thesis). The speciﬁcations (Schmutz, 1993) of
microscopic screening are shown in Table 2.
The statistical assessment was performed with IBM SPSS Statistics
for Windows, Version 19.0 (IBM Corp. Released 2010, Armonk, NY,
USA) and Prism 6 for Mac OS X, Version 6.0 (GraphPad Software). The
results are reported as the means with standard deviations (mean ±
SD) or as numbers and percentages (n, %). In addition, 95% conﬁdence
intervals, R2, two-tailed P test, and one/two-way ANOVAwere calculat-
ed. A p-value b 0.05 was considered statistically signiﬁcant.
3. Results
3.1. Microscopic analysis
The microscopic results of NOS and NLS with LEV (1.6 mg/mL) are
shown in Table 3. The mean of the largest lipid droplet in μm out of 15
visual ﬁelds (n) (MLLDmax) of 4.5 μm as the upper limit value for the
emulsion stability was never reached by any sample over the seven-
day analysis period. Themean value of theMLLDmax for NOS (at all tem-
peratures and throughout the storage duration) was 2.3 ± 0.60 μm
(n = 180) and for NLS was 2.6 ± 0.63 μm (n = 180). There was a
trend for the droplet size to increase over time, as shown in Fig. 2. The
upper limit speciﬁcation (speciﬁcations shown in Table 2) of a LLD in
15 visual ﬁelds of ≤8 μmwas always reached. The LLD measured had a
diameter of 8 μm (n=1). The highest SD was 1.99 μm and was thus al-
ways smaller than the 2.0 μm speciﬁcation. Similarly, the number of
lipid droplets N 5 μmwas three was thus always smaller than the spec-
iﬁcation of nine.
The MLLDmax of NOS and for NLS as blank samples at all tempera-
tures and over the entire storage duration was 2.6 ± 0.77 and 2.7 ±
0.69, respectively, showing comparable emulsion characteristics, and
the datawerewithin the speciﬁcations. Therewas no statistically signif-
icant difference between the blank samples and the sampleswith added
LEV (p = 0.1602, two-way ANOVA). These speciﬁcations were not de-
pendent on temperature (4–37 °C), and no difference of the different
lipid compositions of NOS and NLS could be detected. The microscopic
assessment of lipid droplets per sample (15 visual ﬁelds) took approxi-
mately 20 min.
3.2. pH determination
The pH of the different PN admixtures samples (with and without
1.6 mg/mL LEV) at three different temperatures decreased negligibly
over time in NOS and NLS but ranged in all samples from 5.47 to 5.63
(mean ± SD: 5.55 ± 0.04, n= 48), with no detectable changes during
the test period. There was no difference regarding the different lipid
compositions, and no temperature dependency was shown.
3.3. Visual inspection
Over seven days, no visual changes were observed in the test sam-
ples stored at +4 °C or at room temperature. There was no creaming
or discoloration, except for the samples stored at+37 °Cwhich showed
yellowish discolorations after 96 h. However, neither precipitates nor
ﬂocculation were visible. A visual inspection was done for the assess-
ment of large particle formation in the critical size 1–5 μm.
3.4. LC-MS/MS analysis
Extraction recoveries andmatrix effects for PN and serumwere test-
ed for two LEV concentrations. Serum analysis is described because this
lab method was validated for therapeutic drug monitoring (TDM) in
serum samples and has therefore to be checked when alternative sam-
ples were measured. Since the PN admixtures samples used produced
no matrix effects, the analysis could be directly used for the stability
measurements in NOS and NLS. The extraction recovery for PN samples
for the lower concentration (0.4 mg/mL) was 98.7% (n=5, SD= 5.53)
resp. 86.0% (n = 5, SD = 5.77) for the higher concentration (4.8
mg/mL). The recovery rate for serum samples was 99% (n = 5, SD =
5.01) resp. 92.7% (n= 5, SD= 6.35). No matrix effects were observed:
Table 2
Speciﬁcations of microscopic i.v. fat emulsion stability screening in 15 visual ﬁelds
(Schmutz, 1993).
Microscopic parameter Abbreviation Unit Speciﬁcation
Largest lipid droplet in 15 ﬁelds LLD 1–15 [μm] ≤8
Mean LLD MLLDmax [μm] b4.5
Standard deviation SDLLD [μm] ≤2.0
Number of lipid droplets N5 μm LD N 5 μm [n] ≤9
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the matrix effect for PN samples ranged from 90.9–101.3% and from
97.2–105.1% for serum samples.
No differences between NOS and NLS (as blanks) were observed for
selected incubation/storage temperatures (one-wayANOVA: F=1.357,
p=0.2655, R2=0.0677). The three different LEV concentrations in NLS
at +37 °C measured over 7 days were 0.43 ± 0.02 mg/mL, 1.76 ± 0.07
mg/mL, and 5.07 ± 0.15mg/mL respectively. At room temperature, the
following LEV concentration over time resulted: 0.43 ± 0.01 mg/mL,
1.83 ± 0.11 mg/mL resp. 5.11 ± 0.23 mg/mL. No storage temperature
dependency was detectable, when comparing room temperature vs.
+37 °C (two-tailed t-test, p = 0.3078). Also no signiﬁcant difference
was shown regarding concentration dependency (one-way ANOVA:
F= 3.084, p=0.0643, R2= 0.2044). Themeasured LEV concentrations
in NOS at +37 °C were 0.43 ± 0.02 mg/mL, 1.72 ± 0.07 mg/mL
resp. 4.96 ± 0.21 mg/mL. The measurements in NOS at room tempera-
ture resulted in 0.41± 0.01mg/mL, 1.8± 0.05mg/mL resp. 5.25± 0.28
mg/mL. There was no signiﬁcant change of the LEV concentration de-
tectable over seven days when comparing the data at RT and +37 °C
(two-tailed t-test, p = 0.2029). Additionally, there was no signiﬁcant
concentration dependency detectable (one-way ANOVA: F = 3.037,
p = 0.0646, R2 = 0.1836). All results were in the range of ±20%. The
imprecision was within ±20%. As the LEV measurements were done
in highly complex o/w PN samples comparable to bioanalytical samples,
the 20% range for deviation was applied. Although the best ﬁt line
showed negative trend over the storage time (y = −0.0259x +
108.7, R2= 0.0847), no signiﬁcant decline of the concentration resulted
fromone-wayANOVA: F=2.124, p=0.1076, R2=0.2537. The individ-
ual dot in the stability over time plot indicates the mean of the three
measurements expressed in % of initial concentration of LEV in NOS at
room temperature and at +37 °C. (Fig. 3).
4. Discussion
Although this stability assessment procedure is aimed for a more
general approach how to evaluate on a short term base drug-PN stabil-
ity and compatibility request in a hospital settingwith easy to realise lab
investigations available in teaching hospitals and pharmacies, it is im-
portant to validate the approach by appropriate investigations on repre-
sentative and relevant drug products. In this studywe selected LEV (Fig.
1), a highly water soluble (N100 g/100mL of water) lowmolecular pyr-
rolidine anticonvulsant representative. This amid drug has a pKa of−2
and is almost not protein-bound. Therefore, it represents a very hydro-























Fig. 2.Mean values of the largest lipid droplet of NOS and NLS with LEV over time at three
different temperatures.
Fig. 3. Stability of LEV in NOS over time determined by LC-MS/MS in mg/mL (room
temperature and at +37 °C).
Table 3
Emulsion stability assessed by microscopic analysis of LEV (1.6 mg/mL) admixed to NOS and NLS and stored at three different temperatures.
PN NOS NLS
Temperature 23 ± 1 °C +37 °C +4 °C 23 ± 1 °C +37 °C +4 °C
Parameter MLLDmax [μm]
Storage duration 0 1.5 1.2 1.8 1.7 2.3 1.5
24 2.3 2.1 1.9 2.5 3.3 2.2
96 3.3 2.4 2.9 2.4 3.3 3.1
168 2.7 2.7 2.6 3.3 2.5 3.1
Parameter LLD 1–15 [μm]
Storage duration 0 3 3 4 5 4 3
24 6 4 5 5 6 4
96 6 4 6 5 5 6
168 6 5 8 7 5 6
Parameter SDLLD [μm]
Storage duration 0 0.74 0.77 0.86 1.23 1.22 1.06
24 1.68 1.06 1.03 0.99 1.53 1.08
96 1.45 1.12 1.41 1.18 1.22 1.30
168 1.45 0.90 1.99 1.53 1.46 1.33
Parameter LD N 5 μm [n]
Storage duration 0 0 0 0 0 0 2
24 1 0 0 0 3 0
96 2 0 1 0 0 1
168 3 0 0 2 0 1
LEV: levetiracetam; NOS: Nutriﬂex® Omega Special; NLS: Nutriﬂex® Lipid Special; RT: room temperature.
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therapeutically in molar doses (1000 mg–6 mol) (AHFS, 2013;
http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/
DevelopmentResources/UCM414456.pdf). A review showed that anti-
convulsants are often used together with PN in traumatic brain injuries
and in cancer patients (Salih et al., 2010). Stability and compatibility
data with PN are scare, although it is a relevant and frequently used
drug for critically ill patients or neonates. Medications often describe
Y-site administration and do not address the chemical stability, which
is important for efﬁcacy and safety.
LEV in a dose range of 0.4–4.8mg/mL (2.35–28.20mmol/L) is a high-
ly dosed i.v. drug and may thus have compatibility concerns. There was
no signiﬁcant decrease over seven days in NOS and NLS at three differ-
ent temperatures. The assessment of the chemical stability of LEV was
done using a validated stability-indicating LC-MS/MS quantiﬁcation
method that is also used for TDM. LC-MS/MS investigations involve
highly sensitive, state-of-the-art identiﬁcation and quantiﬁcation
methodswith drug-speciﬁc detection available inmost tertiary hospital
medical labs (see chromatogram of LEV in Fig. 4). The advantages of the
LC-MS/MS method vs. HPLC-UV or -FLD (with ﬂuorescence detector) -
are the most simple and fast sample preparation, substantially less in-
terference e.g. by co-medications, a shorter run-time and consequently
a higher sample throughput and selectivity - clearly predominate a po-
tential lower precision. But using a (deuterated) internal standards, a
complete and good precision through all clean-up steps of the analysis
can be achieved. Therefore, and as the drug stability/compatibility eval-
uation in PN can rely on an existing validated and veriﬁed LC-MS/MS
method used within the TDM-panel in the institutional routine opera-
tion of a hospital, their use is within the scope of the investigation for
relatively easy access methods to get stability indicating data.
The analysis of thematrix effect and the extraction recovery showed
the applicability for PN samples and using the serum sample cleanup.
The three different LEV concentrations chosen correspond to the usual
LEV dosing from 2 × 250 mg to 2 × 1500 mg applied in usual PN vol-
umes (administered daily). The lower level (250 mg) and upper level
(3000 mg) concentrations admixed to 625 mL PN yielded a concentra-
tion of LEV of 0.4 mg/mL, 1.6 mg/mL and 4.8 mg/mL. Admixed into
1250 mL PN (for adults), this would result in a concentration of 0.2
mg/mL, 0.8 mg/mL and 2.4 mg/mL. In addition, it was shown that LEV
could be dosed in half of the volume due to its high solubility.
All of the measured concentrations of LEV in NOS and NLS were in
the range of ±20% of the theoretical value. The different temperature
(storage) conditions used for two different high drug concentrations
showed no inﬂuence on the stability of LEV. The variability (higher con-
centration after storage) can be explained by pipetting errors during the
sample preparation or by the dilution, which yields an incorrect 100%
target value. The volume ratio for the PN sample and the drug admix-
ture was ≥1:20 and was therefore sensitive to small pipetting errors.
The accuracy of the pipettes is shown above.
The AiO PN admixtures that were chosen are representative treat-
ments for patients; they require PN administration through a centrally
placed i.v. catheter (osmolality≫ 800mosmol). The two products differ
in the fatty acid (FA) composition of the fat emulsion (Table 1). These
PN products are preﬁlled, stable, three-chamber formulations, that can
readily be made and used in most patients. Commercially available
lipid emulsions have a mean particle size of approximately 0.25–
0.5 μm in diameter, which corresponds to chylomicrons. The growth
of the lipid droplets into large fat globules could also block small
blood vessel (N5 μm), e.g., in the lung, and are dangerous formulations
that should not be used in patients (Sobotka, 2011; Pertkiewicz et al.,
2009). The lightmicroscopemethod according to Schmutz et al. is high-
ly sensitive and practicable, with a simple equipment and a convention-
al method validated by Photon Correlation Spectroscopy (PCS) and the
CoulterR method. Using a microscope with a 100-fold magniﬁcation al-
lows the detection of particles approximately 1 μm in size or enlarged
emulsion particles up to 20 μm in size. Furthermore, other non-lipid
globules (such as particulate matters or precipitations) can also be de-
tected using this method. The method provides an easy, sensitive,
cost-efﬁcient, time-sparing, and convenientway to test the physical sta-
bility of a lipid emulsion in the critical droplet size to indicate
destabilisation (large fat droplet assessment ≥ 1–2 μm), and it is suitable
for drug incompatibility testing in AiO PN admixtures (Schmutz, 1993).
LEV did not affect the lipid droplet sizing inmicroscopy assay over at
least 24 h and only showed only a slightly increasing MLLDmax over a
week at elevated temperatures (Figs. 2,3). Because the chemical analy-
siswith LC-MS/MS showed that LEV possessed good stability in all three
concentrations, only the concentration of 1.6 mg/mL was analysed by
microscope. No inﬂuence of the FA composition on lipid stability could
be detected. A single in vitro study showed LEV stability over 91 days
in Ora-Sweet (a syrup vehicle used to simplify the process of ﬂavouring
and sweetening) and Ora-Plus (suspension adjuvant) at two different
temperatures (Ensom et al., 2011). Our results showed that MLLDmax
in each visual ﬁeld over seven days at three different temperatures
Fig. 4. Extracted ion chromatogram (XIC) of levetiracetam (1; yellow and cyan) and internal standard (2; grey).
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  was 2.3±0.60 μm for NOS resp. 2.6±0.63 μm for NLS and did not differ
from the PN without the drug. No trend for an increase in the mean
droplet size was seen when 9.40 mmol/L LEV was added. All other pa-
rameters were according to the specs. This supports the position of
usingphysicochemical drug characteristics as aﬁrst evaluation of the in-
compatibility risk or the critical emulsion deterioration potential. Nev-
ertheless, a lab analysis for such complex pharmaceutical formulation
is necessary to document the pharmaceutical appropriateness of such
medication and needs pharmaceutical expertise in the NST.
The aim of the present study was to use simple and time-saving
evaluation tests to assess physicochemical stability and compatibility
of LEV admixed to two common commercial AiO PN admixtures. The in-
vestigationwas able to demonstrate easy-to-administer tests and docu-
ment the compatibility and stability of the drug in these PN products.
Pharmacists could use such tests in daily practice upon the request of
such data as a prerequisite for safe and efﬁcacious treatment advice
and to prevent incorrect handling and medication errors (Taxis &
Barber, 2003). Another factor indicating the stability of PN AiO admix-
tures is the pH. The pH decreases over time in PN admixtures because
of the hydrolysis of fat triglycerides. Additional chemical reactions
yielding base or acidic products also affect the pH. For the lipid stability
and lecithin emulsiﬁer, a pH range of 5–8 is necessary. The negatively
charged surface (phosphate moiety) prevents the coalescence of the
lipid globules (Mühlebach, 2009). A pH below 5.0 favours lipid instabil-
ities (Driscoll et al., 2009). In our study, there was only a slightly de-
creasing pH over time (most affected the samples at +37 °C) because
of destabilisation, degradation, and polymerisation but not a LEV-
speciﬁc reaction.
All of the presented data are based on tests that were done in 10mL
glass tubes, whereas in reality, the two solutions would be mixed in
either a Y-line, or in the PN bag if the drug was added there. Previous
studies have evaluated the compatibility between PN admixtures
and medications in a static manner (Husson et al., 2003b; McKay
et al., 2009) or by simulating Y-site administration (Husson et al.,
2003a). This study with the aim to get a response on drug stability
and compatibility quickly in a given design simulates “worst-case”
conditions with a deﬁned contact time between the PN admixtures
and a given drug concentration (LEV) but also to check the stability
for drug and PN at daylight and storage at room temperature and at
+37 °C but only in glass containers. To transfer the data to other con-
tainers or medical device materials, further studies have to be done,
especially if reports e.g. drug adsorption or absorption exist like for
lipophilic drugs and some plastics like PVC. This is not the case for
LEV.
A limitation of the study is the fact that these results are related to PN
regimen without vitamins or trace elements and the need for (home)
PN, but there is a low risk from the LEV characteristics that additional in-
teractions with these micronutrients would occur (red-ox reactions).
An additional limitation is that only one specialty of LEV and only two
different PN were checked. However, again, there is limited evidence
of major differences among originator and generic i.v. formulations, al-
though generic drugs may potentially not have identical ingredients or
pH differences. Other PN regimes might differ in composition, but
with a hydrosoluble, almost neutral drug such as LEV, there is a low
risk for major incompatibility. In either case another series with differ-
ent PN regimens could be done in a relatively short time. Additionally,
the neonatal situation was not speciﬁcally assessed. Neonates often
have very limited line access, individual PN regimes and lower medica-
tion dosage, and LEV is a candidate for such an admixture. Because we
performed in vitro pharmaceutical analysis and no in vivo clinical as-
sessment, it would be beneﬁcial to assess this stable pharmaceutical for-
mulation in vivo. The absence of data on in vivo effects is a limit of these
stability assessments andwould be valuable for commondrugs. The aim
of this study was to demonstrate how incompatibilities and, therefore,
unsafe and ineffective admixtures can simply be tested via a pharma-
ceutical approach.
5. Conclusion
We investigated the compatibility and stability of LEV in two com-
mon, commercially available PN AiO admixtures in adults at conditions
of usual handling in a hospital. LEV demonstrated compatibility and sta-
bility in NOS and NLS in a concentration of 1.6 mg/mL (9.40 mmol/L)
at three different temperatures. In addition, these results illustrated
a valuable approach for determining the pharmaceutical stability
and compatibility of drugs with PN in practice. This timely and
cost-effective pharmaceutical approach of documenting the quality
of complex therapeutic regimens increases the convenience and
avoids medical errors in the clinical setting. It is crucial to combine
methods to obtain a robust analysis of the chemical and physical stabil-
ity of such admixtures. The demonstrated example of LEV admixed to
AiO PN is important in patient care, is representative of drugs that are
hydrophilic-neutral or that have weak acidity, and documents pharma-
cists' support for criticalmedication treatments in hospital practice. This
procedure can be easily applied in daily clinical practice to fulﬁll the de-
mands of determining stability and compatibility of different drugs in
PN mixtures, when co-administration with PN and medications cannot
be avoided. In future studies, we will analyse drugs with varying phys-
icochemical proﬁles and clinical importance to further validate the
procedure.
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5 Conclusion	  and	  outlook	  
As	  concluded	  in	  the	  presented	  studies,	  pharmacists	  support	  the	  quality	  management	  of	  PN	  and	  reduce	  
administration,	  handling	  and	  medication	  errors.	  
	  
(I)	   The	  steady	  education	  and	  training	  of	  health	  care	  professionals	  in	  clinical	  nutrition	  management	  
is	   a	   prerequisite	   to	   detect	   and	   treat	   patients	   at	   nutritional	   risk,	   which	   is	   an	   essential	   task	   of	   the	  
pharmacist	  in	  an	  NST.	  The	  first	  study	  showed	  that	  a	  single	  online	  educational	  intervention	  alone	  was	  not	  
effective	  to	  increase	  the	  nutritional	  knowledge	  and	  to	  improve	  malnutrition	  management	  in	  residents.	  
Consequently,	  pharmacists	   in	  an	  NST	  should	  continually	  mention,	  model	  and	  provide	  opportunities	   to	  
observe	  best	  practices	  in	  malnutrition	  management.	  Suitable	  procedures	  could	  be	  professional	  support	  
by	  a	  pharmacist	  during	   clinical	   visits	   and	  a	   continuous	  education	  program	   (during	  graduate	  and	  post-­‐
graduate	  education)	  on	  the	  basics	  of	  clinical	  nutrition	  and	  clinical	  skills	  training	  for	  all	  healthcare	  staff,	  
including	   pharmacists.	   Nutrition	   is	   often	   neglected	   during	   medical	   education	   and	   there	   is	   a	   lack	   of	  
residency	   training	   and	  medical	   practice.	   Further	   research	   is	   needed	   to	   explore	  multimodal	   and	  more	  
compulsory	   educational	   interventions	   including	   well-­‐structured	   and	   validated,	   prolonged	   training	  
programmes	  containing	  didactical	  activities	  such	  as	  bedside	  teaching,	  life	  teaching	  sessions,	  clinical	  skills	  
training	   and	   problem-­‐based	   learning.	   With	   the	   help	   of	   periodical	   and	   interactive	   sessions,	   nutrition	  
awareness	  and	  responsibility	  will	  increase.	  The	  pharmacist	  can	  play	  an	  important	  role	  in	  education	  and	  
training	   of	   health	   care	   professionals	   to	   maintain	   the	   responsibility	   of	   professional	   competencies	   in	  
nutritional	  support.	  For	  this	  reason,	  a	  new	  study	  is	  planned	  and	  the	  previous	  study	  will	  be	  modified	  in	  
order	   to	   improve	   the	   knowledge	   of	   the	   resident	   and	   senior	   physicians	   and	   also	   the	   number	   of	  
prescribed	  nutritional	  therapies	  significantly.	  
	  
(II	  a	  +b)	  Monitoring,	  quality	  assurance	  and	  the	  guarantee	  of	  a	  safe	  and	  effective	  treatment	  are	   further	  
aspects	  of	  pharmaceutical	  competencies	  in	  an	  NST,	  especially	  at	  the	  interface	  hospital	  –	  at	  home,	  when	  
the	   patient	   goes	   home	   with	   a	   HPN	   treatment,	   the	   pharmacist	   of	   an	   NST	   plays	   a	   relevant	   role	  
undertaking	  coordinative	  and	  educative	  functions.	  Monitoring	  of	  HPN	  patients	  over	  a	   longer	  period	  of	  
time	   enables	   the	   evaluation	   and	   comparison	   of	   HPN	   recommendations	   and	   best	   clinical	   practice	   to	  
improve	   treatment	  quality	  and	  patient	   safety.	  This	  unique	  national	   study	  about	  HPN	  patients	   showed	  
different	  quality	  aspects,	  indicating	  improved	  anthropometric	  parameters	  and	  QoL	  over	  this	  rather	  short	  
observational	   period.	   A	   limitation	   of	   the	   Swiss	   HPN	   study	   was	   the	   short	   follow-­‐up	   period	   of	   three	  
months.	  In	  order	  to	  receive	  data	  with	  more	  significance,	  a	  prospective,	  observational	  follow-­‐up	  study	  is	  
planned,	  which	  should	  take	  place	  over	  a	  longer	  period	  of	  time	  (follow-­‐up	  of	  six	  months	  over	  two	  years).	  
Additional	   aspects	   emphasising	   infectious	   and	   mechanical	   catheter-­‐related	   complications	   will	   be	  
included.	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In	   the	   third	   study	   of	   patients	   affected	   by	   systemic	   sclerosis	   and	   GIT	   dysfunction,	   it	   could	   be	  
demonstrated	  that	  HPN	  is	  a	  feasible	  and	  safe	  method	  leading	  to	  a	  health	  benefit	  in	  terms	  of	  improved	  
anthropometric	  parameters	  and	  QoL	  in	  HPN	  patients	  with	  a	  specific	  disorder.	  Both	  studies	  showed	  that	  
good	  monitoring	  and	  implementation	  of	  HPN	  therapy	  can	  lead	  to	  an	  improvement	  in	  the	  QoL	  of	  patients	  
with	   HPN.	   Thus,	   the	   pharmacist	   is	   obligated	   in	   his	   professional	   capacity	   to	   ensure	   well-­‐structured	  
monitoring	   as	  well	   as	   training	   and	   education	   of	   the	   patients	   and	   their	   caregivers	   in	   aseptic	   handling	  
whether	  in	  a	  hospital	  pharmacy	  or	  in	  a	  community	  pharmacy	  (homecare).	  This	  in	  return	  can	  lower	  the	  
complication	  rate	  and	  improve	  the	  well-­‐being	  of	  these	  patients.	  The	  pharmacist	  can	  further	  contribute	  
to	  an	  NST	  and	  patient	  well-­‐being	  by	  ensuring	  the	  supply	  of	  materials	  and	  nutritional	  products,	  providing	  
advice	   about	   medication	   and	   possible	   additions	   to	   the	   PN	   and	   individual	   compounding	   (best	  
pharmaceutical	  practices).	  
	  
(III)	   The	   involvement	   of	   the	   pharmacist	   in	   the	   process	   of	   nutritional	   intervention	   and	   quality	  
assurance	   also	   includes	   the	   compounding	   and	   stability	   assessments	   of	   PN	   admixtures.	   The	  
physicochemical	   stability	   and	   compatibility	   aspects	   of	   PN	   admixtures	   are	   important	   pharmaceutical	  
issues	  with	   possible	   clinical	   implications.	   The	   last	   study	   showed	   in	   an	   example	  with	   the	   antiepileptic	  
levetiracetam	   the	  necessary	   stability	   and	   compatibility	   investigations	   and	   their	   documentation	  before	  
admixing	   into	   an	   AiO	   admixture.	   The	   results	   of	   the	   presented	   study	   showed	   that	   levetiracetam	   was	  
stable	  over	  seven	  days	  in	  two	  different	  PN	  admixtures	  and	  also	  a	  valuable	  approach	  how	  to	  determine	  
stability	  and	  compatibility	  of	  drugs	  with	  PN	  in	  daily	  practice	  to	  support	  complex	  therapeutic	  schemes	  in	  
a	   clinical	   setting.	   This	   timely	   and	   cost-­‐effective	   pharmaceutical	   support	   to	   document	   the	   quality	   of	  
complex	   therapeutic	   regimes	   increases	   convenience	   and	   avoids	  medical	   errors	   in	   the	   clinical	   routine.	  
The	  tested	  methods	  are	  time-­‐efficient,	  easy	  to	  use,	  sensitive,	  convenient	  and	  low	  cost	  to	  apply	  in	  a	  daily	  
routine	   to	   determine	   stability	   and	   compatibility	   of	   levetiracetam	   in	   PN	   mixtures	   and	   to	   apply	   best	  
pharmaceutical	  PN	  practices.	  Further	  aspects	  of	  pharmaceutical	  best	  practices	  are	  compounding	  (GMP)	  
and	  checking	  of	  the	  PN	  admixtures,	  medication	  and	  nutritional	  care	  plan.	  All	  these	  are	  prerequisites	  for	  
a	   safe	   and	   effective	   treatment.	   Further	   studies	   are	   needed,	   to	   analyse	   drugs	   with	   different	  
physicochemical	  profiles	  and	  clinical	  importance	  to	  further	  validate	  the	  procedure.	  	  
	  
According	   to	   the	   presented	   studies,	   the	   question	   remains,	   how	   to	   ensure	   the	   pharmacist	   becomes	   a	  
necessary	  NST	  member?	  Pharmaceutical	  responsibility	  in	  education,	  monitoring,	  GMP	  and	  compounding	  
is	  required	  and	  has	  gained	  in	  importance	  in	  clinical	  nutrition,	  especially	  in	  PN.	  Are	  the	  pharmacists	  ready	  
for	  a	  new	  and	  different	  challenge	  in	  the	  current,	  basic	  education	  at	  university?	  However,	  the	  pharmacist	  
is	  no	   longer	  only	   responsible	   for	   the	  preparation/compounding	  process.	   Their	  expertise	   is	   required	   in	  
community	  pharmacies	  and	  homecare,	  as	  well	  as	   in	  hospital	  pharmacies,	  to	  provide	  safe	  and	  effective	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treatment,	   to	   prevent	   medication	   errors	   and	   complications	   (especially	   in	   HPN)	   and	   to	   optimise	   the	  
comfort,	  autonomy	  and	  QoL	  of	  these	  patients.	  Knowledge	  and	  appropriate	  skills	  are	  required	  in	  order	  to	  
achieve	   these	   challenges	   and	   must	   be	   integrated	   into	   the	   basic	   education	   and	   training	   of	   the	  
pharmacists	  in	  the	  future.	  	  Accordingly,	  the	  curriculum	  and	  course	  content	  at	  the	  universities	  need	  to	  be	  
reconsidered	  and	  adjusted	  appropriately	  going	  forward.	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